<SEC-DOCUMENT>0001193125-22-209154.txt : 20220802
<SEC-HEADER>0001193125-22-209154.hdr.sgml : 20220802
<ACCEPTANCE-DATETIME>20220801211803
ACCESSION NUMBER:		0001193125-22-209154
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220801
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220802
DATE AS OF CHANGE:		20220801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONMED Corp
		CENTRAL INDEX KEY:			0000816956
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				160977505
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39218
		FILM NUMBER:		221126625

	BUSINESS ADDRESS:	
		STREET 1:		11311 CONCEPT BOULEVARD
		CITY:			LARGO
		STATE:			FL
		ZIP:			33773
		BUSINESS PHONE:		727-214-2974

	MAIL ADDRESS:	
		STREET 1:		11311 CONCEPT BOULEVARD
		CITY:			LARGO
		STATE:			FL
		ZIP:			33773

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CONMED CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d220699d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cnmd="http://www.conmed.com/20220801" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-08-01_to_2022-08-01">CONMED Corp</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-08-01_to_2022-08-01">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-08-01_to_2022-08-01">0000816956</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cnmd-20220801.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-08-01_to_2022-08-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000816956</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-08-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-08-01_to_2022-08-01">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt:datemonthdayyearen">August&#160;1, 2022</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">CONMED CORPORATION</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-08-01_to_2022-08-01">001-39218</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-08-01_to_2022-08-01">16-0977505</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-08-01_to_2022-08-01">11311 Concept Boulevard</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-08-01_to_2022-08-01">Largo</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-08-01_to_2022-08-01">FL</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-08-01_to_2022-08-01">33773</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-08-01_to_2022-08-01">(727)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-08-01_to_2022-08-01">392-6464</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Rule 12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-08-01_to_2022-08-01">Common Stock, $0.01 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-08-01_to_2022-08-01">CNMD</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:exchnameen">NYSE</ix:nonNumeric></span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-08-01_to_2022-08-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Biorez Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2022, CONMED Corporation, a Delaware corporation (&#8220;<span style="text-decoration:underline">CONMED</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), by and among CONMED, Prometheus Merger Sub, Inc., a Delaware corporation and newly formed wholly-owned subsidiary of CONMED (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), Biorez, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Biorez</span>&#8221;), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> of Biorez&#8217;s securityholders (the &#8220;<span style="text-decoration:underline">Holder Representative</span>&#8221;). Pursuant to the Merger Agreement, CONMED will acquire Biorez by way of a merger of Merger Sub with and into Biorez (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;), with Biorez surviving the Merger as a wholly-owned subsidiary of CONMED. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, upon consummation of the Merger (the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;), CONMED will pay Biorez&#8217;s securityholders an aggregate upfront payment of $85,000,000 in cash, as adjusted and payable pursuant to the Merger Agreement (the &#8220;<span style="text-decoration:underline">Closing Purchase Price</span>&#8221;). The adjustments to the Closing Purchase Price include, among others, (i)&#160;an upward adjustment for any cash held by Biorez at the Closing, (ii)&#160;a downward adjustment for Biorez&#8217;s outstanding indebtedness, transaction expenses and other related fees and expenses and (iii)&#160;an upward or downward, as applicable, net working capital adjustment based on a target range. The Merger Agreement also provides for <span style="white-space:nowrap">earn-out</span> payments to Biorez&#8217;s securityholders in an amount up to $165,000,000 based on the achievement of certain revenue targets for Biorez&#8217;s products during a period of four years commencing on October&#160;1, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations, warranties and covenants of CONMED, Merger Sub and Biorez, as well as the Holder Representative, including an agreement by Biorez to conduct its business in the ordinary course until the Closing. Pursuant to the Merger Agreement, CONMED and Biorez&#8217;s securityholders have also agreed to customary indemnification obligations for damages that result from any breaches of the respective representations, warranties and covenants of CONMED and Biorez, subject to stated thresholds and limitations specified in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is subject to customary conditions to Closing, including, among others, the adoption of the Merger Agreement by the requisite holders of Biorez&#8217;s shares of common stock and preferred stock. Completion of the Merger is expected to occur in early August 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants contained in the Merger Agreement (i)&#160;were made solely for the purposes of the Merger Agreement, (ii)&#160;were made solely for the benefit of the parties to the Merger Agreement, (iii)&#160;were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement, (iv)&#160;have been included in the Merger Agreement as a method of allocating risks and governing the contractual rights and relationships among the parties to the Merger Agreement rather than establishing matters as facts, (v)&#160;have been qualified by certain confidential disclosures not reflected in the text of the Merger Agreement, and (vi)&#160;may apply standards of materiality and other qualifications, exceptions and limitations that may differ from what may be viewed as material by investors. Accordingly, none of CONMED&#8217;s stockholders or any other third parties should rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts, circumstances or conditions of CONMED, Merger Sub, Biorez, any of CONMED&#8217;s subsidiaries, any of the parties&#8217; respective affiliates or any other person. The Merger Agreement and the summaries thereof are not intended to modify or supplement any factual disclosures about CONMED and should not be relied upon as disclosure about CONMED or its business. The Merger Agreement should not be read alone, but should instead be read in conjunction with other information regarding CONMED that is or will be disclosed in reports that CONMED files from time to time with the Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">SEC</span>&#8221;). Factual disclosures about CONMED contained in public reports filed with the SEC may supplement, update or modify the factual disclosures contained in the Merger Agreement. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Amendment to Credit Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2022, CONMED and its subsidiary Linvatec Nederland B.V. entered into the Second Amendment (the &#8220;<span style="text-decoration:underline">Second Amendment</span>&#8221;) to CONMED&#8217;s Seventh Amended and Restated Credit Agreement, dated as of July&#160;16, 2021 (the &#8220;<span style="text-decoration:underline">Base Credit Agreement</span>&#8221; and, as amended by the First Amendment, dated as of June&#160;6, 2022 (the &#8220;<span style="text-decoration:underline">First Amendment</span>&#8221;) and the Second Amendment, the &#8220;<span style="text-decoration:underline">Credit Agreement</span>&#8221;), among CONMED, the Foreign Subsidiary Borrowers (as defined therein) from time to time party thereto, the several banks and other financial institutions or entities from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Base Credit Agreement was filed as Exhibit 10.1 to CONMED&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on July&#160;16, 2021 and the First Amendment was filed as Exhibit 10.25 to CONMED&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> filed with the SEC on June&#160;7, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Second Amendment (i)&#160;increases from $75&#160;million to $100&#160;million the amount of cash that may be netted for purposes of calculating the Consolidated Senior Secured Leverage Ratio and the Consolidated Total Leverage Ratio (each as defined in the Credit Agreement) and (ii)&#160;provides that <span style="white-space:nowrap">earn-out</span> consideration payable by CONMED in connection with acquisitions will not constitute &#8220;Indebtedness&#8221; (as defined in the Credit Agreement), unless and until such obligation is finally determined to be due and payable under the applicable acquisition agreement and solely if not paid within five days after the date it is finally determined to be due and payable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, the Second Amendment amends the financial covenant requiring CONMED to maintain a particular Consolidated Total Leverage Ratio. In particular, the Second Amendment increases the maximum permitted Consolidated Total Leverage Ratio from the currently applicable 5:00 to 1:00 to (i)&#160;6.25 to 1.00 for the fiscal quarters ending June&#160;30, 2022, September&#160;30, 2022 and December&#160;31, 2022, (ii)&#160;6.00 to 1.00 for the fiscal quarters ending March&#160;31, 2023 and June&#160;30, 2023, (iii)&#160;5.75 to 1.00 for the quarters ending September&#160;30, 2023 and December&#160;31, 2023, and (iv)&#160;5.50 to 1.00 thereafter. The Second Amendment also permits CONMED to increase the maximum permitted Consolidated Total Leverage Ratio by 0.50 to 1.00 in connection with certain Material Acquisitions (as defined in the Credit Agreement), so long as the Consolidated Total Leverage Ratio in effect as a result of any such <span style="white-space:nowrap">step-up</span> does not exceed 6:00 to 1:00 and certain other conditions are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Second Amendment, a copy of which is filed as Exhibit 10.2 hereto and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 of this current report on Form <span style="white-space:nowrap">8-K</span> under the heading &#8220;Amendment to Credit Agreement&#8221; is incorporated into this Item 2.03 by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2022, CONMED issued a press release announcing the execution of the Merger Agreement. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The information under this Item 7.01 of this current report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), as amended or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Statement Regarding Forward-Looking Statements. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This current report on Form <span style="white-space:nowrap">8-K</span> and the other documents referenced herein may contain certain forward-looking statements (including &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) with respect to the financial condition, results of operations and business of CONMED and certain plans and objectives of CONMED. All statements other than statements of historical or current fact included in this Form <span style="white-space:nowrap">8-K</span> are statements that could be deemed forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;expected,&#8221; &#8220;scheduled,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;anticipates&#8221; or &#8220;believes,&#8221; or variations of such words and phrases, or can state that certain actions, events, conditions, circumstances or results &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. These forward-looking statements are based upon the current beliefs and expectations of CONMED, members of its senior management team and its Board of Directors, and are subject to certain assumptions and contingencies that involve risks and uncertainties, including factors outside of CONMED&#8217;s control. Such risks and uncertainties contained in forward-looking statements can include, without limitation: risks posed to CONMED&#8217;s business, financial condition, and results of operations by the <span style="white-space:nowrap">COVID-19</span> global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes and disruption to potential supply chain reliability; the ability of CONMED to advance Biorez&#8217;s product lines following the Merger, including challenges and uncertainties inherent in product research and development and the uncertain impact, outcome and cost of ongoing and future clinical trials and market studies; uncertainties as to the timing for completion of the Merger; the possibility that various conditions to complete the Merger may not be satisfied or waived; transaction costs in connection with the Merger; the potential effects of the Merger on relationships with employees, customers, other business partners or governmental entities; any assumptions underlying any of the foregoing; as well as risk factors discussed in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the full year ended December&#160;31, 2021 and other risks and uncertainties which may be detailed from time to time in reports filed by CONMED with the SEC. CONMED&#8217;s shareholders and other investors are cautioned that any such forward-looking statements are not guarantees of future performance and to not place undue reliance on these forward-looking statements, as actual results may differ materially from those currently anticipated. All forward-looking statements are based on information currently available to CONMED, and CONMED undertakes no obligation to update any such forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#160;&#160;&#160;&#160;No.&#160;&#160;&#160;&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description of Exhibit</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1+&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d220699dex101.htm">Agreement and Plan of Merger, dated as of August&#160;1, 2022, by and among CONMED Corporation, Prometheus Merger Sub, Inc., Biorez, Inc. and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> of Biorez&#8217;s securityholders. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Portions of this exhibit (indicated by bracketed asterisks) are omitted in accordance with the rules of the SEC because they are both not material and the Company customarily and actually treats such information as private or confidential.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d220699dex102.htm">Second Amendment, dated August&#160;1, 2022, to the Seventh Amended and Restated Credit Agreement, dated as of July&#160;16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d220699dex991.htm">Press Release, dated August&#160;1, 2022, issued by CONMED Corporation. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">CONMED CORPORATION <br />(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel S. Jonas</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Daniel S. Jonas</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President &#8211; Legal Affairs, General Counsel&#160;&amp; Secretary</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&#160;1, 2022 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d220699dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BY &#147;[***]&#148;, HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I)&nbsp;NOT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MATERIAL AND (II)&nbsp;IS THE TYPE THE COMPANY TREATS AS PRIVATE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AGREEMENT AND
PLAN OF MERGER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BIOREZ, INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONMED
CORPORATION, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROMETHEUS MERGER SUB, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SHAREHOLDER REPRESENTATIVE
SERVICES LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of August&nbsp;1, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">THE MERGER; CLOSING; EFFECTIVE TIME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION AND BYLAWS </P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF THE SURVIVING CORPORATION </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">DIRECTORS AND OFFICERS OF THE SURVIVING CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">CONSIDERATION; EFFECT ON CAPITAL STOCK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Merger on Capital Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment for and Exchange of Company Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;V</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties of Parent and Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ARTICLE&nbsp;VI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">COVENANTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interim Operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Solicitation or Negotiation of Alternative Proposals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Requisite Stockholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Stockholder Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Statement; Stockholders Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Access and Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publicity; Employee Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance and Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Indebtedness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third-Party Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RWI Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;VII</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONDITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Each Party&#146;s Obligation to Effect the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Obligations of Parent and Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Obligation of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;VIII</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Mutual Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Either Parent or the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;IX</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">SURVIVAL AND INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;X</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS AND GENERAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Holder Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Actions of the Holder Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Modification or Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL; SPECIFIC PERFORMANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations of Parent and of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation; Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Conflicts; Privilege</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Annexes</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">A-1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibits</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sample Working Capital Calculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E1-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agreed Accounting Principles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E2-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Stockholder Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E3-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E4-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Option Cancellation Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E5-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Cancellation Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E6-1</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedules</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;4.2(d)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Participating Employees&#146; Percentage Interests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;5.1(c)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Payment Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;7.2(c)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Transaction Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AGREEMENT AND PLAN OF MERGER </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT AND PLAN OF MERGER (this &#147;<I><U>Agreement</U></I>&#148;), dated as of August&nbsp;1, 2022 (the &#147;<I><U>Effective
Date</U></I>&#148;), is by and among Biorez, Inc., a Delaware corporation (the &#147;<I><U>Company</U></I>&#148;), CONMED Corporation, a Delaware corporation (&#147;<I><U>Parent</U></I>&#148;), Prometheus Merger Sub, Inc., a Delaware corporation and
a wholly-owned subsidiary of Parent (&#147;<I><U>Merger Sub</U></I>&#148;), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> of the Holders (&#147;<I><U>Holder Representative</U></I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the respective boards of directors of each of Parent, Merger Sub and the Company have approved this Agreement and the merger of
Merger Sub with and into the Company (the &#147;<I><U>Merger</U></I>&#148;) on the terms and subject to the conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, promptly following the execution and delivery of this Agreement, and as an inducement to Parent&#146;s and Merger Sub&#146;s
willingness to enter into this Agreement, the Company has agreed to use its best efforts to obtain a written consent from certain stockholders of the Company pursuant to which such stockholders will approve and adopt this Agreement in accordance
with Section&nbsp;228 and Section&nbsp;251(c) of the General Corporation Law of the State of Delaware (the &#147;<I><U>DGCL</U></I>&#148;) as more particularly set forth herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, as an inducement to Parent&#146;s and Merger Sub&#146;s willingness to enter into
this Agreement, Parent, Merger Sub and/or the Company, as applicable, are entering into, with those individuals listed on Section&nbsp;A to the Company Disclosure Letter (each of such individuals, a &#147;<I><U>Key Employee</U></I>&#148;),
(a)&nbsp;new employment agreements or retention arrangements and/or offer letters and/or (b)&nbsp;covenants not to compete (each of the foregoing, a &#147;<I><U>New Employment Agreement</U></I>&#148;), that will, in each case, become effective at
the Effective Time; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Parent, Merger Sub and the Holder Representative desire to make certain representations,
warranties, covenants and agreements in connection with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, and of the
representations, warranties, covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;I </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>The Merger; Closing; Effective Time </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1. <U>The Merger</U>. On the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be
merged with and into the Company and the separate corporate existence of Merger Sub shall thereupon cease. The Company shall be the surviving corporation in the Merger (sometimes hereinafter referred to as the &#147;<I><U>Surviving
Corporation</U></I>&#148;), and the separate corporate existence of the Company, with all its rights, privileges, immunities, powers and franchises, shall continue unaffected by the Merger, except as set forth in
<U>Article</U><U></U><U>&nbsp;II</U>. The Merger shall have the effects specified in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2. <U>Closing</U>. Unless otherwise
mutually agreed in writing between the Company and Parent, the closing of the Merger (the &#147;<I><U>Closing</U></I>&#148;) shall take place by conference call and electronic exchange of signatures, documents and other deliverables required to be
executed and/or delivered at the Closing no later than five (5)&nbsp;business days (the actual date of the Closing, the &#147;<I><U>Closing Date</U></I>&#148;) following the day on which the last to be satisfied or waived of the conditions set forth
in <U>Article</U><U></U><U>&nbsp;VII</U> shall be satisfied or waived in writing in accordance with this Agreement (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of
such conditions); <U>provided</U>, that the Closing shall not occur prior to August&nbsp;1, 2022. For purposes of this Agreement, the term &#147;<I><U>business day</U></I>&#148; means any day other than a Saturday, a Sunday or other day on which
bank institutions in New York, New York are authorized or required by Law to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3. <U>Effective Time</U>. As soon as
practicable following, and on the date of, the Closing, the Company and Parent shall cause a Certificate of Merger (the &#147;<I><U>Delaware Certificate of Merger</U></I>&#148;) to be executed, acknowledged and filed with the Secretary of State of
the State of Delaware as provided in Section&nbsp;251 of the DGCL. The Merger shall become effective at the time when the Delaware Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time
as may be agreed by the parties in writing and specified in the Delaware Certificate of Merger (the time the Merger becomes effective, the &#147;<I><U>Effective Time</U></I>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;II </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Certificate of Incorporation and Bylaws </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>of the Surviving Corporation </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1. <U>The Certificate of Incorporation</U>. At the Effective Time, the certificate of incorporation of the Surviving Corporation (the
&#147;<I><U>Charter</U></I>&#148;) shall, by virtue of the Merger, be amended and restated to be identical to the certificate of incorporation of Merger Sub in effect immediately prior to the Effective Time, until thereafter amended as provided
therein or by applicable Law, except that the name of the Surviving Corporation shall be &#147;<I>Biorez, Inc.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2. <U>The
Bylaws</U>. The bylaws of Merger Sub in effect immediately prior to the Effective Time shall be the bylaws of the Surviving Corporation (the &#147;<I><U>Bylaws</U></I>&#148;), until thereafter amended as provided therein or by applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;III </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors and Officers of the Surviving Corporation </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1. <U>Directors</U>. The board of directors of Merger Sub immediately prior to the Effective Time shall, from and after the Effective Time,
be the directors of the Surviving Corporation until their successors shall have been duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance with the Charter and the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2. <U>Officers</U>. The officers of Merger Sub immediately prior to the Effective Time shall, from and after the Effective Time, be the
officers of the Surviving Corporation until their successors shall have been duly elected or appointed or until their earlier death, resignation or removal in accordance with the Charter and the Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;IV </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Consideration; Effect on Capital Stock </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1. <U>Closing Consideration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Closing Consideration</U>. The aggregate consideration for the Merger shall be an amount equal to (i)&nbsp;the Closing Consideration,
as calculated pursuant to this <U>Section</U><U></U><U>&nbsp;4.1(a),</U> <I>plus</I> (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (to the extent it becomes payable up to the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap) on the terms and subject to the conditions set forth in <U>Section</U><U></U><U>&nbsp;4.2</U> and <U>Article</U><U></U><U>&nbsp;IX</U> (the &#147;<I><U>Aggregate
Consideration</U></I><U>&#148;</U><U>)</U>. The consideration to be paid by Parent at the Closing (the &#147;<I><U>Closing Consideration</U></I>&#148;) shall be an amount in cash, calculated pursuant to <U>Section</U><U></U><U>&nbsp;4.1(b)</U>,
equal to (i) $85,000,000, <I>plus</I> (ii)&nbsp;the Company Cash,<I> minus</I> (iii)&nbsp;the Funded Debt, <I>plus</I> (iv)&nbsp;the amount, if any, by which the Closing Net Working Capital exceeds the Net Working Capital Upper Boundary, <I>minus
</I>(v)&nbsp;the amount, if any, by which the Closing Net Working Capital is less than the Net Working Capital Lower Boundary, <I>minus</I> (vi) $750,000 (the &#147;<I><U>Purchase Price Adjustment Holdback</U></I>&#148;), <I>minus</I> (vii)&nbsp;the
Holder Representative Expense Amount. The Closing Consideration shall be distributed to the holders of the Company&#146;s securities (each such holder of securities, a &#147;<I><U>Holder</U></I>&#148;) in the manner specified on the Payment
Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) For the avoidance of doubt, in no event shall Parent or its Affiliates be obligated to make any payments to any Holders
pursuant to this Agreement that, together with the Purchase Price Adjustment Holdback (to the extent it becomes payable), in the aggregate exceed the Aggregate Consideration, other than any payments made by Parent or its Affiliates in respect of the
New Employment Agreements. For purposes of this Agreement, &#147;<I><U>Affiliate</U></I>&#148; shall mean, with respect to any specified Person, any other Person directly or indirectly controlling or controlled by or under direct or indirect common
control with such specified Person; for purposes of this definition, &#147;<I>control</I>&#148; when used with respect to any specified Person shall mean the power to direct the management and policies of such Person, directly or indirectly, whether
through the ownership of voting securities, by contract or otherwise, and &#147;<I>controlling</I>&#148; and &#147;<I>controlled</I>&#148; shall have meanings correlative to the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Calculation of Closing Consideration</U>. Not less than three (3)&nbsp;business days
prior to the Closing Date, the Company shall prepare, or cause to be prepared, and deliver to Parent a certificate containing a statement (the &#147;<I><U>Estimated Closing Statement</U></I>&#148;) representing the Company&#146;s good faith estimate
of the Closing Consideration and each component thereof (the &#147;<I><U>Estimated </U></I><I><U>Closing Consideration</U></I>&#148;) as of immediately prior to the Closing. The Estimated Closing Statement and all estimates and calculations
contained therein shall be prepared in accordance with the Agreed Accounting Principles and shall include supporting information and data reasonably necessary to support the calculations and estimates contained therein. After delivery of the
Estimated Closing Statement, the Company shall make its representatives reasonably available to Parent to discuss the Estimated Closing Statement and related supporting documentation. No failure by Parent to dispute the Company&#146;s calculation of
the Estimated Closing Consideration prior to the Closing shall be considered agreement with such amount for purposes of calculating the Closing Consideration or any component thereof. For the purposes of this Agreement, &#147;<I><U>Agreed Accounting
Principles</U></I>&#148; means the Company&#146;s accounting methods, policies, practices and procedures, applied consistently with the classification and estimation methodology used to prepare the Financial Statements, in the form set forth on
<U>Exhibit</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Cash</U>. The Estimated Closing Statement shall set forth the Company Cash
that the Company estimates will be held as of immediately prior to the Closing. For purposes of the Agreement, &#147;<I><U>Company Cash</U></I>&#148; shall mean the amount of cash and cash equivalents of the Company and its Subsidiaries,
<I>minus</I> the amount necessary to cover all overdrafts and all outstanding checks and wire transfers that have been mailed, transmitted or otherwise delivered by the Company or any of its Subsidiaries but have not cleared their respective bank or
other accounts prior to the Closing, determined without duplication in accordance with the Agreed Accounting Principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Funded
Debt</U>. The Estimated Closing Statement shall set forth each of the following amounts that the Company estimates will be outstanding immediately prior to the Closing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) the total amount of (1)&nbsp;all Indebtedness of the Company and its Subsidiaries outstanding immediately prior to the
Closing, <I>plus</I> (2)&nbsp;all obligations in respect of breakage costs, close out amounts, unwind costs, termination costs, redemption costs and other similar charges of the Company and its Subsidiaries under derivatives, swap or exchange
agreements, hedging transactions or similar instruments resulting from all events occurring prior to or as of immediately prior to the Closing (the sum of clauses&nbsp;(1)-(2), collectively, the &#147;<I><U>Debt Repayment Amount</U></I>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) the total amount of all of the fees and expenses outstanding as of the Closing or payable after the Closing incurred by or
on behalf of the Company or any of its Subsidiaries on or prior to the Closing in connection with the Merger and the other Transactions, including (1)&nbsp;all brokers&#146; or finders&#146; fees (if any) incurred by the Company or any of its
Subsidiaries; <I>plus</I> (2)&nbsp;all fees and expenses of counsel, advisors, consultants, investment bankers (including Canaccord Genuity Group Inc. (&#147;<I><U>Canaccord</U></I>&#148;)), accountants or other professionals incurred by the Company
or any of its Subsidiaries; <I>plus</I> (3)&nbsp;any Liabilities with respect to any costs of (a)&nbsp;sale, change in control, transaction, retention, deal completion or similar bonuses (in each case regardless of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
whether any such bonuses are paid on or after the Closing Date, and which shall, for the avoidance of doubt, include the Special Merger Bonuses set forth in Section&nbsp;5.1(h) of the Company
Disclosure Letter), (b) severance (and other post-termination) obligations to any Person whose employment has been terminated on or prior to the Closing, and (c)&nbsp;the employer&#146;s portion of any applicable payroll Taxes attributable to each
of (i)&nbsp;the foregoing clauses&nbsp;(a) through (b)&nbsp;and (ii) the payments in respect of Company Options as set forth on the Payment Schedule&nbsp;(the sum of clauses&nbsp;(1) through (3), collectively, the &#147;<I><U>Transaction
Expenses</U></I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (w) &#147;<I><U>Funded Debt</U></I>&#148; shall mean (A)&nbsp;the sum (without
duplication) of (1)&nbsp;the Debt Repayment Amount, <I>plus</I> (2)&nbsp;the Transaction Expenses, <I>minus </I>(B)&nbsp;the total amount payable by the Company to any insurer with respect to the D&amp;O Insurance and Products Liability Insurance
obtained by the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.10</U>; (x) &#147;<I><U>Indebtedness</U></I>&#148;<I> </I>shall mean any of the following with respect to the Company and its Subsidiaries: (i)&nbsp;any obligations for borrowed
money; (ii)&nbsp;any obligations evidenced by bonds, debentures, notes or other similar instruments; (iii)&nbsp;any obligations as a lessee under leases that are required under U.S. generally accepted accounting principles
(&#147;<I><U>GAAP</U></I>&#148;) to be treated as capital leases or to pay the deferred and unpaid purchase price of any business, line of business, property or equipment (including obligations related to
<FONT STYLE="white-space:nowrap">earn-out</FONT> arrangements) other than to the extent such obligations are taken into account in the calculation of Net Working Capital; (iv)&nbsp;all net cash payment obligations under swaps, options, derivatives
and other hedging Contracts that would be payable upon the termination thereof (calculated assuming termination on the date of determination); (v) any accrued and unpaid interest, premiums, fees, charges, reimbursements and other expenses owed with
respect to the foregoing, including, but not limited to, prepayment penalties; (vi)&nbsp;any guarantee of any of the foregoing types of Indebtedness referred to in clauses&nbsp;(i)-(v) of any Person; (vii)&nbsp;all Indebtedness of any other Person
secured by a Lien on any property or asset of the Company; and (viii)&nbsp;any Accrued Taxes; <U>provided</U>, that Indebtedness shall not include undrawn letters of credit, surety bonds and similar instruments, except to the extent such instruments
relate to obligations of an entity other than the Company or its Subsidiaries; and (y) &#147;<I><U>Accrued Taxes</U></I>&#148; shall mean an amount (not less than zero) equal to the liabilities or obligations of the Company and its Subsidiaries,
without duplication of any other amount taken into account as Transaction Expenses or in Net Working Capital, for any income Taxes with respect to a <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period to the extent first due and payable
after and not satisfied prior to the Closing Date, taking into account with respect to each particular type of Tax any refunds or previous overpayments, prepayments, or deposits of estimated Taxes in respect of that particular Tax, which calculation
shall be made (i)&nbsp;consistent with past practices of the Company and its Subsidiaries except as otherwise required by a change in applicable Laws, (ii)&nbsp;without recalculating any Taxes previously shown as due and payable on a Tax Return
filed by the Company or any of its Subsidiaries, except as required by a final &#147;determination&#148; under Section&nbsp;1313 of the Internal Revenue Code of 1986 (the &#147;<I><U>Code</U></I>&#148;) (or any similar provision of state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> law), (iii) without regard to any <FONT STYLE="white-space:nowrap">non-tax,</FONT> accounting concepts of deferred Tax liabilities or deferred Tax assets, (iv)&nbsp;considering transaction-related Tax
deductions only to the extent such deductions (A)&nbsp;have the effect of reducing (not below zero) the particular current Tax liability to which such deductions are relevant and (B)&nbsp;are deductible by a member the Company or any of its
Subsidiaries at least at a &#147;more likely than not&#148; level of confidence and taking into account any safe harbors that may apply to success-based fees, and (v)&nbsp;solely by taking into account only those jurisdictions (I)&nbsp;with respect
to which the Company and its Subsidiaries have historically and consistently filed Tax Returns and paid Taxes (i.e., by applying the past principles and practices of the Company and its Subsidiaries for purposes of determining their Tax liabilities
and payment and filing obligations) or (II)&nbsp;in which the Company and its Subsidiaries have first commenced operations on or before the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Working Capital</U>. The Estimated Closing Statement shall set forth each of the
following amounts: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) the Company&#146;s estimate of the Net Working Capital as of the Closing Date (the
&#147;<I><U>Closing Net Working Capital</U></I>&#148; and such estimate, the &#147;<I><U>Estimated Closing Net Working Capital</U></I>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) the amount, if any, by which the Estimated Closing Net Working Capital is less than negative one hundred and eighty-five
thousand dollars <FONT STYLE="white-space:nowrap">(-$165,000)</FONT> (the &#147;<I><U>Net Working Capital Lower Boundary</U></I>&#148;); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) the amount, if any, by which the Estimated Closing Net Working Capital exceeds $0 (the &#147;<I><U>Net Working Capital
</U></I><I><U>Upper Boundary</U></I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<I><U>Net Working Capital</U></I>&#148; shall mean
(i)&nbsp;the current assets of the Company and its Subsidiaries (<I>excluding</I> (1)&nbsp;Company Cash and (2)&nbsp;all deferred Tax assets and income Tax assets) <I>minus</I> (ii)&nbsp;the current liabilities of the Company and its Subsidiaries
(<I>including</I> any dividends or distributions declared by the Company, but <I>excluding</I> (1)&nbsp;Funded Debt and (2)&nbsp;all deferred Tax liabilities and income Tax liabilities), in each case calculated in accordance with the Agreed
Accounting Principles and the line items in the illustrative net working capital calculation set forth on <U>Exhibit</U><U></U><U>&nbsp;1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Post-Closing Adjustments to Closing Consideration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Final Closing Statement</U>. Within ninety (90)&nbsp;days following the Closing Date, Parent shall deliver to the Holder
Representative a statement (the &#147;<I><U>Closing Statement</U></I>&#148; and, in its final and binding form as determined below, the &#147;<I><U>Final Closing Statement</U></I>&#148;) setting forth the Closing Consideration and each component
thereof as of immediately prior to the Closing, including final determinations as to the amounts of (A)&nbsp;the Company Cash, (B)&nbsp;the Funded Debt and (C)&nbsp;the Closing Net Working Capital. The Final Closing Statement and the components
thereof shall be prepared in accordance with the Agreed Accounting Principles. The Holder Representative shall cooperate as reasonably requested in connection with the preparation of the Closing Statement. During the thirty <FONT
STYLE="white-space:nowrap">(30)-day</FONT> period immediately following the Holder Representative&#146;s receipt of the Closing Statement, the Holder Representative shall be permitted to review Parent&#146;s working papers related to the preparation
of the Closing Statement and determination of the Closing Consideration and the components thereof. The Closing Statement shall become final and binding upon the parties upon the earlier of (x)&nbsp;thirty (30) days following the Holder
Representative&#146;s receipt thereof, unless the Holder Representative shall give written notice of its disagreement (a &#147;<I><U>Notice of Disagreement</U></I>&#148;) to Parent prior to such date and (y)&nbsp;the date that the Holder
Representative notifies Parent of its acceptance thereof. Any Notice of Disagreement shall specify in reasonable detail the nature and dollar amount of any disagreement so asserted. The Closing Statement shall become final and binding upon the
resolution in writing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of all disagreements the parties may have with respect thereto (whether by the written agreement of the parties or pursuant to the arbitration provisions set forth below). During the thirty
(30)&nbsp;days following delivery of a Notice of Disagreement, Parent and the Holder Representative shall seek in good faith to resolve in writing any differences which they may have with respect to the matters specified in the Notice of
Disagreement. Following delivery of a Notice of Disagreement, Parent and its agents and Representatives shall be permitted to review the Holder Representative&#146;s and its Representatives&#146; working papers relating to the Notice of
Disagreement. If, at the end of the thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> period referred to above, the matters in dispute have not been fully resolved, then the parties shall submit to Ernst&nbsp;&amp; Young LLP (or such other
mutually agreed independent accountants of nationally recognized standing) (any such accounting firm, the &#147;<I><U>Accounting Firm</U></I>&#148;) for review and resolution of all matters (but only such matters) which remain in dispute, and the
Accounting Firm shall make a final determination of the Closing Consideration and the components thereof to the extent such amounts are in dispute, in accordance with the guidelines and procedures set forth in this Agreement. The parties will
reasonably cooperate with the Accounting Firm during the term of its engagement. The Accounting Firm shall be provided reasonable access to the books, records and other relevant information of the Company, Parent and the Holder Representative to the
extent necessary to calculate the Closing Consideration. In resolving any matters in dispute, the Accounting Firm may not assign a value to any item in dispute greater than the greatest value for such item assigned by Parent in the Closing
Statement, on the one hand, or the Holder Representative in the Notice of Disagreement, on the other hand, or less than the smallest value for such item assigned by Parent in the Closing Statement, on the one hand, or the Holder Representative in
the Notice of Disagreement, on the other hand. The Accounting Firm&#146;s determination shall be based solely on presentations by Parent and the Holder Representative which are in accordance with the guidelines and procedures set forth in this
Agreement (i.e., not on the basis of an independent review). Absent fraud committed by the Accounting Firm or manifest error (as to which Parent and the Holder Representative mutually agree), the Closing Statement and the determination of the
Closing Consideration and the components thereof shall become final and binding on the parties on the date the Accounting Firm delivers its final resolution in writing to the parties (which the Accounting Firm shall be instructed to deliver not more
than forty-five (45)&nbsp;days following submission of such disputed matters). The Accounting Firm shall act as an expert and not as an arbitrator to determine solely the matters in dispute based solely on the submissions and responses of Parent, on
the one hand, and the Holder Representative, on the other hand. The Accounting Firm shall allocate its costs and expenses between Parent and the Holder Representative, on behalf of the Holders, based upon the percentage of the contested amount
submitted to the Accounting Firm that is ultimately awarded to Parent, on the one hand, or the Holder Representative on behalf of the Holders, on the other hand, such that Parent bears a percentage of such costs and expenses equal to the percentage
of the contested amount awarded to the Holders and the Holders bear a percentage of such costs and expenses equal to the percentage of the contested amount awarded to Parent (such amount payable by the Holder Representative on behalf of the Holders
to be deducted from the Purchase Price Adjustment Holdback and retained by Parent in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)(ii)</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Closing Consideration Adjustments</U>. At the Effective Time, Parent shall hold an amount equal to the Purchase Price Adjustment
Holdback, which shall constitute a holdback from the Closing Consideration used to satisfy amounts owed to Parent pursuant to this <U>Section</U><U></U><U>&nbsp;4.1(c)(ii)</U>. Within five (5)&nbsp;business days following the determination of the
Final Closing Statement: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) in the event that the Closing Consideration (as finally determined
pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>) is greater than the Estimated Closing Consideration (the positive number equal to the difference between the Closing Consideration and the Estimated Closing Consideration, the
&#147;<I><U>Upward Adjustment Amount</U></I>&#148;), then Parent shall deposit with the Paying Agent for the benefit of the Holders such Upward Adjustment Amount, together with the Purchase Price Adjustment Holdback (after deduction of any
applicable Accounting Firm costs and expenses payable by the Holder Representative on behalf of the Holders pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>), in immediately available funds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) in the event that the Estimated Closing Consideration is greater than the Closing Consideration (as finally determined
pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>) (the absolute value of the negative number equal to the difference between the Estimated Closing Consideration and the Closing Consideration, the &#147;<I><U>Downward Adjustment
Amount</U></I>&#148;), then Parent shall (1)&nbsp;retain from the Purchase Price Adjustment Holdback, an amount in cash equal to the Downward Adjustment Amount and (2)&nbsp;deposit with the Paying Agent for the benefit of the Holders the remainder
(if any) of the Purchase Price Adjustment Holdback after deducting the Downward Adjustment Amount and any applicable Accounting Firm costs and expenses payable by the Holder Representative on behalf of the Holders pursuant to
<U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>, in each case in immediately available funds; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) in the event that the
Closing Consideration (as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>) equals the Estimated Closing Consideration, then Parent shall deposit with the Paying Agent for the benefit of the Holders the Purchase Price
Adjustment Holdback (after deduction of any applicable Accounting Firm costs and expenses payable by the Holder Representative on behalf of the Holders pursuant to <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>) in immediately available funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Modifications to Payment Schedule</U>. The Company may, in its reasonable discretion, modify, change or amend the Payment Schedule at
any time and from time to time prior to the Closing Date to correct any inaccuracy in the Payment Schedule or to otherwise update the Payment Schedule to reflect changes to the Company&#146;s capital structure permitted in accordance with
<U>Section</U><U></U><U>&nbsp;6.1</U>; <U>provided</U>, that the Company will provide the final Payment Schedule to Parent no later than 5:00 P.M. (Eastern Time) on the date that is at least two (2)&nbsp;business days prior to the Closing Date. For
the avoidance of doubt, no modification, amendment or change made to the Payment Schedule shall alter the aggregate amount of Closing Consideration or Aggregate Consideration payable by Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Holder Representative Expense Amount</U>. At the Closing, Parent shall deposit into an account designated by the Holder Representative
(the &#147;<I><U>Holder Representative Expense Account</U></I>&#148;) an amount equal to $100,000 (the &#147;<I><U>Holder Representative Expense Amount</U></I>&#148;). The Holder Representative Expense Amount may be used at any time by the Holder
Representative to fund any expenses incurred by it in the performance of its duties and obligations hereunder, including those duties and obligations identified in <U>Article</U><U></U><U>&nbsp;X</U>. The Holder Representative Expense Amount will be
held by the Holder Representative for so long as the Holder Representative determines is reasonably necessary for it to fulfill its obligations and duties under this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>provided</U>, that, following the completion of all such obligations and duties and the satisfaction of all expense reimbursements to which the Holder Representative is entitled in connection
therewith, the Holder Representative shall deliver any amounts remaining in the Holder Representative Expense Account to the Paying Agent for further distribution to the Holders in accordance with the Payment Schedule. The Holders will not receive
any interest or earnings on the Holder Representative Expense Amount and will irrevocably transfer and assign to the Holder Representative any ownership right that they may otherwise have had in any such interest or earnings. The Holder
Representative will hold these funds separate from its company funds, will not use these funds for any purpose inconsistent with this Agreement and will not voluntarily make these funds available to its creditors in the event of bankruptcy. For tax
purposes, the Holder Representative Expense Amount will be treated as having been received and voluntarily set aside by the Holders at the time of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2. <U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the occurrence of the Closing and the terms and conditions set forth in this <U>Section</U><U></U><U>&nbsp;4.2</U> and
<U>Article</U><U></U><U>&nbsp;IX</U>, Parent shall pay or cause to be paid additional consideration (the &#147;<I><U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</U></I>&#148;) of up to $165,000,000 (the &#147;<I><U><FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Cap</U></I>&#148;) to the Holders, pursuant to their respective allocations set forth on the Payment Schedule, to the extent achieved during the time period commencing on the first day of the Quarter
beginning immediately following the Closing Date (the &#147;<I><U>Commencement Date</U></I>&#148;) and ending on the day before the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Commencement Date (the
&#147;<I><U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period</U></I>&#148;), as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If the aggregate Applicable Revenue
for any period of four (4)&nbsp;full successive Quarters during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period (each, an &#147;<I><U>Applicable L4Q Period</U></I>&#148;), is greater than both (i)&nbsp;the prior four
(4)&nbsp;Quarters&#146; aggregate Applicable Revenue and (ii)&nbsp;the greatest Applicable Revenue for any prior four-Quarter period commencing with the last completed period of four (4)&nbsp;full successive Quarters immediately preceding the
Commencement Date (the greater of clause (i)&nbsp;or (ii) on any measurement date, the &#147;<I><U>Highwater Mark</U></I>&#148;), then <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration for such Applicable L4Q Period shall be payable to
the Holders, pursuant to their respective allocations set forth on the Payment Schedule, in an amount in the aggregate equal to (A)&nbsp;(1) the Applicable Revenue for such Applicable L4Q Period <I>minus</I> (2)&nbsp;the Highwater Mark,
<I>multiplied by </I>(B) [***]. For the avoidance of doubt, commencing with the initial <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration to be paid with respect to, and following the completion of, the first Applicable L4Q Period
ending on or after the first anniversary of the Commencement Date (if and to the extent due), additional Earn-Out Consideration may be payable following each completed Quarter during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period (if
and to the extent due), in each case subject to the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement,
the term &#147;<I><U>Applicable Revenue</U></I>&#148; shall mean revenues calculated in accordance with GAAP as reported by Parent for purposes of its filings with the Securities and Exchange Commission (the &#147;<I><U>SEC</U></I>&#148;) for
commercial sales of the Company Product anywhere in the world, less (a)&nbsp;outbound shipping charges actually paid or allowed by the selling party (and not reimbursed), (b) amounts actually allowed or credited due to returns or retroactive price
decrease (solely to the extent refunded by the selling party after the selling party&#146;s receipt of the gross revenues from such sale and not deducted prior to the receipt of such gross revenues), and (c)&nbsp;credits or allowances given or made
for any recall of the Company Product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(whether voluntary or involuntary). By way of clarification, and without amending any of the foregoing, inter-company transfers and transfers to Affiliates shall not be considered as revenues of
Parent. For purposes of this <U>Section</U><U></U><U>&nbsp;4.2</U>, the term &#147;<I><U>Company Product</U></I>&#148; shall mean (A)&nbsp;the BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> implant, including any modified or
improved versions thereof, (B)&nbsp;any other product or device that is based upon, embodies or is derived from, in whole or in part, any of the Company Intellectual Property and is covered by any valid claim(s) of any issued patents included in, or
any patents that issue from any pending patent applications or continuations included in, the Company Intellectual Property as of the Closing Date, and (C)&nbsp;any porous or <FONT STYLE="white-space:nowrap">bio-inductive</FONT> implant that
(i)&nbsp;contains xenogenic-derived collagen, (ii)&nbsp;is indicated for and sold for purposes of the augmentation or reinforcement of soft tissue in orthopedic shoulder, knee, hip, foot, ankle or elbow or hernia repair surgery<B> </B>and
(iii)&nbsp;is acquired or otherwise sold by Parent or its Affiliates during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period, in each case of clauses (A)&nbsp;through (C), for the avoidance of doubt, that are commercially released and
sold by Parent or any of its Affiliates during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period; <U>provided</U>, that the term Company Product excludes any product or device that is or has been sold, commercialized, promoted or
distributed by Parent or any of its Affiliates prior to the Closing Date, and, any modified or improved versions thereof developed after the Closing Date, except to the extent such modified or improved versions are covered by any valid claim(s) of
any issued patents included in, or any patents that issue from any pending patent applications or continuations included in, the Company Intellectual Property as of the Closing Date. If any Company Product is sold by Parent or any of its Affiliates
as part of a bundle or kit that incorporates or includes any other products or devices of Parent or any of its Subsidiaries for an aggregate price, then any calculation of Applicable Revenue for purposes of this <U>Section</U><U></U><U>&nbsp;4.2</U>
will include revenues reasonably allocated to the value of such Company Product in such bundle or kit as determined by Parent in good faith and in an amount that is not less than the average sales price of such Company Product to end users on a
standalone basis during the relevant Quarter. For the avoidance of doubt, in the event that any product becomes a Company Product pursuant to clause (C)&nbsp;of the definition thereof during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Period, then (1)&nbsp;Applicable Revenue with respect to such product shall be measured beginning on the date during the Applicable L4Q Period that such product becomes a Company Product and (2)&nbsp;the calculation of the Highwater Mark for such
Applicable L4Q Period and future Applicable L4Q Periods shall be adjusted to include the historical Applicable Revenue for such product in the relevant historical comparison periods (it being understood and agreed that only growth in Applicable
Revenue of such product from and after the date it becomes a Company Product, and not the amount of Applicable Revenue of the product on the date that it becomes a Company Product, will be included in the calculation of the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U>). For purposes of this Agreement, a &#147;<I><U>Quarter</U></I>&#148; refers to a three (3)&nbsp;calendar month period beginning on
January&nbsp;1, April&nbsp;1, July&nbsp;1, or October&nbsp;1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) For the avoidance of doubt, under no circumstances
will the aggregate of all of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration, if any, exceed the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Within seventy-five (75)&nbsp;days following the end of the first Applicable L4Q Period and within seventy-five (75)&nbsp;days following
each completed Quarter during the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period thereafter, Parent shall prepare and deliver its good faith calculation of (i)&nbsp;the aggregate Applicable Revenue and (ii)&nbsp;the Highwater Mark, in each
case for each of (x)&nbsp;such Quarter and (y)&nbsp;the Applicable L4Q Period ended as of the end of such Quarter (each, a &#147;<I><U>Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement</U></I>&#148;) to the Holder Representative,
together with a statement of the amount of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any) payable with respect to such Applicable L4Q Period. Parent shall deliver a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement to the Holder Representative following the completion of each Quarter after the Commencement Date until the earlier of the date
of delivery of (A)&nbsp;the Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement showing that the aggregate <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration has or, with the payment of the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration payable under such Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement, will have, reached the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap and (B)&nbsp;the Parent <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Statement with respect to the final Applicable L4Q Period of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period (the last Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement that is
required to be delivered under this <U>Section</U><U></U><U>&nbsp;4.2</U>, the &#147;<I><U>Final Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement</U></I>&#148;). Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statements
delivered on a semi-annual basis in connection with Quarters beginning on April&nbsp;1 or October&nbsp;1 shall also include a summary of material developments (as determined by Parent) with respect to the Company Product. A sample Parent <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Statement is attached to this Agreement as <U>Exhibit</U><U></U><U>&nbsp;4</U>. Parent shall prepare each Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement in a manner that is consistent in
form and substance in all respects with <U>Exhibit</U><U></U><U>&nbsp;4</U>, unless otherwise approved in writing by the Holder Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) From and after the delivery of each Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement, the Holder Representative and its
Representatives shall be permitted reasonable access to review Parent&#146;s working papers and supporting documents primarily related to the preparation of the Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement. The Parent <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Statement, and the amount of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any) set forth therein, shall become final and binding upon the parties upon the earlier of (x)&nbsp;thirty
(30) days following the Holder Representative&#146;s receipt thereof, unless the Holder Representative gives written notice of its disagreement (an &#147;<I><U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Notice of Disagreement</U></I>&#148;),
identifying in reasonable detail the specific items or amounts that are in dispute (the &#147;<I><U>Disputed Calculations</U></I>&#148;), to Parent on or prior to such date and (y)&nbsp;the date that Holder Representative notifies Parent of its
acceptance thereof. In the event that the Holder Representative submits an <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Notice of Disagreement, Parent and the Holder Representative will negotiate in good faith to resolve any differences in their
respective positions with respect to the Disputed Calculations set forth therein. If Parent and Holder Representative are unable to agree on the Disputed Calculations within forty-five (45)&nbsp;days of Parent&#146;s receipt of an <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Notice of Disagreement, then either Parent or Holder Representative may submit such Disputed Calculations to the Accounting Firm for review and resolution of the Disputed Calculations in accordance with the
procedures set forth in <U>Section</U><U></U><U>&nbsp;4.1(c)(i)</U>, except to the extent such disagreements rely on an interpretation of any Law or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Within ten (10)&nbsp;business days of the final determination of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if
any) achieved with respect to an Applicable L4Q Period in accordance with <U>Section</U><U></U><U>&nbsp;4.2(c)</U> above, Parent will (x)&nbsp;deposit with the Paying Agent for further distribution to the Holders in accordance with the Payment
Schedule an amount equal to the product of (A)&nbsp;the excess, if any, of (i)&nbsp;the applicable <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration, <I>minus</I> (ii)&nbsp;the aggregate amount of any and all Unpaid Indemnification
Claims as of such time that have not previously been deducted from a prior <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration payment (the &#147;<I><U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Payout Amount</U></I>&#148;),
<I>multiplied by</I> (B)&nbsp;the Holders&#146; Percentage, and (y)&nbsp;cause to be paid to the Participating Employees in accordance with the allocations set forth across from their respective names on <U>Schedule 4.2(d)</U>, through payroll on
the next regularly scheduled payroll date, an amount equal to the product of (A)&nbsp;the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Payout Amount, <I>multiplied by</I> (B)&nbsp;such Participating Employees&#146; Percentage. For purposes of
this <U>Section</U><U></U><U>&nbsp;4.2(d)</U>: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<I><FONT STYLE="white-space:nowrap">Carve-Out</FONT> Plan</I>&#148; means the
Biorez, Inc. Management <FONT STYLE="white-space:nowrap">Carve-Out</FONT> Plan adopted by the Company on August&nbsp;1, 2022, as amended from time to time in accordance with the terms thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<I><U>Holders&#146; Percentage</U></I>&#148; means, as of the applicable date of determination, an amount, expressed as a
percentage, equal to (x) 100%, <I>minus</I> (y)&nbsp;the Participating Employees&#146; Percentage; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<I><U>Participating
Employee</U></I>&#148; means each Employee set forth on <U>Schedule 4.2(d)</U> who has satisfied the eligibility requirements with respect to the payment of any Transaction Bonus (as defined in the <FONT STYLE="white-space:nowrap">Carve-Out</FONT>
Plan) pursuant to the terms and conditions of the <FONT STYLE="white-space:nowrap">Carve-Out</FONT> Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<I><U>Percentage
Interest</U></I>&#148; means, with respect to each Participating Employee, the &#147;Percentage Interest&#148; set forth next to the name of each Participating Employee on <U>Schedule 4.2(d)</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) &#147;<I><U>Participating Employees&#146; Percentage</U></I>&#148; means, as of the applicable date of determination, an amount,
expressed as a percentage, equal to the sum of the Percentage Interests of all Participating Employees, which amount shall in no event exceed 16.3641%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The right and power to enforce this <U>Section</U><U></U><U>&nbsp;4.2</U> against Parent shall reside entirely with the Holder
Representative (on behalf of the Holders), and none of the Holders shall be entitled to bring, commence, continue or prosecute any claim, legal action or proceeding under, in relation to, arising out of or in connection with a breach of this
<U>Section</U><U></U><U>&nbsp;4.2</U> or otherwise claiming that Parent has not complied with this <U>Section</U><U></U><U>&nbsp;4.2</U>. No Holder is permitted to assign its interest in the <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Consideration to any Person without the prior written consent of Parent; <U>provided</U>, <U>however</U>, that a Holder who is a natural person may assign its interest in the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration upon
written notice to Parent, the Holder Representative and the Paying Agent for bona fide estate planning purposes, either during his or her lifetime or on death by will or intestacy; <U>provided</U>, <U>further</U>, that the Holder Representative
shall be responsible for updating the Payment Schedule to reflect any valid assignment of a Holder&#146;s interest in the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company, the Holder Representative and the Holders hereby acknowledge and agree that, other than as required pursuant to
<U>Section</U><U></U><U>&nbsp;4.2(i)</U>, Parent (i)&nbsp;will have full control and sole discretion over the research and development, manufacturing, distribution, marketing and sales of the Company Product, including, for the avoidance of doubt,
all decisions regarding product design, clinical testing and research, licensing, product safety, regulatory approvals, compliance with Regulatory Laws and any orders or other requirements of the Federal Food and Drug Administration (the
&#147;<I><U>FDA</U></I>&#148;) or any other Governmental Entity, product recalls (whether voluntary or involuntary), (ii) disclaims any obligation or duty to take any action, or fail to take any action, including any obligation to commercialize or
employ any minimum level of efforts with respect to the commercialization of, the Company Product for any purpose, and (iii)&nbsp;together with its Subsidiaries and Affiliates, currently and may in the future develop, acquire and/or commercialize
products that compete with or replace the Company Product, and nothing set forth in this Agreement will restrict Parent or any of its Subsidiaries or Affiliates from such competitive activities. Notwithstanding the foregoing, during the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Period, Parent shall, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and shall cause the Surviving Corporation to, (i)&nbsp;generate and maintain accurate and complete books, records and financial statements necessary to allow Parent to accurately prepare the
Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statements, (ii)&nbsp;not, directly or indirectly, take any actions (or omit to take any actions) with the exclusive or primary purpose of avoiding or reducing the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U> and (iii)&nbsp;respond within a reasonable time period to reasonable requests for information by the Holder Representative with respect
to the Company Product and Applicable Revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) After the Closing, until the earlier of (A)&nbsp;the time when the aggregate <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration has reached the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap and (B)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period, Parent will not, and will cause
its Affiliates not to, consummate any transaction whereby a third-party purchaser acquires, directly or indirectly, (i)&nbsp;all or substantially all of the assets or (ii)&nbsp;beneficial ownership of more than fifty percent (50%) of the combined
voting power (including by merger, consolidation, recapitalization or other transaction) of any business unit or Subsidiary of Parent which conducts the sale of the Company Product (the &#147;<I><U>Change of Control Transaction</U></I>&#148;),
unless such third-party purchaser agrees in writing to assume all of Parent&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4.2(a)</U> upon the consummation of such Change of Control Transaction. Further to the foregoing, in the event that
both (x)&nbsp;a Change of Control Transaction is consummated on or prior to the first anniversary of the Closing Date and (y)&nbsp;during the one (1)-year period immediately following the consummation of the Change of Control Transaction, Parent and
its Affiliates permanently reduce budgeted spend on clinical trials for the Company Product as set forth in the operating plan applicable to the Company Product by more than 25% as compared to the one (1)-year period immediately prior to the
consummation of the Change of Control Transaction (other than, in each case, based on a commercially reasonable determination by Parent or any of its Affiliates made in connection with any adverse clinical trial results, patient or physician safety
concerns or compliance with applicable Laws), then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration payable in connection with the Final Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement shall equal the greater of
(x)&nbsp;the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration that would be payable for such Applicable L4Q Period in accordance with the terms and conditions of <U>Sections 4.2(a)(i)</U> and <U>(ii)</U>&nbsp;and (y) the Residual <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration. For purposes of this <U>Section</U><U></U><U>&nbsp;4.2(g)</U>, the &#147;<I><U>Residual <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</U></I>&#148; means an amount equal to
the lesser of (1)&nbsp;an amount equal to (A)&nbsp;the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap, <I>minus</I> (B)&nbsp;the aggregate <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration that is paid to the Holders prior to the
expiration of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period, and (2) $16,750,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The parties hereto further understand
and agree that, for U.S. federal income tax purposes, any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration received pursuant to this Agreement shall be treated as installment payments from an installment sale described in
Section&nbsp;453 of the Code, unless any Holder makes an election pursuant to Section&nbsp;453(d) of the Code, and a portion of which may be treated as imputed interest under Section&nbsp;483 of the Code. The parties shall report consistently with
such treatment, except as required by a final &#147;determination&#148; under Section&nbsp;1313 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) During the <FONT
STYLE="white-space:nowrap">Earn-out</FONT> Period, Parent agrees that it and its Subsidiaries shall not, and it shall cause its other Affiliates not to, without the prior written consent of the Holder Representative: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) provide clinical trial assistance to the Company (or other Subsidiary of division of
Parent that is operating the business of the Company and its Subsidiaries, as applicable) with respect to the BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> implant, including any modified or improved versions thereof, that is
worse in any material respect than the clinical trial assistance Parent provides for similarly situated products of Parent and its Subsidiaries, measured by type of product and revenue from commercial sales attributable to such other products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) discontinue the existence of the Surviving Corporation as a separate legal entity; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) fail to make timely maintenance fees or necessary filings, abandon, or allow to lapse or expire any Company Registered IP that is used
in, or required for the development, commercialization or manufacture of, the Company Products; <U>provided</U>, that the foregoing does not apply to any Company Registered IP exclusively licensed to the Company or its Subsidiaries, for which the
Company or its applicable Subsidiary is not responsible for maintenance or prosecution pursuant to the applicable Contract; <U>provided</U>, <U>further</U>, that in no event shall the foregoing require Parent or its Subsidiaries to engage in any
maintenance or prosecution with respect to such Company Registered IP except to the extent that the failure to maintain or prosecute would result in maintenance or prosecution provided for such Company Registered IP that is worse in any material
respect than the maintenance or prosecution commonly provided by Parent and its Subsidiaries in respect of registered Intellectual Property Rights of Parent and its Subsidiaries (other than the Surviving Corporation) that is similarly situated with
respect to commercial importance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Each party hereto acknowledges and agrees that the failure of a party to strictly comply with the
timing, documentation and other procedural requirements set forth in subsections (b), (c) and (d)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4.2</U>, as applicable, will not constitute a material breach or default under this Agreement, if any such
failure or breach, to the extent it is susceptible to cure, is cured promptly (and in any event within five (5)&nbsp;business days) following written notice of such failure from the Holder Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3. <U>Effect of the Merger on Capital Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Merger Sub</U>. At the Effective Time, by virtue of the Merger and without any action on the part of Parent or Merger Sub, each share
of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into one validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of
common stock, par value $0.001 per share, of the Surviving Corporation, and such shares shall constitute the only outstanding shares of capital stock of the Surviving Corporation. From and after the Effective Time, all certificates representing the
common stock of Merger Sub shall be deemed for all purposes to represent the number of shares of common stock of the Surviving Corporation into which they were converted in accordance with the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Securities and Equity Awards</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Shares</U>. At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or
the Holders, each Share shall no longer be outstanding and shall automatically be cancelled and retired and cease to exist, and each holder of a certificate representing any of the Shares (each, a &#147;<I><U>Certificate</U></I>&#148;) or a <FONT
STYLE="white-space:nowrap">non-certificated</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Share represented by book entry (a &#147;<I><U>Book-Entry Share</U></I>&#148;) shall cease to have any right with respect thereto (except (A)&nbsp;the right to receive the amount of Closing
Consideration (as described in further detail in <U>Section</U><U></U><U>&nbsp;4.4(b)(ii)</U> or <U>Section</U><U></U><U>&nbsp;4.4(b)(iii)</U>), (B) <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration allocated to each such Share pursuant
to the Payment Schedule, and (C)&nbsp;any amounts distributable to the Holders from the Holder Representative Expense Amount in accordance with <U>Section</U><U></U><U>&nbsp;4.1(e)</U> or the Purchase Price Adjustment Holdback pursuant to
<U>Section</U><U></U><U>&nbsp;4.1(c)</U> (collectively, with respect to each Holder, the &#147;<I><U>Holder Entitlement</U></I>&#148;)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Company Options</U>. Each Company Option (whether vested or unvested) that is unexpired and unexercised immediately prior to the
Effective Time shall, automatically and without any required action on the part of any Holder thereof, be deemed exercised and cancelled as of the Effective Time and converted into the right for the Holder thereof to receive (A)&nbsp;at the Closing,
cash in an amount equal to (1)&nbsp;the excess, if any, of the Closing Consideration allocated pursuant to the Payment Schedule to each Common Share covered by such Company Option immediately prior to the Effective Time (the &#147;<I><U>Per Share
Amount</U></I>&#148;) minus the per share exercise price of such Company Option, <I>multiplied by</I> (2)&nbsp;the number of Common Shares covered by such Company Option immediately prior to the Effective Time (it being understood that any Company
Option with an exercise price greater than the Per Share Amount will receive no cash at Closing in respect of this clause (A)) and (B)&nbsp;after the Closing, any other cash disbursements required to be paid to such Holder pursuant to the
Holder&#146;s applicable Holder Entitlement (as allocated to such Holder pursuant to the Payment Schedule, without duplication of any amounts paid in respect of clause (A)) (it being understood that any Company Option with an exercise price greater
than the Per Share Amount will receive cash in respect of this clause (B)&nbsp;solely to the extent such post-Closing per share cash disbursements plus the Per Share Amount exceed the exercise price of such Company Option and otherwise will be
cancelled without consideration), in each case, less applicable Taxes (clauses (A)&nbsp;and (B), collectively, the &#147;<I><U>Option Cashout Amount</U></I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Company Warrants</U>. Each Company Warrant that is unexpired and unexercised immediately prior to the Effective Time shall,
automatically and without any required action on the part of any Holder thereof, be deemed exercised and cancelled as of the Effective Time and converted into the right for the Holder thereof to receive such Holder&#146;s applicable Holder
Entitlement based on the number of Shares underlying such Company Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Convertible Promissory Notes.</U> Prior to the
Effective Time, the Company shall use its reasonable best efforts to obtain the written consent of the Holders of more than fifty percent (50%) of the outstanding aggregate principal amount of the Convertible Promissory Notes (but excluding any
Holder thereof who is related to, or is an entity formed, owned or controlled by the Company&#146;s Chief Executive Officer) of their election to treat the Convertible Promissory Notes in accordance with Section&nbsp;4.1.3(b) of the Convertible
Promissory Notes (the &#147;<I><U>Convertible Promissory Note Holder Election</U></I>&#148;). The outstanding principal and accrued, but unpaid, interest on each Convertible Promissory Note that is outstanding immediately prior to the Effective Time
shall, automatically and without any further action required on the part of any Holder thereof, be deemed cancelled as of the Effective Time and converted into the right for the Holder thereof to receive such Holder&#146;s applicable Holder
Entitlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Actions</U>. Prior to the Effective Time, the Company shall take all actions
reasonably necessary to effect the transactions anticipated by <U>Section</U><U></U><U>&nbsp;4.3(b)(ii)</U> under the Stock Plans and any award agreement applicable to any Company Option (whether written or oral, formal or informal), including by
obtaining, with respect to each Holder of Company Options, the receipt of an option cancellation agreement in the form attached as <U>Exhibit</U><U></U><U>&nbsp;5</U> (an &#147;<I><U>Option Cancellation Agreement</U></I>&#148;), and delivering
evidence reasonably satisfactory to Parent that all necessary determinations by the Company Board or applicable committee of the Company Board to treat the Company Options in accordance with <U>Section</U><U></U><U>&nbsp;4.3(b)(ii)</U> have been
made, and (B)&nbsp;by obtaining, with respect to each Holder of Company Warrants, the receipt of a warrant cancellation agreement in the form attached as <U>Exhibit</U><U></U><U>&nbsp;6</U> (a &#147;<I><U>Warrant Cancellation
Agreement</U></I>&#148;). The Company shall take all actions reasonably necessary to terminate the Stock Plans, such termination to be effective as of immediately prior to the Effective Time. Without limiting the foregoing, the Company shall take
all actions reasonably necessary to ensure that the Company will not at the Effective Time be bound by any options, stock appreciation rights, restricted stock units, warrants or other rights or agreements which would entitle any Person, other than
Parent, to own any capital stock of the Surviving Corporation or to receive any payment in respect thereof other than as provided for in this Agreement (including, for the avoidance of doubt, any payment set forth in an Option Cancellation
Agreement, or a Warrant Cancellation Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4. <U>Payment for and Exchange of Company Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Paying Agent</U>. At or prior to the Closing Date, Parent shall make available, or deposit, or cause to be made available to Acquiom
Financial LLC, a Colorado limited liability company in its capacity as payments administrator (the &#147;<I><U>Paying Agent</U></I>&#148;) a cash amount in immediately available funds equal to the Estimated Closing Consideration <I>minus </I>the
aggregate amount of the Closing Consideration required to be paid in respect of the Company Options held by employees of the Surviving Corporation in accordance with the Payment Schedule&nbsp;(such cash, as it may thereafter be adjusted, being
hereinafter referred to as the &#147;<I><U>Exchange Fund</U></I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Letter of Transmittal</U>. Promptly after the Effective Time, the Paying Agent shall deliver to each Holder identified in the Payment
Schedule&nbsp;(A) a letter of transmittal in customary form as mutually agreed to by Parent and the Company (the &#147;<I><U>Letter of Transmittal</U></I>&#148;) which shall specify that delivery shall be effected and risk of loss and title to the
applicable equity security shall pass, only upon proper delivery of Book-Entry Shares and Certificates, as applicable, to the Paying Agent, and (B)&nbsp;instructions for effecting the surrender of the Book-Entry Shares or Certificates (or affidavits
of loss in lieu of the Certificates as provided in <U>Section</U><U></U><U>&nbsp;4.4(e)</U>) to the Paying Agent representing Shares in exchange for the Closing Consideration. Proper delivery shall include (x)&nbsp;with respect to Book-Entry Shares,
only delivery of an authorization form in customary form regarding the <FONT STYLE="white-space:nowrap">book-entry</FONT> transfer of the <FONT STYLE="white-space:nowrap">Book-Entry</FONT> Shares (or such other evidence, if any, of the transfer as
the Paying Agent may reasonably request) and (y)&nbsp;with respect to Certificates, only delivery of the Certificates (or affidavits of loss in lieu of the Certificates as provided in <U>Section</U><U></U><U>&nbsp;4.4(e)</U>) to the Paying Agent.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Certificates</U>. Upon surrender of a Certificate (or an affidavit of loss in lieu
of the Certificate as provided in <U>Section</U><U></U><U>&nbsp;4.4(e)</U>) representing Shares to the Paying Agent, together with a duly-executed Letter of Transmittal and such other documents as may be reasonably required by Parent, the Paying
Agent or the Holder Representative (after the Closing), the holder of such Shares shall be entitled to receive in exchange therefor the portion of the Closing Consideration (and, (x)&nbsp;following the final determination thereof in accordance with
this Agreement, the portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any), (y) the portion of the Holder Representative Expense Amount (if any) released in accordance with <U>Section</U><U></U><U>&nbsp;4.1(e)</U> and
(z)&nbsp;the portion of the Purchase Price Adjustment Holdback (if any) that is paid to the Paying Agent in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)</U>, in each case allocated to such Holder in respect of such Shares as set forth on the
Payment Schedule) to which the holder of such Shares is entitled in accordance with the Payment Schedule, and the Certificates so surrendered shall forthwith be cancelled. No interest will be paid or will accrue on any amounts payable upon due
surrender of any such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Book-Entry Shares</U>. Each Holder of one or more Book-Entry Shares shall, upon receipt by the
Paying Agent of the &#147;agent&#146;s message&#148; (or such other evidence, if any, as the Paying Agent may reasonably request), be entitled to receive the portion of the Closing Consideration (and, (x)&nbsp;following the final determination
thereof in accordance with this Agreement, the portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any), (y) the portion of the Holder Representative Expense Amount (if any) released in accordance with
<U>Section</U><U></U><U>&nbsp;4.1(e)</U> and (z)&nbsp;the portion of the Purchase Price Adjustment Holdback (if any) that is paid to the Paying Agent in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)</U>, in each case allocated to such Holder
in respect of such Shares as set forth on the Payment Schedule) to which the holder of such Shares is entitled in accordance with the Payment Schedule, and the Book-Entry Shares so surrendered shall forthwith be cancelled. No interest will be paid
or will accrue on any amounts payable upon due surrender of any such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Equity Awards</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) <U>Employees</U>. At or prior to the Closing Date, Parent shall make available, or deposit, or cause to be made available
to the Surviving Corporation a cash amount in immediately available funds equal to the portion of the Closing Consideration (and, (x)&nbsp;following the final determination thereof in accordance with this Agreement, the portion of the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any), (y) the portion of the Holder Representative Expense Amount (if any) released in accordance with <U>Section</U><U></U><U>&nbsp;4.1(e)</U> and (z)&nbsp;the portion of the Purchase
Price Adjustment Holdback (if any) that is paid to the Paying Agent in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)</U>) required to be paid in respect of the Company Options held by employees of the Surviving Corporation as of the date of
such required payment in accordance with the Payment Schedule, and Parent shall cause the Surviving Corporation to promptly (but in any event, not later than the next payroll date following the required date of payment) pay such amounts to the
holders of Company Options who are employees of the Surviving Corporation through the payroll processing system of the Surviving Corporation in accordance with standard payroll practices and <U>Section</U><U></U><U>&nbsp;4.3(b)(ii)</U>;
<U>provided</U>, that the Surviving Corporation shall not be required to distribute the portion of the Closing Consideration (and, (x)&nbsp;following the final determination thereof in accordance with this Agreement, the portion of the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any), (y) the portion of the Holder Representative Expense Amount (if any) released in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;4.1(e)</U> and (z)&nbsp;the portion of the Purchase Price Adjustment Holdback (if any) that is paid to the Paying Agent in accordance with
<U>Section</U><U></U><U>&nbsp;4.1(c)</U>) payable to such Holders of Company Options prior to the receipt of an Option Cancellation Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) <U><FONT STYLE="white-space:nowrap">Non-Employees</FONT></U>. Each Holder of Company Options who is not an employee of the
Surviving Corporation on the Closing Date shall, upon receipt by the Paying Agent of an Option Cancellation Agreement, be entitled to receive the applicable Option Cashout Amount to which the Holder of such Company Options is entitled in accordance
with the Payment Schedule pursuant to <U>Section</U><U></U><U>&nbsp;4.3(b)(ii)</U>, and the Company Options held by such Holder shall forthwith be cancelled. No interest will be paid or will accrue on any amounts payable upon due surrender of any
such Company Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Warrants</U>. Each Holder of Company Warrants shall, upon receipt by the Paying Agent of a Warrant
Cancellation Agreement, be entitled to receive the portion of the Closing Consideration (and, (x)&nbsp;following the final determination thereof in accordance with this Agreement, the portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Consideration (if any), (y) the portion of the Holder Representative Expense Amount (if any) released in accordance with <U>Section</U><U></U><U>&nbsp;4.1(e)</U> and (z)&nbsp;the portion of the Purchase Price Adjustment Holdback (if any) that is
paid to the Paying Agent in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)</U>) to which the Holder of such Company Warrants is entitled in accordance with the Payment Schedule pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U>, and the Company
Warrants held by such Holder shall forthwith be cancelled. No interest will be paid or will accrue on any amounts payable upon due surrender of any such Company Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) <U>Other Equity Securities</U>. Reasonable procedures for delivering, surrendering and cancelling the Company&#146;s other equity
securities (other than Shares, Company Options and Company Warrants), if any, shall be communicated to the holders thereof promptly after the Effective Time, after consultation with the Holder Representative, and compliance with such procedures
shall be a condition of such Holders&#146; right to receive the applicable portion of the Closing Consideration in accordance with the Payment Schedule pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Transfers</U>. From and after the Effective Time, there shall be no transfers on the stock transfer books of the Company of the Shares
or other securities of the Company that were outstanding immediately prior to the Effective Time. If, after the Effective Time, any Certificate or other instrument representing Shares or other equity securities (other than Company Options) is
presented to the Surviving Corporation, Parent or the Paying Agent for transfer, it shall be (subject to compliance with the exchange procedures of <U>Section</U><U></U><U>&nbsp;4.4(b)</U>) cancelled and exchanged for the cash amount in immediately
available funds to which the Holder thereof is entitled pursuant to this <U>Article</U><U></U><U>&nbsp;IV</U>. In the event of a transfer of ownership of Shares that is not registered in the transfer records of the Company, a check for any cash to
be exchanged upon due surrender of the Certificate may be issued to such transferee if the Certificate formerly representing such Shares is presented to the Paying Agent, accompanied by all documents reasonably required to evidence and effect such
transfer and to evidence that any applicable stock transfer taxes have been paid or are not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Exchange Fund</U>. Any portion of the Exchange Fund that remains
unclaimed by the Holders three hundred and sixty-five (365)&nbsp;calendar days after the Effective Time shall be delivered to Parent. Following receipt of such payment by Parent, any Holder who has not theretofore complied with this
<U>Article</U><U></U><U>&nbsp;IV</U> shall thereafter look only to Parent and the Surviving Corporation as unsecured creditors for payment of their claim for Closing Consideration. Notwithstanding the foregoing, none of Parent, the Surviving
Corporation, the Holder Representative, the Paying Agent or any other Person shall be liable to any former holder of Shares in respect of any Closing Consideration properly delivered to a public official pursuant to any applicable abandoned
property, escheat or similar Law. For the purposes of this Agreement, the term &#147;<I><U>Person</U></I>&#148; shall mean any individual, corporation (including
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit),</FONT></FONT> general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, Governmental Entity or other entity
of any kind or nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Lost, Stolen or Destroyed Instruments</U>. If any Certificate or other instrument representing Shares or
other equity securities (other than Company Options) shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate or other instrument to be lost, stolen or destroyed and subject to
such other reasonable conditions as may be imposed by the Paying Agent (including, if required by the Paying Agent, the posting by such Person of a bond in such reasonable amount as the Paying Agent may reasonably direct as indemnity against any
claim that may be made against it with respect to such Certificate or other instrument), the Paying Agent shall pay in respect of such lost, stolen or destroyed Certificate or other instrument, without interest, the portion of the Closing
Consideration (and, (x)&nbsp;following the final determination thereof in accordance with this Agreement, the portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (if any), (y) the portion of the Holder Representative
Expense Amount (if any) released in accordance with <U>Section</U><U></U><U>&nbsp;4.1(e)</U> and (z)&nbsp;the portion of the Purchase Price Adjustment Holdback (if any) that is paid to the Paying Agent in accordance with
<U>Section</U><U></U><U>&nbsp;4.1(c)</U>) to which the holder of such Shares or other equity securities (other than Company Options), as applicable, is entitled in accordance with the Payment Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Appraisal Rights</U>. No Person who has perfected a demand for appraisal rights pursuant to Section&nbsp;262 of the DGCL (each such
Person, a &#147;<I><U>Dissenting Stockholder</U></I>&#148;) shall be entitled to receive the portion of the Aggregate Consideration to which such Person would otherwise be entitled pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> with respect to
the Shares owned by such Person unless and until such Person shall have effectively withdrawn or lost such Person&#146;s right to appraisal under the DGCL. Each Dissenting Stockholder shall be entitled to receive only the payment provided by
Section&nbsp;262 of the DGCL with respect to Shares owned by such Dissenting Stockholder. The Company shall give Parent (i)&nbsp;prompt notice of any written demands for appraisal, attempted withdrawals of such demands, and any other instruments
served pursuant to applicable Laws that are received by the Company relating to stockholders&#146; rights of appraisal and (ii)&nbsp;the opportunity to direct all negotiations and proceedings with respect to Dissenting Stockholders under the DGCL,
provided that the Company (prior to the Closing) and the Holder Representative (following the Closing) shall have the right to participate in such negotiations and proceedings at their own expense. Except to the extent otherwise permitted pursuant
to <U>Section</U><U></U><U>&nbsp;6.1(a)</U>, the Company shall not, except with the prior written consent of Parent, voluntarily make any payment with respect to any demands for appraisal, offer to settle or settle any such demands or approve any
withdrawal of any such demands. Parent shall be entitled to retain any portion of Aggregate Consideration not paid on account of such Shares owned by such Dissenting Stockholder pending resolution, withdrawal or loss of claims of such holders. If
any Person who would otherwise be deemed a Dissenting Stockholder shall have failed properly to perfect or shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have effectively withdrawn or lost the right to dissent with respect to any Shares, such Shares shall thereupon be treated as though such Shares had been converted into the right to receive a
portion of the Aggregate Consideration in accordance with the Payment Schedule pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U>. The aggregate amount, if any, by which any payment provided to Dissenting Stockholders by Section&nbsp;262 of the DGCL
exceeds the portion of the Closing Consideration to which such Dissenting Stockholders would otherwise be entitled pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> shall be subject to the indemnification obligations set forth in
<U>Section</U><U></U><U>&nbsp;9.2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Withholding Rights</U>. Each of Parent and the Surviving Corporation shall be entitled
to deduct and withhold from any consideration payable or otherwise deliverable to any Holder pursuant to this Agreement such amounts as it is required to deduct or withhold therefrom with respect to the making of such payment under the Code or any
other applicable state, local or foreign Tax Law; <U>provided</U>, <U>however</U>, that unless such deduction or withholding results from making a compensatory payment or as a result of the Company&#146;s failure to deliver the certificate described
in <U>Section</U><U></U><U>&nbsp;6.14(d)</U>, Parent and the Surviving Corporation shall provide five (5)&nbsp;business days&#146; notice to the applicable payee(s) prior to making such deduction or withholding (to the extent reasonably practicable
otherwise as soon as reasonably practicable), and shall reasonably cooperate with the applicable payee(s) to mitigate the imposition of any such deduction or withholding, to the extent commercially reasonable. To the extent such amounts are so
deducted or withheld by the Surviving Corporation or Parent, as the case may be, and timely paid over to the applicable Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to the Holder in
respect of which such deduction and withholding was made by the Surviving Corporation or Parent, as the case may be. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;V
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and Warranties </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1. <U>Representations and Warranties of the Company</U>. Except as set forth in the corresponding sections or subsections of the disclosure
letter delivered to Parent by the Company concurrently with the execution of this Agreement (the &#147;<I><U>Company Disclosure Letter</U></I>&#148;), the Company hereby represents and warrants to Parent and Merger Sub as of the date hereof and as
of the Closing Date (except in the case or representations and warranties that are made as of a specified date, in which case such representations and warranties are true and correct as of such specified date) that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization, Good Standing and Qualification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company and each of its Subsidiaries is a legal entity duly organized, validly existing and in good standing under the Laws of its
respective jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets and to carry on its business as presently conducted, except in the case of the Company&#146;s
Subsidiaries as would not reasonably be expected to be material to the operations of the Company and its Subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company and each of its Subsidiaries is qualified to do business and is in good
standing as a foreign corporation or other legal entity in each jurisdiction where the ownership, leasing or operation of its properties or assets or conduct of its business requires such qualification, except where the failure to obtain such
qualification or good standing would not be reasonably expected to have a Material Adverse Effect on the operations of the Company and its Subsidiaries, taken as whole. The Company has made available to Parent complete and correct copies of the
certificate of incorporation, bylaws or comparable governing documents in effect as of the date hereof (the &#147;<I><U>Organizational Documents</U></I>&#148;) of the Company and its Subsidiaries, and each such Organizational Document as so
delivered is in full force and effect. Section&nbsp;5.1(a) of the Company Disclosure Letter contains a correct and complete list of each jurisdiction where the Company and its Subsidiaries are organized and qualified to do business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term (i) &#147;<I><U>Subsidiary</U></I>&#148; means, with respect to any Person, any other Person of which at
least a majority of the securities or ownership interests having by their terms ordinary voting power to elect a majority of the board of directors (or other Persons performing similar functions) is directly or indirectly owned or controlled by such
Person and/or by one or more of its Subsidiaries, and (ii) &#147;<I><U>Material Adverse Effect</U></I>&#148; means any event, change, effect, development, state of facts, condition, circumstance or occurrence that (x)&nbsp;would reasonably be
expected to prevent, materially delay or materially impair the ability of the Company or Merger Sub to consummate the Transactions on the terms set forth herein or (y)&nbsp;has had or is reasonably expected to have, individually or taken together
with any or all other events, changes, effects, developments, state of facts, conditions, circumstances or occurrences, a material adverse effect on the condition (financial or otherwise), properties, assets, liabilities (contingent or otherwise),
business or results of operations of the Company and its Subsidiaries taken as a whole; <U>provided</U>, <U>however</U>, that none of the following, in and of itself or themselves, shall constitute a Material Adverse Effect: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) changes in the economy or financial markets generally in the United States or other countries in which the Company or its
Subsidiaries conducts material operations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) any acts of war (whether or not declared), armed hostilities, sabotage
(including by cyberattack), national emergency, or terrorism, or, in each case, the escalation or worsening thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)
changes that are the result of factors generally affecting the medical device industry in the United States or other countries in which the Company or its Subsidiaries conducts material operations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) changes in Laws (including changes in interpretations and enforcement thereof) or GAAP after the date hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(E) any loss of, or adverse change in, the relationship of the Company or its Subsidiaries with its customers, employees,
distributors, suppliers or other business relationships that was proximately caused by the pendency or the announcement of the transactions contemplated by this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(F) natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters,
earthquakes, hurricanes, tsunamis, tornadoes, hail, storms, lightning, droughts, floods, mudslides or other natural or manmade disasters, acts of God, weather-related conditions, health conditions, explosions or fires in the United States, or, in
each case, any worsening thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(G) any changes in financial, banking or securities markets in general, including any
disruption thereof and any decline in the price of any security or any market index or any change in prevailing interest, currency or exchange rates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(H) the continuation or worsening of effects caused by <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any other pandemic
or public health emergency; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(I) any action expressly required to be taken (or omitted to be taken) by this Agreement by
the Company or its Subsidiaries; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(J) any failure by the Company or its Subsidiaries to meet any internal or published
projections, forecasts or revenue or earnings predictions (but not any of the events underlying such failure to the extent such events would otherwise constitute a Material Adverse Effect under this definition); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>further</U>, that, with respect to clauses&nbsp;(A) through (G)&nbsp;such events, changes, effects, developments, state of facts,
conditions, circumstances or occurrences shall be taken into account in determining whether a &#147;Material Adverse Effect&#148; is occurring, has occurred, or would reasonably be expected to occur to the extent it disproportionately adversely
affects the Company and its Subsidiaries as compared to other companies of similar size operating in the medical device industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Capital Structure</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The authorized capital stock of the Company consists only of (A)&nbsp;10,500,000 shares of common stock,
par value $0.001 per share (the &#147;<I><U>Common Shares</U></I>&#148;), and (B)&nbsp;7,138,615 shares of preferred stock, par value $0.001 per share, comprised of (1)&nbsp;1,789,174 shares designated as &#147;Series
<FONT STYLE="white-space:nowrap">Seed-1</FONT> Preferred Stock&#148;, (2)&nbsp;1,762,441 shares designated as &#147;Series <FONT STYLE="white-space:nowrap">Seed-2</FONT> Preferred Stock&#148;, and (3)&nbsp;3,587,000 shares designated as <FONT
STYLE="white-space:nowrap">&#147;Series-3</FONT> Preferred Stock&#148;, (collectively, the &#147;<I><U>Preferred Shares</U></I>&#148;, and with the Common Shares, the &#147;<I><U>Shares</U></I>&#148;). As of the close of business on August&nbsp;1,
2022, only 775,370 Common Shares, 1,727,636 shares of Series <FONT STYLE="white-space:nowrap">Seed-1</FONT> Preferred Stock, 1,700,903 shares of Series <FONT STYLE="white-space:nowrap">Seed-2</FONT> Preferred Stock, and 3,587,000 shares of Series <FONT
STYLE="white-space:nowrap">Seed-3</FONT> Preferred Stock were outstanding. All of the outstanding Shares have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Other than (w)
1,825,080 Common Shares reserved for issuance pursuant to outstanding stock options (each such stock option, a &#147;<I><U>Company Option</U></I>&#148;) granted under the Company&#146;s 2009 Equity Compensation Plan, 2013 Equity Compensation Plan
and 2021 Equity Incentive Plan (collectively, the &#147;<I><U>Stock Plans</U></I>&#148;), (x) warrants to purchase 46,668 Common Shares, (y)&nbsp;warrants to purchase 61,538 shares of Series <FONT STYLE="white-space:nowrap">Seed-1</FONT> Preferred
Stock and (z)&nbsp;warrants to purchase 61,538 shares of Series <FONT STYLE="white-space:nowrap">Seed-2</FONT> Preferred Stock (the warrants referred to in clauses (x)&nbsp;through (z), collectively, the &#147;<I><U>Company Warrants</U></I>&#148;),
the Company has no additional Shares reserved for issuance. Upon any issuance of any Shares in accordance with the terms of the Stock Plan, such Shares will be duly authorized, validly issued, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free and clear of any lien, charge, pledge, security interest, claim or other encumbrance (each, a
&#147;<I><U>Lien</U></I>&#148;). As of August&nbsp;1, 2022, the Company has <FONT STYLE="white-space:nowrap">fifty-one</FONT> (51)&nbsp;convertible promissory notes (the &#147;<I><U>Convertible Promissory Notes</U></I>&#148;) issued and outstanding,
each of which shall be cancelled in accordance with <U>Section</U><U></U><U>&nbsp;4.3(b)(iv)</U>. Other than the Convertible Promissory Notes, the Company does not have outstanding any bonds, debentures, notes or other obligations the holders of
which have the right to vote (or which are convertible into or exercisable for securities having the right to vote) with the stockholders of the Company on any matter. The Company has delivered to Parent a true and complete copy of each form of
award agreement pertaining to each Company Option, and has also delivered any other award agreements pertaining to Company Options to the extent there are variations from the general forms, specifically identifying the Persons to which such variant
forms apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Set forth in Section&nbsp;5.1(b)(ii) of the Company Disclosure Letter is a true and correct list of each Holder
(which, for the avoidance of doubt, includes, but is not limited to, holders of the Shares, the Company Options, the Company Warrants and the Convertible Promissory Notes) as of the date hereof, that includes with respect to each Holder:
(A)&nbsp;the name of the Holder, (B)&nbsp;the number and type of securities held by the Holder, (C)&nbsp;in the case of the Preferred Shares, the series of Preferred Shares, the amount of accrued and unpaid dividends with respect to the Preferred
Shares and the number of Common Shares into which the Preferred Shares are convertible (including for purposes of the number of votes entitled to be cast by the Holder of such Preferred Shares on any matter submitted to the holders of Shares), in
each case as of the date of this Agreement, (D)&nbsp;in the case of Company Options, the purchase price or exercise price per Share, if applicable, and whether such Company Option is an incentive stock option or nonqualified stock option,
(E)&nbsp;in the case of the Company Warrants, the series of Company Warrants, and the exercise price per Share, and (F)&nbsp;in the case of the Convertible Promissory Notes, the amount of principal outstanding, the amount of accrued and unpaid
interest on the unpaid principal balance and the number of Shares into which each Convertible Promissory Note is convertible, in each case as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Except for the Company Options, the Company Warrants, the Convertible Promissory Notes and as otherwise set forth in
Section&nbsp;5.1(b)(iii) of the Company Disclosure Letter, there are no preemptive or other outstanding rights, options, warrants, conversion rights, stock appreciation rights, phantom stock rights, restricted stock rights, redemption rights,
repurchase rights, agreements, arrangements, calls, commitments or rights of any kind that obligate the Company or any of its Subsidiaries to issue or sell any shares of capital stock or other securities of the Company or any of its Subsidiaries or
any securities or obligations convertible or exchangeable into or exercisable for, or giving any Person a right to subscribe for or acquire, any securities of the Company or any of its Subsidiaries, and no securities or obligations evidencing such
rights are authorized, issued or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Section&nbsp;5.1(b)(iv) of the Company Disclosure Letter sets forth (A)&nbsp;each of
the Company&#146;s Subsidiaries and the ownership interest of the Company in each such Subsidiary, as well as the ownership interest of any other Person or Persons in each such Subsidiary and (B)&nbsp;the Company&#146;s or its Subsidiaries&#146;
capital stock, equity interest or other direct or indirect ownership interest in any other Person other than securities in a publicly traded company held for investment by the Company or any of its Subsidiaries and consisting of less than one
percent (1%) of the outstanding capital stock of such company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Each Company Option (A)&nbsp;was granted in compliance with all applicable Laws and, if
applicable, in compliance with all of the terms and conditions of the Stock Plans and award agreement pursuant to which it was issued, (B)&nbsp;has an exercise price per Share equal to or greater than the fair market value of a Share at the close of
business on the date of such grant, (C)&nbsp;has a grant date identical to or after the date on which the board of directors of the Company (the &#147;<I><U>Company Board</U></I>&#148;) or compensation committee thereof actually awarded such Company
Option, (D)&nbsp;qualifies for the Tax and accounting treatment afforded to such Company Option in the Company&#146;s Tax Returns, and (E)&nbsp;does not trigger any liability for the holder thereof under Section&nbsp;409A of the Code. Any Company
Option granted under the Stock Plans was granted in a compensatory capacity to employees or service providers (or former employees or service providers) of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment Schedule</U>. Set forth in <U>Schedule</U><U></U><U>&nbsp;5.1(c)</U> is a true and correct calculation as of the date of this
Agreement of the respective percentages of the Closing Consideration and the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration entitled to be received in accordance with <U>Article</U><U></U><U>&nbsp;IV</U> by holders of each of the
Company&#146;s outstanding (i)&nbsp;Common Shares, (ii)&nbsp;Preferred Shares, (iii)&nbsp;Company Options (taking into account the exercise price of each such Company Option), (iv) Company Warrants (taking into account the exercise price of each
such Company Warrant), (v) Convertible Promissory Notes and (v)&nbsp;any other securities of the Company (such schedule, including any amendments thereto, the &#147;<I><U>Payment Schedule</U></I>&#148;). Except as set forth in the Payment Schedule,
no other Person is entitled to any portion of the Closing Consideration or the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration pursuant to this Agreement. The Payment Schedule provides for the allocation and payment of the Aggregate
Consideration to the holders of Common Shares and Preferred Shares in a manner that is consistent with Section&nbsp;2.4.1 of Part C of Article FOURTH of the Company&#146;s certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Agreements with Holders</U>. The Contracts listed in Section&nbsp;5.1(d) of the Company Disclosure Letter will terminate and be of no
further force or effect from and after the Effective Time. No holders of the Company&#146;s equity securities will have any rights, and the Company will not have any obligations, under such Contracts from and after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Corporate Authority; Approval</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company has all requisite corporate power and authority and has taken all corporate action necessary in order to execute, deliver and
perform its obligations under this Agreement, and to consummate the Merger, subject only to adoption of this Agreement by the holders of a sufficient number of Shares required to approve such matter under the DGCL and the Company&#146;s
Organizational Documents (such approval, the &#147;<I><U>Requisite Stockholder Approval</U></I>&#148;). This Agreement has been duly executed and delivered by the Company and constitutes a valid and binding agreement of the Company enforceable
against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#146; rights and to general equity
principles (the &#147;<I><U>Bankruptcy and Equity Exception</U></I>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company Board has (A)&nbsp;unanimously determined that the Merger is fair to, and
in the best interests of, the Company and its stockholders, approved and declared advisable this Agreement, the Merger and the other transactions contemplated hereby (collectively, the &#147;<I><U>Transactions</U></I>&#148;) and resolved to
recommend adoption of this Agreement to the Company&#146;s stockholders (the &#147;<I><U>Company Recommendation</U></I>&#148;) and (B)&nbsp;directed that this Agreement be submitted to the stockholders for their adoption. The Company Board has taken
all action so that Parent will not be an &#147;interested stockholder&#148; or prohibited from entering into or consummating a &#147;business combination&#148; with the Company (in each case as such term is used in Section&nbsp;203 of the DGCL) as a
result of the execution of this Agreement or the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Requisite Stockholder Approval requires the
approval of the holders of (A)&nbsp;a majority of the Shares, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and (B)&nbsp;a majority of the Preferred Shares, voting together as a single class on
an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and no other approval or consent of any Holder is required for the Company to execute, deliver and perform its obligations under this Agreement or to consummate the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Governmental Filings; No Violations; Certain Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Other than the filings and/or notices pursuant to <U>Section</U><U></U><U>&nbsp;1.3</U> (the &#147;<I><U>Company
Approvals</U></I>&#148;), no notices, reports or other filings are required to be made by the Company with, nor are any consents, registrations, approvals, permits or authorizations required to be obtained by the Company from, any domestic or
foreign governmental or regulatory authority, agency, commission, body, court or other legislative, executive or judicial governmental entity (each a &#147;<I><U>Governmental Entity</U></I>&#148;), in connection with the execution, delivery and
performance of this Agreement by the Company and the consummation of the Merger and the other Transactions, or required in connection with the operation of the business of the Company and its Subsidiaries following the Effective Time, except those
that the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to prevent or materially delay or impair the ability of the Company and its Subsidiaries to consummate the Merger and the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as set forth in Section&nbsp;5.1(f)(ii) of the Company Disclosure Letter, the execution, delivery and performance of this
Agreement by the Company does not, and the consummation of the Merger and the other Transactions will not, constitute or result in (A)&nbsp;a breach or violation of, or a default under, the Organizational Documents of the Company or any of its
Subsidiaries, (B)&nbsp;with or without notice, lapse of time or both, a material breach or violation of, a termination (or right of termination) or a default under, the creation or acceleration of any obligations under or the creation of a Lien on
any of the assets of the Company or any of its Subsidiaries pursuant to any agreement, lease, license, contract, note, mortgage, indenture, arrangement or other obligation (each, a &#147;<I><U>Contract</U></I>&#148;) binding and material to on the
Company or any of its Subsidiaries or under any Law to which the Company or any of its Subsidiaries is subject, or (C)&nbsp;the loss or impairment of, payment of any additional amounts with respect to, or the consent of any other Person being
required in respect of, the Company&#146;s or any of its Subsidiaries&#146; ownership or use of, or its rights in or to, any Intellectual Property Rights. Section&nbsp;5.1(f)(ii) of the Company Disclosure Letter sets forth a correct and complete
list of Material Contracts pursuant to which consents or waivers are required prior to consummation of the Transactions (whether or not subject to the exception set forth with respect to clauses&nbsp;(B) and (C)&nbsp;above). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Financial Statements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company has made available to Parent true and complete copies of (A)&nbsp;the unaudited balance sheets of the Company as of
December&nbsp;31, 2021 and 2020, together with the related unaudited profits and losses statements of the Company for the fiscal years then ended, (B)&nbsp;the unaudited balance sheet of the Company as of June&nbsp;30, 2022 (the &#147;<I><U>Most
Recent Company Balance Sheet</U></I>&#148;), together with the related unaudited profit and loss statement of the Company for the six (6)&nbsp;month period then ended (clauses (A)&nbsp;and (B), collectively, the &#147;<I><U>Company Financial
Statements</U></I>&#148;), (C) the unaudited balance sheets of the Company&#146;s Subsidiaries as of June&nbsp;30, 2022 (the &#147;<I><U>Most Recent Subsidiary Balance Sheet</U></I>&#148;), June&nbsp;30, 2021 and 2020, together with the related
unaudited profits and losses statements of the Company&#146;s Subsidiaries for the fiscal years then ended (collectively, the &#147;<I><U>Subsidiary Financial Statements</U></I>,&#148; and collectively with the Company Financial Statements, the
&#147;<I><U>Financial Statements</U></I>&#148;). The Financial Statements were prepared in accordance with the Agreed Accounting Principles, consistently applied, and fairly present in all material respects the financial condition of the Company and
its Subsidiaries, taken as a whole, and its results of operations for the periods then ended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The respective books of account and
other records of the Company and its Subsidiaries are, in all material respects, complete and correct. The Company Financial Statements have been prepared in a manner consistent in all material respects with the books of account and other records of
the Company. The Subsidiary Financial Statements have been prepared in a manner consistent in all material respects with the books of account and other records of the Company&#146;s Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Except for (A)&nbsp;those liabilities that are reflected or reserved against on the Most Recent Company Balance Sheet,
(B)&nbsp;liabilities incurred in the ordinary course of business consistent with past practice since the date of the Most Recent Company Balance Sheet, and (C)&nbsp;obligations incurred pursuant to this Agreement, neither the Company nor any of its
Subsidiaries has incurred any liability of the type required to be set forth on a balance sheet prepared in accordance with GAAP that, individually or in the aggregate with other such liabilities, is or would reasonably be expected to be material.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Absence of Certain Changes</U>. Since December&nbsp;31, 2021, the Company and its Subsidiaries have conducted their respective
businesses only in, and have not engaged in any material transaction other than in accordance with, the ordinary course of such businesses consistent with past practices and there has not been, except as set forth in
<U>Section</U><U></U><U>&nbsp;5.1(h)</U> of the Company Disclosure Letter: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any material damage, destruction or other casualty loss with respect to any material asset or property owned, leased or otherwise used
by the Company or any of its Subsidiaries, whether or not covered by insurance; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any material change in any method of accounting or
accounting practice or internal controls (including internal controls over financial reporting) by the Company or any of its Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) except to the extent required by applicable Laws, (A)&nbsp;any (1) increase in the
compensation payable or to become payable to the officers or employees of the Company or any of its Subsidiaries, except increases with respect to employees in the ordinary course of business consistent with past practice or issuances of Company
Options, (2)&nbsp;payment to any director or officer of the Company or any of its Subsidiaries of any material bonus, making to any director or officer of the Company or any of its Subsidiaries of any material profit-sharing or similar payment,
except in the ordinary course of business consistent with past practice, or (3)&nbsp;grant to any director or officer of the Company or any of its Subsidiaries of any rights to receive severance, termination, retention or Tax <FONT
STYLE="white-space:nowrap">gross-up</FONT> compensation or benefits or (B)&nbsp;any establishment, adoption, entry into or amendment of any collective bargaining, bonus, profit sharing, thrift, compensation, employment, termination, severance or
other plan, agreement, trust, fund, policy or arrangement for the benefit of any director, officer or employee; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) taken any other
action that the Company or any of its Subsidiaries would be restricted from taking during the Interim Period pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any agreement to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<I><U>Company&#146;s Knowledge</U></I>,&#148; &#147;<I><U>Knowledge of the Company</U></I>&#148; and
similar formulations mean that one or more of Kevin Rocco, Jeffery Baird, or David Hook (i)&nbsp;has actual knowledge of the fact or other matter at issue or (ii)&nbsp;should have had actual knowledge of such fact or other matter assuming the
diligent exercise of such individual&#146;s duties as a director, officer or employee of the relevant member of the Company, as applicable, and after reasonable due inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Litigation</U>. There are no civil, criminal or administrative actions, suits, claims, hearings, arbitrations, investigations or other
proceedings before or by any Governmental Entity pending or, to the Company&#146;s Knowledge, threatened in writing against the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries is a party to or subject to the
provisions of any judgment, order, writ, injunction, decree or award of any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Employee Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Section&nbsp;5.1(j)(i) of the Company Disclosure Letter sets forth a true and correct list of each material Benefit Plan. For purposes of
this Agreement, &#147;<I><U>Benefit Plans</U></I>&#148; means all benefit and compensation plans, contracts, programs, practices, agreements, policies, arrangements or other obligations covering current or former employees of the Company and its
Subsidiaries (the &#147;<I><U>Employees</U></I>&#148;) and current or former directors or consultants (who are natural persons) of the Company and its Subsidiaries, whether or not in writing and whether or not funded, in each case, which are
sponsored, maintained or contributed to by the Company or any of its Subsidiaries, or to which the Company or any of its Subsidiaries is obligated to contribute, or with respect to which the Company or any of its Subsidiaries or any of their ERISA
Affiliates has any liability, direct or indirect, contingent or otherwise, including, but not limited to, &#147;employee benefit plans&#148; within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974
(&#147;<I><U>ERISA</U></I>&#148;), employment, consulting, retirement, vacation, deferred compensation, severance, termination, change in control, restricted stock, stock unit, phantom stock, stock option, stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase, stock appreciation rights, stock based, incentive, bonus, supplemental retirement, profit-sharing, insurance, medical, welfare, fringe or other benefit or remuneration plans, contracts,
programs, practices, policies or arrangements and including, for the avoidance of doubt, the Stock Plans and any agreements pertaining to the grant of any awards. True and complete copies of (A)&nbsp;all material Benefit Plans listed on
Section&nbsp;5.1(j)(i) of the Company Disclosure Letter, including, but not limited to, any amendments thereto, trust instruments, insurance contracts or other funding vehicles, as well as any summary plan descriptions, (B)&nbsp;a written
description of such Benefit Plan if such plan is not set forth in a written document and (C)&nbsp;all material correspondence to or from any Governmental Entity received in the last three (3)&nbsp;years with respect to any Benefit Plan, have been
made available to Parent. The term &#147;<I><U>ERISA Affiliate</U></I>&#148; means all employers (whether or not incorporated) that would be treated together with the Company or any of its Subsidiaries as a single employer within the meaning of
Section&nbsp;414 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;(A) Each Benefit Plan (including any related trusts) has been established, operated and
administered in compliance with its terms, ERISA, the Code and other applicable Laws in all material respects, (B)&nbsp;all contributions or other amounts payable by the Company or any of its Subsidiaries with respect to each Benefit Plan in respect
of current or prior periods have been paid or accrued in accordance with the Agreed Accounting Principles, and (C)&nbsp;there are no pending or, to the Company&#146;s Knowledge, threatened in writing, claims (other than routine claims for benefits)
or proceedings by a Governmental Entity by, on behalf of or against any Benefit Plan or any trust related thereto which could reasonably be expected to result in any liability to the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Each Benefit Plan which is subject to ERISA (an &#147;<I><U>ERISA Plan</U></I>&#148;) that is an &#147;employee pension benefit
plan&#148; within the meaning of Section&nbsp;3(2) of ERISA (a &#147;<I><U>Pension Plan</U></I>&#148;) and that is intended to be qualified under Section&nbsp;401(a) of the Code, has received a favorable determination letter from the Internal
Revenue Service (the &#147;<I><U>IRS</U></I>&#148;) or is entitled to rely upon a favorable opinion issued by the IRS, and, to the Company&#146;s Knowledge, nothing has occurred that would reasonably be expected to result in the loss of the
qualification of such plan under Section&nbsp;401(a) of the Code. Neither the Company nor any of its Subsidiaries has engaged in any transaction in connection with which the Company or any of its Subsidiaries reasonably could be subject to either a
civil penalty assessed pursuant to Section&nbsp;409 or 502(i) of ERISA or a tax imposed pursuant to Section&nbsp;4975 or 4976 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) With respect to each ERISA Plan, the Company has made available to Parent, to the extent applicable, (A)&nbsp;the most recent summary
plan description together with any summaries of all material modifications thereto, (B)&nbsp;the most recent opinion or determination letter from the IRS, (C)&nbsp;the two most recent annual reports (Form 5500 or 990 series and all schedules and
financial statements attached thereto) and (D)&nbsp;the most recently prepared actuarial report (if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) No Controlled Group
Liability has been incurred by the Company or its ERISA Affiliates that has not been satisfied in full, and, to the Company&#146;s Knowledge, no condition exists that presents a risk to the Company or its ERISA Affiliates of incurring any such
liability. &#147;<I><U>Controlled Group Liability</U></I>&#148; means any and all liabilities (A)&nbsp;under Title&nbsp;IV of ERISA, (B)&nbsp;under Section&nbsp;302 of ERISA, (C)&nbsp;under Sections&nbsp;412 and 4971 of the Code, and (D)&nbsp;as a
result of a failure to comply with the continuation coverage requirements of Section&nbsp;601 <I>et seq.</I> of ERISA and Section&nbsp;4980B of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) None of the Company, any of its Subsidiaries or any ERISA Affiliate has ever
maintained, established, participated in or contributed to, or is or has been obligated to contribute to, or has otherwise incurred any obligation or liability (including any contingent liability) under, any (A) &#147;multiemployer plans&#148;
within the meaning of Section&nbsp;3(37) of ERISA or (B)&nbsp;single employer pension plan within the meaning of Section&nbsp;4001(a)(15) of ERISA for which the Company or any of its Subsidiaries could incur liability under Section&nbsp;4063 or 4064
of ERISA. No Benefit Plan is a &#147;multiple employer welfare arrangement&#148; (as defined in Section&nbsp;3(40) of ERISA). No Benefit Plan is maintained outside the jurisdiction of the United States or covers any employees or other service
providers of the Company or any of its Subsidiaries who reside or work outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) There are no pending or, to
the Company&#146;s Knowledge, threatened, actions, suits, claims, hearings, arbitrations, investigations or other proceedings relating to any Benefit Plan. Neither the Company nor any of its Subsidiaries has any obligations to provide retiree or
post-employment medical, disability, life insurance or other welfare benefits and, except as required by applicable Law, no Benefit Plan provides such benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Each Benefit Plan that is a &#147;nonqualified deferred compensation plan&#148; (as such term is defined in Section&nbsp;409A(d)(1) of
the Code) has been administered in substantial compliance with its terms and the operational and documentary requirements of Section&nbsp;409A of the Code and the regulations and guidance issued by the IRS provided thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) Except as set forth on Section&nbsp;5.1(j)(ix) of the Company Disclosure Letter, none of the execution or delivery of this Agreement,
stockholder adoption or other approval of this Agreement, or the consummation of the Transactions will, either alone or in combination with another event, (A)&nbsp;entitle any Employees, directors, officers or consultants (who are natural persons)
of the Company or any of its Subsidiaries to any payment or benefit (including severance, bonus or otherwise), (B) accelerate the time of payment or vesting or result in any payment or funding (through a grantor trust or otherwise) of compensation
or benefits under, increase the amount payable or result in any other obligation pursuant to, any of the Benefit Plans, (C)&nbsp;limit or restrict the right of the Company or, after the consummation of the Transactions, Parent to merge, amend,
terminate or transfer the assets of any of the Benefit Plans, (D)&nbsp;directly or indirectly cause the Company to transfer or set aside any assets to fund any benefits under any Benefit Plan, (E)&nbsp;otherwise give rise to any liability under any
Benefit Plan or (F)&nbsp;result in the payment of any amount that could, individually or in combination with any other such payment, constitute an &#147;excess parachute payment&#148; as defined in Section&nbsp;280G(b)(1) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) Neither the Company nor any of its Subsidiaries has any obligation to provide, and no Benefit Plan or other agreement provides any
individual with the right to, a <FONT STYLE="white-space:nowrap">&#147;gross-up,&#148;</FONT> indemnification, reimbursement or other payment for any excise or additional taxes, interests or penalties incurred pursuant to Section&nbsp;409A or under
Section&nbsp;4999 of the Code or due to the failure of any payment to such disqualified individual to be deductible under Section&nbsp;280G of the Code, or otherwise. No Benefit Plan provides, or reflects or represents any liability to provide,
post-employment or retiree life insurance, health or other employee welfare benefits to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Person for any reason, except as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or other applicable statute, and the Company has never represented,
promised or contracted (whether in oral or written form) to any Employee (either individually or to Employees as a group) or any other person that such Employee(s) or other person would be provided with post-employment or retiree life insurance,
health or other employee welfare benefits, except to the extent required by statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) Each Benefit Plan can be amended, terminated
or otherwise discontinued after the Effective Time in accordance with its terms, without liability to the Company or any of its Subsidiaries other than ordinary administration expenses typically incurred in a termination event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Compliance with Laws; Licenses; Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2019, the businesses of each of the Company and its Subsidiaries have not been, and are not being, conducted in
material violation of any federal, state, local or foreign law, statute or ordinance, common law, or any rule, regulation, judgment, order, writ, injunction, decree, arbitration award, agency requirement, license or permit of any Governmental Entity
(collectively, &#147;<I><U>Laws</U></I>&#148;) applicable to the Company or its Subsidiaries. Since January&nbsp;1, 2019, except with respect to routine examinations of patent, trademark and copyright applications filed or to be filed with U.S. and
foreign patent offices, no investigation or review by any Governmental Entity with respect to the Company or any of its Subsidiaries is pending or, to the Company&#146;s Knowledge, threatened in writing, nor has any Governmental Entity indicated in
writing an intention to conduct the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) To the Company&#146;s Knowledge, no material change is required in the Company&#146;s or
any of its Subsidiaries&#146; processes, properties or procedures in order for the Company in connection with any such Laws, and the Company has not received any written or, to the Company&#146;s Knowledge, oral notice or communication of any
material noncompliance with any such Laws that has not been cured as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Each of the Company and its Subsidiaries
has obtained and is in compliance in all material respects with all permits, licenses, certifications, approvals, registrations, consents, authorizations, franchises, variances, exemptions and orders issued or granted by a Governmental Entity
(collectively, &#147;<I><U>Permits</U></I>&#148;) necessary to conduct its respective business as presently conducted, except for the failure to obtain a Permit which would not reasonably be expected to be material to the Company or its
Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) As to each product that is developed, manufactured, tested, distributed or marketed by the Company or any of its
Subsidiaries, including the BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> implant (a &#147;<I><U>Medical Device</U></I>&#148;), and that is subject to the Federal Food, Drug, and Cosmetic Act (the
&#147;<I><U>FDCA</U></I>&#148;), or similar Laws (including, to the extent applicable, Council Directive 93/42/EEC, and all related amendments, concerning medical devices and its implementing rules and guidance documents) in any foreign jurisdiction
where the Company or any of its Subsidiaries presently conducts their respective businesses (the FDCA and such similar Laws, collectively, the &#147;<I><U>Regulatory Laws</U></I>&#148;), each such Medical Device has been and is being developed,
manufactured, tested, distributed, promoted, commercialized or marketed in compliance with all applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements under the Regulatory Laws, including those relating to investigational use, premarket clearance or marketing approval to market a Medical Device, good manufacturing practices,
labeling, advertising, record-keeping, filing of reports and security, and, as required under applicable Laws, in compliance with the Advanced Medical Technology Association Code of Ethics on Interactions with Healthcare Professionals, except
failures in compliance that, individually or in the aggregate, have not had, and would not reasonably be expected to have, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Company has not received any written or, to the Company&#146;s Knowledge, oral notice or communication from the FDA or other
Governmental Entity alleging material noncompliance with any applicable Regulatory Laws. To the Knowledge of the Company, there are no pending or completed proceedings seeking the recall, withdrawal, suspension or seizure of any Medical Device
against the Company. To the Knowledge of the Company, the Company is not the subject of any current enforcement proceedings by the FDA or other Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Except as set forth in Section&nbsp;5.1(k)(vi) of the Company Disclosure Letter: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) The Company and its Subsidiaries are, and for the past three (3)&nbsp;calendar years have been, in compliance in all
material respects with, and each Medical Device regulated as a medical device under the Regulatory Laws in current commercial distribution is, and has been, designed, manufactured, prepared, assembled, packaged, labeled, stored, installed, serviced,
and processed in compliance in all material respects with, the Quality System Regulation set forth in 21 C.F.R. Part 820. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) The Company and its Subsidiaries are, and for the past three (3)&nbsp;calendar years have been, in compliance in all
material respects with the written procedures, record-keeping and the FDA reporting requirements for Medical Device Reporting set forth in 21 C.F.R. Part 803 and Reports of Corrections and Removals set forth in 21 C.F.R. Part 806. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) The Company has one Medical Device subject to the Regulatory Laws in current commercial distribution in the United States as an <FONT
STYLE="white-space:nowrap">FDA-regulated</FONT> medical device. This is a Class&nbsp;II medical device as defined under 21 U.S.C. &#167;&nbsp;360c(a)(1)(A), (B) and applicable rules and regulations thereunder, and was first marketed under, and is
covered by, a premarket notification owned and held exclusively by the Company and its Subsidiaries and in material compliance with 21 U.S.C. &#167;&nbsp;360(k) and the applicable rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) During the period of three (3)&nbsp;calendar years preceding the date hereof, the Company has not introduced into commercial
distribution any products manufactured by or on behalf of the Company or distributed any products on behalf of another manufacturer (collectively the &#147;<I><U>FDA Products</U></I>&#148;), which were upon their shipment by the Company adulterated
or misbranded in violation of 21 U.S.C. &#167;&nbsp;331. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) All FDA Products are and, since January&nbsp;1, 2019, have been labeled, promoted, and
advertised in compliance in all material respects with their 510(k) clearance or within the scope of their exemption from 510(k) clearance. The Company and its Subsidiaries&#146; facilities are registered with the FDA and each FDA Product is listed
with the FDA under the applicable registration and listing regulations for medical devices. As of the date hereof, the Company&#146;s facilities have not been inspected by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) The Company has made available to Parent true and complete copies of all material written information, including all existing written
summaries of material oral information, in the possession or control of the Company or any of its Subsidiaries or of which to the Company&#146;s Knowledge concerns the safety or efficacy of the Company&#146;s or any its Subsidiaries&#146; FDA
Products and services (including information associated with or derived from any preclinical or clinical use, studies (including <FONT STYLE="white-space:nowrap">pre-market</FONT> and post-market studies)), investigations or tests of the
Company&#146;s or any of its Subsidiaries&#146; FDA Products and services, including, but not limited to, such studies, investigations or tests submitted to the FDA or any comparable Governmental Entity, conducted by or at the request of the Company
or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) Section&nbsp;5.1(k)(xi) of the Company Disclosure Letter sets forth a list of all registrations,
clearances and approvals issued under the FDCA (collectively, the &#147;<I><U>FDCA Permits</U></I>&#148;) and held exclusively by the Company and its Subsidiaries. Such listed FDCA Permits constitute the only FDCA Permits required for the Company
and its Subsidiaries to conduct their respective businesses in the United States as presently conducted or as proposed to be conducted, except as would not be reasonably be expected to be material to the Company and its Subsidiaries, as a whole.
Each such FDCA Permit is in full force and effect and no suspension, revocation, cancellation or withdrawal of any such FDCA Permit is threatened and, to the Company&#146;s Knowledge, there is no basis for the Company to believe that any such FDCA
Permit will not be renewable upon expiration or will be suspended, revoked, cancelled or withdrawn. To the Company&#146;s Knowledge, there is no event, violation or other circumstance that would inhibit such FDCA Permit from continuing to exist in
full force and effect immediately following the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) Since January&nbsp;1, 2019 no Medical Device has been recalled,
withdrawn, suspended, seized or discontinued (other than for commercial or other business reasons) by the Company or any of its Subsidiaries in the United States or outside the United States (whether voluntarily or otherwise) and as of the date
hereof, none of such actions are under consideration by senior management of the Company or any of its Subsidiaries with respect to any Medical Device. As of the Closing Date, (A)&nbsp;to the Company&#146;s Knowledge, no Medical Device is the
subject of any recall, withdrawal, suspension, seizure or discontinuance by the Company or any of its Subsidiaries in the United States or outside the United States (whether voluntarily or otherwise), where such recall, withdrawal, suspension,
seizure or discontinuance would have a Material Adverse Effect and (B)&nbsp;none of the actions described in, and that would have the effect described in, the immediately preceding clause (A)&nbsp;is reasonably anticipated by senior management with
respect to any Medical Device as of the date hereof. There is no action, suit, claim, hearing, arbitration, investigation or other proceeding against the Company or any of its Subsidiaries or any licensee of any Medical Devices (whether completed or
pending) in the United States or outside of the United States seeking the recall, withdrawal, suspension, seizure or discontinuance of any Medical Device, which would reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) As to each Medical Device for which a premarket approval application, premarket
notification, investigational device exemption or similar state or foreign regulatory application has been approved, the Company and its Subsidiaries are in compliance in all material respects with 21 U.S.C. &#167;&nbsp;360, &#167;&nbsp;360(e) and
&#167;&nbsp;360(j) and 21 C.F.R. Parts 807, 812 and 814, respectively, and all other similar Regulatory Laws and all terms and conditions of such licenses or applications, except for any such failure or failures to be in compliance which would not
reasonably be expected to have a Material Adverse Effect. In addition, the Company and its Subsidiaries are in compliance in all material respects with all applicable registration and listing requirements set forth in 21 U.S.C. &#167;&nbsp;360 and
21 C.F.R. Part 807, Medical Device Reporting requirements set forth in 21 C.F.R. Part 803 and all other similar Regulatory Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv)
No article of any Medical Device manufactured for or distributed by the Company or any of its Subsidiaries is (A)&nbsp;adulterated within the meaning of 21 U.S.C. &#167;&nbsp;351 (or other similar Regulatory Laws), (B) misbranded within the meaning
of 21 U.S.C. &#167;&nbsp;352 (or other similar Regulatory Laws) or (C)&nbsp;a product that is in violation of 21 U.S.C. &#167;&nbsp;360 or &#167;&nbsp;360(e) (or other similar Regulatory Laws), except for any such failure or failures to be in
compliance with any of the foregoing that would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) None of the Company
or its Affiliates has received any written notice or other written communication from the FDA or any other Governmental Entity since January&nbsp;1, 2019 (i) contesting the premarket clearance or approval of, the uses of, or the labeling and
promotion of any product in any material respect, or (ii)&nbsp;otherwise alleging any material violation of any Law applicable to any Medical Device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) To the Company&#146;s Knowledge, all clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and other studies and tests
conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries, or in which the Company, its Subsidiaries, or the Company&#146;s Products have participated, were and, if still pending, are being conducted in compliance in all
material respects with the applicable regulations of any applicable Governmental Entity and other applicable Law, including C.F.R. Parts 50, 54, 56, 58, and 812. No preclinical or clinical trial conducted by or on behalf of the Company has been
terminated or suspended prior to completion for reasons of lack of safety or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable Health Care Laws. Since January&nbsp;1, 2019, the Company has not received any written notice or
correspondence, or other written communication from any Governmental Entity requiring or threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the
Company, its Subsidiaries, or the Company&#146;s Products have participated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) Neither the Company nor any of its Subsidiaries,
nor, to the Company&#146;s Knowledge, any officer, Employee or agent of the Company or any of its Subsidiaries, has made an untrue statement of a material fact or fraudulent statement to the FDA or any other Governmental Entity, failed to disclose a
material fact required to be disclosed to the FDA or any other Governmental Entity, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for
the FDA or any other Governmental Entity to invoke its policy respecting &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#148; set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy under any
other similar Regulatory Law. The Company is not the subject of any pending or, to the Company&#146;s Knowledge, threatened investigation by the FDA pursuant to its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xviii) Since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries has
received any written notice that the FDA or any other Governmental Entity has commenced, or threatened to initiate, any action to (A)&nbsp;withdraw clearance or approval or request the recall of any Medical Device, (B)&nbsp;enjoin production of any
Medical Device or (C)&nbsp;enjoin the production of any medical devices produced at any facility owned or operated by or on behalf of the Company where any Medical Device is manufactured, tested or packaged. There has not been any violation of Law
by the Company or its Subsidiaries in their product development efforts, submissions, record keeping and reports to FDA that could reasonably be expected to require or lead to investigation, corrective action or enforcement, regulatory or
administrative action that would result in a Material Adverse Effect. To the Company&#146;s Knowledge, there are no civil or criminal proceedings relating to the Company or its Subsidiaries or any Company or Subsidiary employee which involve a
matter within or related to the FDA&#146;s jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xix) Without limiting this <U>Section</U><U></U><U>&nbsp;5.1(k)</U>, since
January&nbsp;1, 2019, the Company and its Subsidiaries and their respective operations are and have been conducted in compliance in all material respects with all Health Care Laws applicable to the Company and its Subsidiaries enforced by the United
States Department of Health and Human Services and its constituent agencies, including the Centers for Medicare&nbsp;&amp; Medicaid Services and the Office of Inspector General, and the United States Department of Justice (the
&#147;<I><U>DOJ</U></I>&#148;). For purposes of this Agreement, &#147;<I><U>Health Care Laws</U></I>&#148; means all Laws relating to participation in Federal Health Care Programs, the False Claims Act (31 U.S.C. &#167;&nbsp;3729 <I>et seq.</I>),
the Civil Monetary Penalties Law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a),</FONT> the Physician Payment Sunshine Act, federal and state anti-kickback statutes (including 42 U.S.C.
<FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b),</FONT> federal and state referral laws (including 42 U.S.C. &#167;&nbsp;1395nn), criminal false claims statutes (e.g., 18 U.S.C. &#167;&#167;&nbsp;287 and 1001), the Program Fraud Civil
Remedies Act of 1986 (31 U.S.C. &#167;&nbsp;3801 <I>et seq.</I>), the Beneficiary Inducement Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a(a)(5)),</FONT> and HIPAA and the rules and regulations promulgated under the
foregoing statutes, and comparable laws in other jurisdictions where the Company or its Subsidiaries presently conducts business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xx)
The Company and its Subsidiaries have implemented a compliance program and conflict of interest process that complies in all material respects with the guidance regarding an effective corporate compliance and ethics program identified in U.S.S.G.
&#167;&nbsp;8B2.1 and the principles established by the Department of Health and Human Services, Office of Inspector General (the &#147;<I><U><FONT STYLE="white-space:nowrap">HHS-OIG</FONT></U></I>&#148;). The compliance program includes policies,
procedures, and training addressing, in material respects, compliance with applicable laws described in this <U>Section</U><U></U><U>&nbsp;5.1(k)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxi) Since January&nbsp;1, 2019, the Company has tracked and appropriately reported any reportable payments or transfers of value in
compliance with the federal Physician Payments Sunshine Act, 42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7h</FONT> or a comparable applicable Law, except where failure to do so would not be reasonably expected to cause a Material
Adverse Effect on the Company and its Subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxii) The Company has provided in Section&nbsp;5.1(k)(xxii) of the Company Disclosure
Letter a complete list of physicians and healthcare professionals that, to the Company&#146;s Knowledge, have a contractual or other financial relationship (including any ownership interests) with the Company or any of its Subsidiaries as of the
date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxiii) Neither the Company nor any of its Subsidiaries, nor, to the Company&#146;s Knowledge, any officer, director,
Employee, contractor or agent of the Company or any of its Subsidiaries is, or is in anticipation of being (based on a conviction by the courts or a finding of fault by a Governmental Entity): (A) debarred pursuant to the Generic Drug Enforcement
Act of 1992 (21 U.S.C. &#167;&nbsp;335a), or any similar applicable Law; (B)&nbsp;disqualified from participating in clinical trials pursuant to 21 C.F.R. &#167;&nbsp;312.70 or &#167;&nbsp;812.119; (C) disqualified as a testing facility under 21
C.F.R. Part 58, Subpart K; (D)&nbsp;excluded, debarred or suspended from or otherwise ineligible to participate in a &#147;Federal Health Care Program&#148; as defined in 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(f)</FONT> or any other
governmental payment, procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> program; or (E)&nbsp;included on the <FONT STYLE="white-space:nowrap">HHS-OIG</FONT> List of Excluded Individuals/Entities, the General Services
Administration&#146;s List of Parties Excluded from Federal Programs, or the FDA Debarment List. To the Company&#146;s Knowledge, none of the Company&#146;s officers, directors, Employees, contractors, or agents have engaged in any activity that
would reasonably be expected to lead to any of the results described in this <U>Section</U><U></U><U>&nbsp;5.1(k)(xxiii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxiv)
Neither the Company nor any of its Subsidiaries has been or is the subject of any material actions, suits, claims, hearings, arbitrations, investigations or other proceedings that have been filed, commenced or, to the Company&#146;s Knowledge,
threatened in writing, by any Person, including by the U.S. Department of Health and Human Services, the Centers for Medicare&nbsp;&amp; Medicaid Services, the <FONT STYLE="white-space:nowrap">HHS-OIG,</FONT> the DOJ, state Attorneys General, state
Medicaid agencies, state Medicaid Fraud Control Units, or any other Person against the Company nor any of its Subsidiaries or, to the Company&#146;s Knowledge, any of its or their respective members, directors, managers, officers, employees, or
independent contractors acting on behalf of the Company or any of its Subsidiaries, alleging any failure to comply with any Health Care Law in the conduct of their respective businesses. The Company has not received from any Governmental Entity any
inspection reports, written notices of adverse findings, warning letters, untitled letters, suspension, consent decree, written notice of criminal investigation, indictment, sentencing memorandum, plea agreement, court order or target or <FONT
STYLE="white-space:nowrap">no-target</FONT> letter or other correspondence concerning the Company or the Medical Devices in which any Governmental Entity asserted that the Medical Devices or the Company&#146;s operations or business may not be in
material compliance with applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxv) None of the Company, its Subsidiaries or, to the Company&#146;s Knowledge, any of their
Representatives has directly or indirectly offered, paid or accepted any remuneration or other thing of value that is prohibited by applicable Law, including without limitation the Federal Anti-Kickback Statute, 42 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(b)</FONT> and the United States Foreign Corrupt Practices Act of 1977. None of the Company, its Subsidiaries or, to the Company&#146;s Knowledge, any of their Representatives has directly or indirectly
made or agreed to make any contribution, gift, bribe, rebate, payoff, influence payment, kickback or similar payment to any Person, including (A)&nbsp;to obtain favorable treatment in securing business, (B)&nbsp;to pay for favorable treatment for
business secured, (C)&nbsp;to obtain special concessions or pay for special concessions already obtained, or (D)&nbsp;in connection with the approval or regulatory status of the Medical Devices or the facilities in which the Medical Devices are
manufactured, packaged or stored, or from which Medical Devices are initially distributed, except where, in each case, solely with respective to their Representatives, such action would be reasonably expected to have a Material Adverse Effect on the
Company and its Subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxvi) To the Company&#146;s Knowledge, there are no facts, circumstances or conditions
that would reasonably be expected to form the basis for any investigation, suit, claim, action, proceeding or imposition of any penalties against or affecting the Company and its Subsidiaries relating to or arising under (x)&nbsp;the FDCA or
(y)&nbsp;the federal health care programs under Section&nbsp;1128 or Section&nbsp;1877 of the Social Security Act of 1935 or regulations of the <FONT STYLE="white-space:nowrap">HHS-OIG,</FONT> in each case that has had, or would reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Material Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Section&nbsp;5.1(l)(i) of the Company Disclosure Letter sets forth an accurate and complete list of each Contract that is described in
any of the following subsections&nbsp;(A) through (M)&nbsp;to which the Company is a party (collectively, the &#147;<I><U>Material Contracts</U></I>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) any Contract involving the fixed payment (or present obligation to pay) or receipt of royalties or other amounts of more
than $100,000 in the aggregate in any twelve (12)-month period calculated based upon the revenues or income of the Company or any of its Subsidiaries or income or revenues related to any product of the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) any Contract with any Holder, other than consulting agreements, offer letters and employment agreements in each case
entered into in the ordinary course of business, agreements for the purchase of equity securities of the Company, award agreements for Company Options or Company Warrants and Convertible Promissory Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) any Contract containing any standstill or similar agreement pursuant to which the Company or any of its Subsidiaries has
agreed not to acquire assets or securities of another Person or any of its Affiliates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) any Contract providing for
indemnification by the Company or any of its Subsidiaries of any Person, except for <FONT STYLE="white-space:nowrap">non-material</FONT> Contracts entered into in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(E) any Contract that was not negotiated and entered into on an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT>
basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(F) any <FONT STYLE="white-space:nowrap">non-competition</FONT> Contract or other Contract that (1)&nbsp;purports
to limit in any material respect either the type of business in which the Company or any of its Subsidiaries (or, after the Effective Time, Parent or its Subsidiaries) may engage or the manner or locations in which any of them may so engage in any
business, (2)&nbsp;provides for, in all or certain circumstances, the disposition of any material assets or line of business of the Company or any of its Subsidiaries or, after the Effective Time, Parent or its Subsidiaries, (3)&nbsp;grants
&#147;most favored nation&#148; status that, following the Merger, would apply to Parent or its Subsidiaries, including the Company or its Subsidiaries or (4)&nbsp;prohibits or limits the Company&#146;s or any of its Subsidiaries&#146; right to
make, sell or distribute any products or services or use, transfer, license, distribute or enforce any Company Intellectual Property; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(G) any Contract pursuant to which the Company or any of its Subsidiaries
(1)&nbsp;grants or shares any license, sublicense, covenant not to sue, ownership right (including joint ownership right), option to acquire, release or similar right under any Intellectual Property Rights material to their respective businesses,
other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted to customers (solely to permit such customers&#146; use of the Company&#146;s and its Subsidiaries&#146; products and services) or third-party service providers
(solely for the purpose of facilitating their provision of services to or on behalf of the Company and its Subsidiaries), in each case, in the ordinary course of business, or (2)&nbsp;receives any license, sublicense, covenant not to sue, ownership
right (including joint ownership right), option to acquire, release, or similar right under any Intellectual Property Rights material to their respective businesses, other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted
on standardized, commercially available terms for <FONT STYLE="white-space:nowrap">non-customized</FONT> software; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(H)
any Contract that contains a put, call or similar right pursuant to which the Company or any of its Subsidiaries could be required to purchase or sell, as applicable, any equity interests of any Person or assets that have a fair market value or
purchase price of more than $100,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(I) any joint venture Contract, partnership arrangements or other Contracts
involving a sharing with any third party of profits, losses, costs or liabilities by the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(J) any Contract that restricts the ability of the Company or any of its Subsidiaries from (1)&nbsp;paying dividends or making
any other distributions in respect of any capital stock or other equity interests of such Person, or paying Indebtedness owed to any of its Affiliates, (2)&nbsp;making loans or advances to, or other investments in, any of its Affiliates, or
(3)&nbsp;transferring any of its assets to any of its Affiliates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(K) except for the Convertible Promissory Notes, any
Contract relating to Indebtedness and any swap, option, derivative or other hedging agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(L) any Contract involving
payments by the Company in excess of $100,000 in the aggregate in any twelve (12)-month period (1)&nbsp;relating to research or development or clinical studies to gather safety and effectiveness data about a Medical Device to support a premarket
application or premarket notification, (2)&nbsp;relating to the sale, distribution, supply, licensing, <FONT STYLE="white-space:nowrap">co-promotion,</FONT> marketing or manufacturing of any Medical Device, or (3)&nbsp;with any distributor of any
Medical Device, except in each case for any such Contract that is entered into in the ordinary course of business; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(M) any Contract that would prevent, materially delay or materially impede the Company&#146;s ability to consummate the Merger
or other Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each of the Material Contracts is valid and binding on the Company or any of its
Subsidiaries, as the case may be, and, to the Company&#146;s Knowledge, each other party thereto and is in full force and effect, except for such failures to be valid and binding or to be in full force and effect as would not, or would not
reasonably be expected to, individually or in the aggregate, be material to the Company or any of its Subsidiaries. There is no default under any such Contracts by the Company or any of its Subsidiaries and, to the Company&#146;s Knowledge, no event
has occurred that with the lapse of time or the giving of notice or both would constitute a default thereunder by the Company or any of its Subsidiaries, in each case except as would not, individually or in the aggregate, reasonably be expected to
be material to the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Real Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) With respect to the real property leased or subleased to the Company or any of its Subsidiaries (the &#147;<I><U>Leased Real
Property</U></I>&#148;), the lease or sublease for such property is valid, legally binding, enforceable and in full force and effect, and none of the Company or any of its Subsidiaries is in breach of or default under such lease or sublease, to the
Company&#146;s Knowledge, and no event has occurred which, with notice, lapse of time or both, would constitute a breach or default by the Company or any of its Subsidiaries or permit termination, modification or acceleration by any third party
thereunder, or prevent, materially delay or materially impair the consummation of the Merger or the other Transactions, except in each case, for such invalidity, failure to be binding, unenforceability, ineffectiveness, breaches, defaults,
terminations, modifications, accelerations or repudiations that are not, or would not, individually or in the aggregate, reasonably be expected to be material to the Company or any of its Subsidiaries. The Company has made available to Parent a
complete and correct copy of all leases pertaining to the Leased Real Property, each as amended to the date hereof, and each as so delivered is in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Company, or one of its Subsidiaries, owns good title to, or holds pursuant to valid and enforceable lease agreements, all of the
personal property shown to be owned or leased by it on the Most Recent Company Balance Sheet or Most Recent Subsidiary Balance Sheet (other than assets disposed of in the ordinary course subsequent to the date of the Most Recent Company Balance
Sheet or Most Recent Subsidiary Balance Sheet), free and clear of all Liens other than Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <U>Takeover Statutes</U>. No
&#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share acquisition&#148; or other similar anti-takeover statute or regulation (each, a &#147;<I><U>Takeover Statute</U></I>&#148;) or any anti-takeover provision in the Company&#146;s
Organizational Documents is applicable to the Company, the Shares, the Merger or the other Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <U>Environmental Matters</U>. (i)&nbsp;Since January&nbsp;1, 2019, the Company and its
Subsidiaries have complied at all times in all material respects with all applicable Environmental Laws and are currently in material compliance with all applicable Environmental Laws; (ii)&nbsp;to the Company&#146;s Knowledge, no real property
currently leased or operated by the Company or any of its Subsidiaries is contaminated with any Hazardous Substance requiring remediation pursuant to any Environmental Law; (iii)&nbsp;neither the Company nor any of its Subsidiaries is subject to
liability for any Hazardous Substance disposal or contamination on any third-party property; (iv)&nbsp;since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries has received any written notice, demand, letter, claim or request for
information alleging that the Company or any of its Subsidiaries may be in violation of, or subject to liability under, any Environmental Law; (v)&nbsp;neither the Company nor any of its Subsidiaries is subject to any order, decree, or injunction
with any Governmental Entity or any indemnity or other agreement with any third party relating to liability under any Environmental Law or liability relating to Hazardous Substances; (vi)&nbsp;the Company has delivered to Parent copies of all
environmental reports, studies, assessments, sampling data and other environmental information in its possession relating to the Company or any of its Subsidiaries or their respective current properties or operations; (vii)&nbsp;to the
Company&#146;s Knowledge, no events have occurred involving Company or any of its Subsidiaries that could reasonably be expected to result in any material claim, liability or investigation pursuant to any Environmental Law; and (viii)&nbsp;the
Company and its Subsidiaries possess all permits, licenses, registrations, identification numbers, authorizations and approvals required under applicable Environmental Laws, except where the failure to possess any such permit would not have a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#147;<I><U>Environmental Law</U></I>&#148; means any Law relating to: (x)&nbsp;the
protection, investigation or restoration of the environment, health, safety, or natural resources, (y)&nbsp;the handling, use, presence, disposal, release or threatened release of any Hazardous Substance or (z)&nbsp;noise, odor, indoor air, employee
exposure, wetlands, pollution, contamination or any injury or threat of injury to persons or property relating to any Hazardous Substance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#147;<I><U>Hazardous Substance</U></I>&#148; means any substance that is: (x)&nbsp;listed, classified or regulated
as a &#147;Hazardous Substance,&#148; &#147;Hazardous Waste,&#148; &#147;Hazardous Material,&#148; or &#147;Toxic Substance&#148; pursuant to any Environmental Law; (y)&nbsp;medical waste, infectious or biohazardous substances, any petroleum product
or <FONT STYLE="white-space:nowrap">by-product,</FONT> asbestos-containing material, lead-containing paint or plumbing, polychlorinated biphenyls, mold, per and polyfluoroalkyl substances, radioactive material or radon; and (z)&nbsp;any other
substance which is regulated under Environmental Law due to a potential for harm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <U>Taxes</U>. Except as disclosed on
Section&nbsp;5.1(p) of the Company Disclosure Letter: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company and each of its Subsidiaries: (A)&nbsp;have duly and timely filed
(taking into account any valid extension of time within which to file) all U.S. federal income, and other material Tax Returns required to be filed by any of them with the appropriate taxing authority and all such filed Tax Returns are complete and
accurate in all material respects; (B)&nbsp;have duly and timely paid all U.S. federal income, and other material Taxes that are required to be paid by the Company or any of its Subsidiaries (whether or not shown on any Tax Returns); (C) have
withheld and timely paid to the appropriate taxing authorities all material Taxes in material compliance with all Tax withholding provisions; and (D)&nbsp;have materially complied with all information reporting (and related withholding) and record
retention requirements in respect of any material Tax matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) There are no material closing agreements, private letter rulings, gain recognition
agreements, technical advance memoranda or similar agreements or rulings that have been entered into by the Company or issued by any taxing authority in respect of any Tax matters with respect to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) No issues that have been raised by the relevant taxing authority in connection with any examination of the Tax Returns referred to in
<U>Section</U><U></U><U>&nbsp;5.1(p)(i)</U> above are currently pending, no such Tax Return is currently being examined by any taxing authority to the Knowledge of the Company, nor have the Company or any of its Subsidiaries received any notice in
writing or to the Knowledge of the Company from a taxing authority that it intends to conduct such examinations, and all deficiencies asserted or assessments made, if any, as a result of any such examinations have been paid in full, settled or
withdrawn. There are no Liens for Taxes (other than Taxes not yet due and payable or that are being contested in good faith and for which appropriate reserves have been established in accordance with GAAP) upon any of the assets of the Company or
any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Neither the Company nor any of its Subsidiaries is a party to any material Contract or arrangement
providing for allocation, sharing or indemnification with respect to Taxes with a Person other than the Company or any of its Subsidiaries (other than any such customary commercial Contract or arrangement entered into in the ordinary course of
business consistent with past practice, the primary subject matter of which is not Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) No written claim which has not been
finally resolved has been made by a Governmental Entity in a jurisdiction where the Company or any of its Subsidiaries does not file Tax Returns that it is or may be subject to taxation by, or required to file any Tax Return in, that jurisdiction
and no claim which has not been finally resolved has been made by a Governmental Entity in a jurisdiction where the Company or any of its Subsidiaries does not file a Tax Return with respect to any type of Tax that the Company or any of its
Subsidiaries is required to file any Tax Return with respect to Taxes of such type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Neither the Company nor any of its Subsidiaries
is, or during the past five (5)&nbsp;years has been, a &#147;United States real property holding corporation&#148; within the meaning of Section&nbsp;897 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Neither the Company nor any of its Subsidiaries has participated in any &#147;listed transaction&#148; (within the meaning of
Section&nbsp;6011 of the Code and the Treasury Regulations thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Neither the Company nor any of its Subsidiaries has ever
been a member of any consolidated, combined, unitary or similar Tax group other than a group of which the Company or any of its Subsidiaries is or was a common parent or has transferee or successor liability for the unpaid Taxes of any other Person
under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or foreign Law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) Neither the Company nor any of its Subsidiaries (A)&nbsp;has been granted any
extension for the assessment or collection of Taxes (other than pursuant to extensions of time to file Tax Returns either granted automatically or obtained in the ordinary course of business), (B) has extended or waived the application of any
statute of limitations of any jurisdiction regarding the assessment or collection of any Taxes or (C)&nbsp;has granted to any Person any power of attorney that is currently in force with respect to any Tax matter (except for a power of attorney that
will not be in force after the Closing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) Neither the Company nor any of its Subsidiaries will be required to include any material
item of income in, or to exclude any material item of deduction from, taxable income in any taxable period (or portion thereof) ending after the Closing Date as a result of any closing agreement as described in Section&nbsp;7121 of the Code (or any
similar provision of state, local or foreign Law), installment sale or open transaction on or prior to the Closing Date, any accounting method change or agreement with any Tax authority, any prepaid amount received on or prior to the Closing Date,
any intercompany transaction or excess loss account described in Section&nbsp;1502 of the Code (or any corresponding provision of state, local or foreign Law), or any election pursuant to Section&nbsp;108(i) of the Code (or any similar provision of
state, local or foreign Law) made with respect to any taxable period ending on or prior to the Closing Date. Neither the Company nor any of its Subsidiaries will be liable for Tax in any Straddle Period or the period beginning after the Closing Date
as a result of any election under Section&nbsp;965(h) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) Neither the Company nor any of its Subsidiaries has distributed
stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&nbsp;355 or Section&nbsp;361 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) Neither the Company nor any of its Subsidiaries has extended or waived the application of any statute of limitations of any
jurisdiction regarding the assessment or collection of any Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) The Company has set forth in Section&nbsp;5.1(p) of the Company
Disclosure Letter the name, identification number, jurisdiction of formation, tax residence, percentage of ownership and classification for U.S. federal income tax purposes of each of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) The Company has been properly classified for United States federal income tax purposes as a C corporation at all times since formation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) Neither the Company nor any of its Subsidiaries has availed itself of any government grants, Tax holidays, loans, or other Tax
benefits or relief related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including a loan under the Paycheck Protection Program or relief pursuant to Section&nbsp;2301 or Section&nbsp;2302 of the Coronavirus Aid, Relief, and Economic Security
Act (P.L. <FONT STYLE="white-space:nowrap">116-136),</FONT> as amended, or any similar applicable federal, state, or local Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi)
Neither the Company nor any of its Subsidiaries has ever been subject to Tax in any jurisdiction outside of its country of organization by reason of having employees, a permanent establishment, an office or other place of business in such
jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, (x)&nbsp;the term &#147;<I><U>Tax</U></I>&#148; includes all
federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income, license, profits, franchise, gross receipts, environmental, customs duty, capital stock, severances, stamp, payroll, sales, employment, social security (or similar),
unemployment, disability, use, real property, personal property, transfer, registration, withholding, excise, medical device excise, production, value added, occupancy, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, estimated
and other taxes, duties or assessments of any kind whatsoever in the nature of a tax, together with all interest, penalties and additions imposed with respect to such amounts and any interest in respect of such penalties and additions, whether
disputed or not and including any obligations to indemnify or otherwise assume or succeed to the Tax liability of any other Person, and (y)&nbsp;the term &#147;<I><U>Tax Return</U></I>&#148; includes all returns and reports (including elections,
declarations, disclosures, schedules, estimates, claims for refund and information returns, including any attachments thereto and amendments thereof) supplied or required to be supplied to a Tax authority relating to Taxes. Notwithstanding anything
to the contrary in this Agreement, the representations and warranties in this <U>Section</U><U></U><U>&nbsp;5.1(p)</U> and the representations and warranties contained in <U>Sections</U><U></U><U>&nbsp;5.1(b)</U>, <U>5.1(g)</U> and <U>5.1(j)</U> to
the extent specifically addressing Taxes shall be the only representations or warranties of the Company and its Subsidiaries in this Agreement with respect to Tax matters. Nothing in this <U>Section</U><U></U><U>&nbsp;5.1(p)</U> or otherwise in this
Agreement shall be construed as a representation or warranty with respect to the amount or availability in a Taxable period (or portion thereof) beginning after the Closing Date of any net operating loss, capital loss, Tax credit carryover or other
Tax asset generated or arising in or in respect of a Taxable period (or portion thereof) ending on or before the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)
<U>Labor Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) As of the date of hereof, (A)&nbsp;neither the Company nor any of its Subsidiaries is a party to any
collective bargaining agreement or other agreement with a labor union or like organization, (B)&nbsp;to the Company&#146;s Knowledge, there are no activities or proceedings of any individual or group of individuals, including representatives of any
labor organizations or labor unions, to organize any employees of the Company or any of its Subsidiaries and, since January&nbsp;1, 2019, no demand for recognition as the exclusive bargaining representative of any employees has been made in writing
or to the Company&#146;s Knowledge by or on behalf of any labor or like organization, (C)&nbsp;there is no strike, lockout, slowdown, work stoppage, job action, picketing, unfair labor practice or other labor dispute, question regarding
representation or union organizing activity or any similar activity pending or, to the Company&#146;s Knowledge, threatened, that may interfere in any material respect with the respective business activities of the Company or any of its
Subsidiaries, (D)&nbsp;no employees of the Company or any of its Subsidiaries are represented by any labor union or works council, (E)&nbsp;there is no unfair labor practice charge against the Company or any of its Subsidiaries pending before the
National Labor Relations Board or any comparable labor relations authority, and (F)&nbsp;there is no pending or, to the Company&#146;s Knowledge, threatened arbitration or grievance, charge, complaint, audit or investigation by or before any
Governmental Entity with respect to any Employees of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company and each of its
Subsidiaries is in material compliance with all applicable Laws respecting labor, employment, fair employment practices (including equal employment opportunity laws), terms and conditions of employment, including proper classification of independent
contractors or employees, workers&#146; compensation, occupational safety and health, affirmative action, employee privacy, plant closings, wages and hours. The Company has paid in full to all current and former Employees, independent contractors,
and consultants all wages, salaries, commissions, bonuses, benefits, and other compensation that are due, owing and required to be paid to such persons on or prior to the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-42- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) There are no actions, suits, claims, hearings, arbitrations, investigations or other
proceedings pending or, to the Company&#146;s Knowledge, threatened against the Company or any of its Subsidiaries in any forum by or on behalf of any Employee of the Company or any of its Subsidiaries, any applicant for employment or classes of the
foregoing alleging breach of any express or implied employment contract, violation of any Law governing employment or the termination thereof, or any other discriminatory, wrongful or tortious conduct on the part of the Company or any of its
Subsidiaries in connection with the employment relationship that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries has incurred any liability or obligation under the Worker
Adjustment and Retraining Notification Act and the regulations promulgated thereunder or any similar state or local Law that remains unsatisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Since January&nbsp;1, 2019, no allegations of sexual harassment or sexual misconduct while employed by, or providing services to, the
Company have been made, or to the Company&#146;s Knowledge, threatened, against any current or former officer, employee, manager or director of the Company. Since January&nbsp;1, 2019, the Company has not entered into any settlement agreement or
conducted any investigation related to allegations of sexual harassment or sexual misconduct by or regarding any current or former officer, employee, manager or director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) No notice, consent or consultation obligations with respect to any employees of the Company or any of its Subsidiaries, or any labor
union or other employee representative body, trade union or works council, will be a condition precedent to, or triggered by, the execution of this Agreement or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) <U>Intellectual Property; Data Privacy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Section&nbsp;5.1(r)(i) of the Company Disclosure Letter sets forth a true, correct, and complete list of all Company Registered IP,
indicating for each item, as applicable: (A)&nbsp;the name of the applicant/registrant and current legal and beneficial owner(s); (B) the jurisdiction where the application/registration is located (or, for Internet domain names, the applicable
registrar); (C) the application or registration number; and (D)&nbsp;the filing date, issuance/registration/grant date and expiration date. All Company Registered IP is subsisting, valid and, other than Company Registered IP constituting
applications, enforceable, and since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries has received any written notice challenging the validity or enforceability of, or the Company&#146;s or any of its Subsidiaries&#146; rights
in or to, any Company Registered IP. All Company Registered IP: (x)&nbsp;has been duly filed or registered with the applicable Governmental Entity or Internet domain name registrar and properly maintained, including by the timely submission of all
necessary filings and payment of fees in accordance with the legal and administrative requirements in the appropriate jurisdictions; (y)&nbsp;has not lapsed or expired or been cancelled or abandoned; and (z)&nbsp;in the case of any Company
Registered IP constituting applications, are pending and in good standing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-43- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company and its Subsidiaries exclusively own or hold an exclusive license under,
all Company Intellectual Property, free and clear of all Liens. No material Company Intellectual Property is subject to any outstanding order, judgment, decree or Contract adversely affecting the Company&#146;s or its Subsidiaries&#146; ownership or
use of, or its rights in or to, such material Company Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Company and its Subsidiaries own or have
sufficient and valid rights to use all Intellectual Property Rights necessary for, or otherwise used in and material to, their respective businesses as presently conducted and as currently proposed to be conducted, all of which rights shall survive
the consummation of the Transactions to the same extent as available to the Company and its Subsidiaries on the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Except as has not resulted in, and would not reasonably be expected to result in, individually or in the aggregate, material liability
or business disruption, neither the Company nor any of its Subsidiaries, nor the operation of their respective businesses (including the development, manufacture, use, sale, commercialization or other exploitation of any product, service or other
offering currently provided or under development by the Company or any of its Subsidiaries) has, since January&nbsp;1, 2019, infringed, misappropriated or otherwise violated the Intellectual Property Rights of any other Person. No actions, suits,
claims, hearings, arbitrations, investigations or other proceedings regarding any of the foregoing are pending or threatened in writing against the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Except as has not been, and would not reasonably be expected to be, individually or in the aggregate, material to the Company or any of
its Subsidiaries, to the Company&#146;s Knowledge, no third party is infringing, misappropriating, or otherwise violating any Company Intellectual Property, and neither the Company nor any of its Subsidiaries has asserted or threatened to assert a
claim of such infringement, misappropriation or violation against any third party since January&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The Company and its
Subsidiaries have taken reasonable measures to maintain and preserve the enforceability of all material Company Intellectual Property, and to protect and preserve the confidentiality and value of all material Trade Secrets that are owned, used or
held for use by the Company or any of its Subsidiaries. No such material Trade Secrets have been made available to or, to the Company&#146;s Knowledge, discovered by any Person except pursuant to valid and appropriate confidentiality and <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> obligations requiring any such Person to maintain the confidentiality thereof, and not to use such Trade Secrets except as authorized by the Company or the applicable Subsidiary, and such obligations
have not, to the Company&#146;s Knowledge, been breached in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Except as set forth on Section&nbsp;5.1(r)(vii)
of the Company Disclosure Letter, the Company has acquired all right, title and interest in all Intellectual Property Rights material to any business of the Company or any of its Subsidiaries, either by (A)&nbsp;operation of law, or (B)&nbsp;by
execution and delivery of a valid written Contract containing an irrevocable assignment to the Company or one of its Subsidiaries, as applicable, from all current and former Employees, officers, directors, consultants and contractors of the Company
or any of its Subsidiaries who have contributed to the creation or development of any such Intellectual Property Rights. No Employee, officer, director, stockholder, consultant, or contractor of the Company or any of its Subsidiaries
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-44- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retains, or to the Company&#146;s Knowledge claims to retain, any material rights in, nor to the Company&#146;s Knowledge has any of them made application for, any such Intellectual Property
Rights. All rights in, to and under all Intellectual Property Rights created or developed by any of the Company&#146;s or any of its Subsidiaries&#146; founders materially related to or used in the businesses of the Company or any of its
Subsidiaries or in contemplation of forming such Company or any of its Subsidiaries (or any predecessor thereto) have been duly, validly and irrevocably assigned to such Company or its applicable Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Neither the Company nor any of its Subsidiaries has distributed, made available for remote interaction, incorporated or linked to any
Software that is subject to any open source license, in each case, in a manner that requires the Company or any of its Subsidiaries to (A)&nbsp;disclose, distribute or make available any proprietary source code constituting Company Intellectual
Property, (B)&nbsp;refrain from charging fees or other consideration, or limit the fees or consideration that it may charge, in connection with their material proprietary Software, (C)&nbsp;grant any license or other right to decompile or
reverse-engineer any of their material proprietary Software or (D)&nbsp;permit any Person to make derivative works of any of their material proprietary Software. The Company and its Subsidiaries have complied in all material respects with their
respective obligations arising under any open source licenses relating to their material proprietary Software. None of the Company&#146;s or its Subsidiaries&#146; material proprietary Software is subject to any escrow agreement or similar
contingent obligation to disclose any of their material proprietary Software in source code format. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) The IT Assets owned, used or
held for use (including through cloud-based or other third-party service providers) by the Company or any of its Subsidiaries (A)&nbsp;operate and perform in all material respects in accordance with their documentation and functional specifications
and otherwise as required by the Company or any of its Subsidiaries in connection with their respective businesses, (B)&nbsp;have not materially malfunctioned or failed to function since January&nbsp;1, 2019, and (C)&nbsp;except as would not
reasonably be expected to have a material effect on the operations of the Company and its Subsidiaries, taken as whole, are free from material bugs, defects, &#147;back doors,&#148; &#147;drop dead devices,&#148; &#147;time bombs,&#148; &#147;Trojan
horses,&#148; &#147;viruses,&#148; &#147;worms,&#148; &#147;spyware&#148; (in each case, as such terms are commonly understood in the software industry) or any other disabling or malicious code. Since January&nbsp;1, 2019, to the Company&#146;s
Knowledge, there has been no material unauthorized access to or misuse of such IT Assets. The Company and its Subsidiaries have implemented reasonable backup and disaster recovery technology consistent with best industry practices to protect the
confidentiality, integrity and security of such IT Assets, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) The Company and its Subsidiaries have complied in all
material respects with all applicable Privacy Laws and Company Privacy Commitments and, to the Company&#146;s Knowledge, no circumstance has arisen in which Privacy Laws, or any applicable guidance or codes of practice promulgated under Privacy
Laws, would require the Company or any of its Subsidiaries to notify a Governmental Entity of any actual or suspected unauthorized acquisition of or access to Personal Information. Since January&nbsp;1, 2019, the Company and its Subsidiaries have
not received any written notice, order, inquiry, investigation, complaint or other communication alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Privacy Laws or Company Privacy Commitments. To the Company&#146;s Knowledge,
there has been no material loss, theft, misuse of, or unauthorized access to, or acquisition, use, modification or disclosure of, any Personal Information processed, collected, stored, transferred or otherwise used by or on behalf of the Company or
any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-45- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) For purposes of this Agreement, the following terms have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Company Intellectual Property</U></I>&#148; means all Intellectual Property Rights owned or purported to be owned by, or
exclusively licensed or purported to be exclusively licensed to, the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Company Privacy
Commitments</U></I>&#148; means all contractual obligations, commitments, policies and public statements of the Company or any of its Subsidiaries with respect to Personal Information, privacy or data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Company Registered IP</U></I>&#148; means all Intellectual Property Rights included in the Company Intellectual Property that are
issued by, registered with, renewed by or the subject of a pending application before any Governmental Entity or Internet domain name registrar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Intellectual Property Rights</U></I>&#148; means all rights anywhere in the world in or to any of the following:
(A)&nbsp;trademarks, service marks, brand names, certification marks, collective marks, d/b/a&#146;s, internet domain names, logos, symbols, trade dress, trade names, slogans, and other indicia of origin, all applications and registrations for any
of the foregoing, and all goodwill associated therewith and symbolized thereby, including all renewals of same; (B)&nbsp;patents, patent applications, invention disclosures, provisional patent applications and similar instruments (including any and
all substitutions, divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, extensions, reexaminations, patents of addition, supplementary protection
certificates, utilization models, industrial designs, inventors&#146; certificates, or the like); (C) confidential or proprietary information, trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> including inventions and discoveries
(whether patentable or not, or reduced to practice or not), product specifications, processes, schematics, business methods, formulae, drawings, prototypes, models, designs, customer lists and supplier lists (&#147;<I><U>Trade
Secrets</U></I>&#148;); (D) published and unpublished works of authorship, whether copyrightable or not (including software, website and mobile content, data, databases and other compilations of information), copyrights therein and thereto, and
registrations and applications therefor, and all renewals, extensions, restorations and reversions thereof; (E)&nbsp;Internet domain names and URLs; and (F)&nbsp;all other intellectual property, industrial or proprietary rights (in each case of
clauses&nbsp;(A) &#150; (F), whether or not subject to statutory registration or protection). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>IT Assets</U></I>&#148; means
technology devices, computers, software, firmware, middleware, servers, workstations, networks, routers, hubs, switches, data communications lines, and all other information technology equipment, and all data stored therein or processed thereby, and
all associated documentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Personal Information</U></I>&#148; means any information that (A)&nbsp;alone or in combination
with other information held by the Company, can be used to identify an individual person, household, device or browser, or (B)&nbsp;is otherwise protected under applicable Privacy Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-46- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Privacy Laws</U></I>&#148; means all applicable Laws relating to data
protection and privacy, electronic communications, electronic marketing and information security, including the Health Insurance Portability and Accountability Act of 1996 and all implementing regulations thereof, the Health Information Technology
for Economic and Clinical Health Act and all implementing regulations thereof and state health privacy laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;<I><U>Software</U></I>&#148; means any computer program, application, microcode, firmware or software, including operating systems,
software implementations of algorithms, models and methodologies, in each case, whether in source code, object code or other form or format, including libraries, subroutines and other components thereof, and all documentation relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) <U>No Trade Loading; Inventory</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries has engaged in (A)&nbsp;any trade loading practices or any
other promotional sales or discount activity or other practice with the effect of accelerating sales to the trade or otherwise that would otherwise be expected to occur in later periods, (B)&nbsp;any practice which would have the effect of
accelerating collections of receivables that would otherwise be expected to be in later periods, (C)&nbsp;any practice which would have the effect of postponing payments by the Company that would otherwise be expected to be made in earlier periods,
or (D)&nbsp;any promotional sales, discount activity, deferred revenue activity or inventory overstocking or understocking activity, in each case of clauses (A)&nbsp;through (D) above in a manner materially outside of the ordinary course of business
or contrary to generally accepted industry practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Since January&nbsp;1, 2019, neither the Company nor any of its Subsidiaries
has sold, transferred or otherwise moved any raw materials, packaging materials, Medical Devices or components thereof or other supplies related thereto, in each case related to the Company&#146;s business, while and to the extent under the
ownership of the Company, whether located at any premises of the Company or elsewhere (collectively, &#147;<I><U>Inventory</U></I>&#148;) from the Company other than in the ordinary course of business. Neither the Company nor any of its Subsidiaries
or distributors currently holds, or will at any time at or prior to the Closing hold, more than ninety (90)&nbsp;days of Inventory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t)
<U>Insurance</U>. All material fire and casualty, general liability, business interruption, product liability, and sprinkler and water damage insurance policies maintained by the Company or any of its Subsidiaries (&#147;<I><U>Insurance
Policies</U></I>&#148;) are with reputable insurance carriers, provide reasonable coverage for all normal risks incident to the business of the Company and its Subsidiaries and their respective properties and assets, except for any such failures to
maintain insurance policies that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Each Insurance Policy is in full force and effect and all premiums due with respect to all Insurance Policies
have been paid, with only such exceptions that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) <U>Brokers and Finders</U>. Except for Canaccord, neither the Company nor any of its Subsidiaries has engaged any broker or finder or
incurred any liability for any brokerage fees, commissions or finders&#146; fees in connection with the Merger or the other Transactions except that the Company has engaged Canaccord as its financial advisor. The Company has made available to Parent
a complete and accurate copy of all agreements pursuant to which Canaccord is entitled to any fees and expenses in connection with any of the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-47- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2. <U>Representations and Warranties of Parent and Merger Sub</U>. Except as set forth in
the forms, statements, certifications, reports and documents filed with or furnished to the SEC prior to the date hereof by Parent pursuant to the Securities Exchange Act of 1934 or the Securities Act of 1933 (excluding, in each case, any
disclosures set forth in any risk factor section or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), each of Parent and Merger Sub hereby represents and warrants to the
Company as of the date hereof and as of the Closing Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization, Good Standing and Qualification</U>. Each of Parent
and Merger Sub is a legal entity duly organized, validly existing and in good standing under the Laws of its respective jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its
properties and assets and to carry on its business as presently conducted and is qualified to do business and is in good standing as a foreign corporation in each jurisdiction where the ownership, leasing or operation of its assets or properties or
conduct of its business requires such qualification, except with respect to its Subsidiaries where the failure to be so organized, qualified or in such good standing, or to have such power or authority, would not, individually or in the aggregate,
reasonably be expected to prevent, materially delay or impair the ability of Parent and Merger Sub to consummate the Merger and the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Corporate Authority</U>. Each of Parent and Merger Sub has all requisite corporate power and authority and has taken all corporate
action necessary in order to execute, deliver and perform its obligations under this Agreement, subject only to the adoption of this Agreement by Parent, in its capacity as the sole stockholder of Merger Sub. No vote of holders of capital stock of
Parent is necessary to approve this Agreement and the Merger and the other Transactions. This Agreement has been duly executed and delivered by each of Parent and Merger Sub and is a valid and binding agreement of each of Parent and Merger Sub
enforceable against each of Parent and Merger Sub in accordance with its terms, subject to the Bankruptcy and Equity Exception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Governmental Filings; No Violations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Other than the filings and/or notices pursuant to <U>Section</U><U></U><U>&nbsp;1.3</U>
(the &#147;<I><U>Parent Approvals</U></I>&#148;), no notices, reports or other filings are required to be made by Parent or Merger Sub with, nor are any consents, registrations, approvals, permits or authorizations required to be obtained by Parent
or Merger Sub from, any Governmental Entity in connection with the execution, delivery and performance of this Agreement by Parent and Merger Sub and the consummation by Parent and Merger Sub of the Merger and the other Transactions, except those
that the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to prevent or materially delay or impair the ability of Parent or Merger Sub to consummate the Merger and the other Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-48- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The execution, delivery and performance of this Agreement by Parent and Merger Sub do
not, and the consummation by Parent and Merger Sub of the Merger and the other Transactions will not, constitute or result in (A)&nbsp;a breach or violation of, or a default under, the certificate of incorporation or bylaws of Parent or Merger Sub
or the comparable governing instruments of any of its Subsidiaries, (B)&nbsp;with or without notice, lapse of time or both, a breach or violation of, a termination (or right of termination) or a default under, the creation or acceleration of any
obligations under or the creation of a Lien on any of the assets of Parent or any of its Subsidiaries pursuant to, any Contracts binding upon Parent or any of its Subsidiaries or any Laws or governmental or
<FONT STYLE="white-space:nowrap">non-governmental</FONT> permit or license to which Parent or any of its Subsidiaries is subject; or (C)&nbsp;any change in the rights or obligations of any party under any of such Contracts, except, in the case of
clause&nbsp;(B) or (C)&nbsp;above, for any breach, violation, termination, default, creation, acceleration or change that would not, individually or in the aggregate, reasonably be expected to prevent or materially delay the ability of Parent or
Merger Sub to consummate the Merger and the other Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) As of the date hereof, there are no civil, criminal or
administrative actions, suits, claims, hearings, arbitrations, investigations or other proceedings before or by any Governmental Entity pending or, to Parent&#146;s knowledge, threatened in writing against Parent or any of its Subsidiaries, except
as would not, individually or in the aggregate, reasonably be expected to prevent or materially delay or impair the ability of Parent or Merger Sub to consummate the Merger and the other Transactions. As of the date hereof, neither Parent nor any of
its Subsidiaries is a party to or subject to the provisions of any judgment, order, writ, injunction, decree or award of any Governmental Entity, except as would not, individually or in the aggregate, reasonably be expected to prevent or materially
delay or impair the ability of Parent or Merger Sub to consummate the Merger and the other Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Available Funds</U>.
Parent and Merger Sub have available to them, or will have available to them, as and when needed to consummate the Transactions contemplated by this Agreement, all funds necessary to satisfy all of their obligations under this Agreement and to make
all payments hereunder including, without limitation, the Closing Consideration, the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration and payment of the Purchase Price Adjustment Holdback as if the full amount thereof is payable to the
Paying Agent for distribution to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;4.1(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Capitalization of Merger
Sub</U>. The authorized capital stock of Merger Sub consists solely of 1,000 shares of common stock, par value $0.001 per share, all of which are validly issued and outstanding. All of the issued and outstanding capital stock of Merger Sub is, and
at the Effective Time will be, owned by Parent or a direct or indirect wholly-owned Subsidiary of Parent. Merger Sub has not conducted any business prior to the date hereof and has no, and prior to the Effective Time will have no, assets,
liabilities or obligations of any nature other than those incident to its formation and pursuant to this Agreement, the Merger and the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Brokers and Finders</U>. Neither Parent nor Merger Sub, nor any of their respective officers, directors or employees has engaged any
broker or finder or incurred any liability for any brokerage fees, commissions or finders&#146; fees in connection with the Merger or the other Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-49- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;VI </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Covenants </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.
<U>Interim Operations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company covenants and agrees as to itself and its Subsidiaries that, during the period beginning as of
the execution of this Agreement on the Effective Date and ending on the earlier of the Effective Time and the termination of this Agreement in accordance with <U>Article</U><U></U><U>&nbsp;VIII</U> (such period, the &#147;<I><U>Interim
Period</U></I>&#148;), unless Parent shall otherwise approve in advance in writing (such approval not to be unreasonably withheld, conditioned or delayed), and except as otherwise expressly required by this Agreement or applicable Laws, the business
of the Company and its Subsidiaries shall be conducted in the ordinary course consistent with past practice and, to the extent consistent therewith, the Company and its Subsidiaries shall use their respective commercially reasonable efforts to
preserve their business organizations intact and maintain existing relations and goodwill with Governmental Entities, customers, licensors, suppliers, distributors, creditors, lessors, Employees, sales representatives and business associates and
keep available the services of its and its Subsidiaries&#146; present Employees and agents. Without limiting the generality of the foregoing, and in furtherance thereof, during the Interim Period, except (A)&nbsp;as otherwise expressly required or
permitted by this Agreement or applicable Law, (B)&nbsp;as Parent may approve in advance in writing (such approval not to be unreasonably, delayed, conditioned or withheld) or (C)&nbsp;as set forth in Section&nbsp;6.1(a) of the Company Disclosure
Letter, the Company shall not and shall not permit its Subsidiaries to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) adopt or propose any change in its certificate of
incorporation or bylaws or other applicable governing instruments; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) merge or consolidate the Company or any of its Subsidiaries with
any other Person, or restructure, reorganize or completely or partially liquidate or otherwise enter into any agreements or arrangements imposing material changes or restrictions on its assets, operations or businesses; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) acquire assets outside of the ordinary course of business from any other Person, other than acquisitions pursuant to Contracts in
effect as of the date hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) issue, sell, pledge, dispose of, grant, transfer, encumber, or authorize the issuance, sale, pledge,
disposition, grant, transfer, or encumbrance of, any shares of capital stock of the Company or any of its Subsidiaries (other than the issuance of shares (A)&nbsp;by a <FONT STYLE="white-space:nowrap">wholly-owned</FONT> Subsidiary of the Company to
the Company or another <FONT STYLE="white-space:nowrap">wholly-owned</FONT> Subsidiary or (B)&nbsp;in respect of the exercise of Company Options or Company Warrants outstanding as of the date of this Agreement in accordance with their terms and,
with respect to Company Options, as applicable, the Stock Plans as in effect as of the date of this Agreement), or securities convertible or exchangeable into, exercisable for or with a value measured by reference to any shares of such capital
stock, or any options, warrants or other rights of any kind to acquire any shares of such capital stock or such convertible or exchangeable securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-50- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) create or incur any Lien (other than a Permitted Lien) not incurred in the ordinary
course of business consistent with past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) make any loans, advances, guarantees or capital contributions to or investments
in any Person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) incur any Indebtedness, or issue or sell any debt securities or warrants or other rights to acquire any debt
security of the Company or any of its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) except as set forth in the capital budgets in Section&nbsp;6.1(a)(viii) of
the Company Disclosure Letter and in material compliance therewith, make or authorize any capital expenditure in excess of $50,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix)
enter into any Contract that would have been a Material Contract had it been entered into prior to this Agreement, in each case not done in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) make any changes with respect to accounting policies or procedures, except as required by changes in applicable generally accepted
accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) settle any actions, suits, claims, hearings, arbitrations, investigations or other proceedings before a
Governmental Entity for an amount in excess of $50,000 or any obligation or liability of the Company in excess of such amount; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii)
amend, modify or terminate any Material Contract, or cancel, modify or waive any material debts or claims held by it or waive any material rights; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;(A) make, change, or rescind any material Tax election (other than an election made on a Tax Return filed in the ordinary course
of business consistent with past practice); (B) file any material amended Tax Return; (C)&nbsp;adopt or change any material method or period of Tax accounting; (D)&nbsp;settle or compromise any material claim, audit, assessment or dispute relating
to Taxes; (E)&nbsp;surrender any material claim for a refund of Taxes; (F)&nbsp;enter into any closing agreement relating to Taxes; (G)&nbsp;file any material Tax Return that is inconsistent with past practice; or (H)&nbsp;consent to any extension
or waiver of the limitation period applicable to any Tax claim or assessment (other than pursuant to extensions of time to file Tax Returns obtained in the ordinary course of business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) transfer, assign, sell, lease, license, grant any material right in, mortgage, pledge, surrender, encumber, divest, fail to maintain,
cancel, abandon or allow to lapse or expire or otherwise dispose of any assets or properties (tangible or intangible, including any Intellectual Property Rights), licenses, operations, rights, product lines, businesses or interests therein of the
Company or any of its Subsidiaries, including capital stock of any of its Subsidiaries, except for Permitted Liens or in connection with services provided in the ordinary course of business and sales of obsolete assets and except for sales, leases,
licenses or other dispositions of assets with a fair market value not in excess of $50,000 in the aggregate, other than pursuant to Contracts in effect prior to the date hereof; <U>provided</U>, that with respect to Company Intellectual Property,
the foregoing exceptions shall be limited to granting <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to customers (solely to permit such customers&#146; use of the Company&#146;s and its Subsidiaries&#146; products and services) or
to third-party service providers (solely for the purpose of facilitating their provision of services to or on behalf of the Company and its Subsidiaries), in each case, in the ordinary course of business consistent with past practice; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-51- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) except (1)&nbsp;as required pursuant to existing written, binding agreements in effect
prior to the date hereof, (2)&nbsp;as set forth in Section&nbsp;5.1(j)(i) of the Company Disclosure Letter or (3)&nbsp;as otherwise required by applicable Law, (A)&nbsp;grant or provide any severance or termination payments or benefits to any
director, officer, employees or consultants of the Company or any of its Subsidiaries, (B)&nbsp;increase in any manner the compensation or consulting fees, bonus, pension, welfare, fringe, severance, termination pay or other benefits of, or pay any
bonus to, any current or former director, officer, employee or consultant (who is a natural person) of the Company or any of its Subsidiaries, (C)&nbsp;grant any new awards, or amend or modify the terms of any outstanding awards, under any Benefit
Plan, (D)&nbsp;become a party to, establish, adopt, commence participation in, amend or terminate any Benefit Plan or any arrangement that would have been a Benefit Plan had it been entered into prior to this Agreement, other than termination of the
Company 401(k) Plan pursuant to <U>Section</U><U></U><U>&nbsp;6.9(b)</U>, (E)&nbsp;take any action to accelerate the vesting, lapsing of restrictions or payment in respect of any award or benefit provided pursuant to any Benefit Plan, other than
acceleration of vesting of Company Options pursuant to <U>Section</U><U></U><U>&nbsp;4.3</U>, (F)&nbsp;fund or in any other way secure the payment of compensation or benefits under any Benefit Plan, (G)&nbsp;hire any employee or engage any
consultant (who is a natural person), (H)&nbsp;change any actuarial or other assumptions used to calculate funding obligations with respect to any Benefit Plan or to change the manner in which contributions to such plans are made or the basis on
which such contributions are determined, except as may be required by GAAP, (I)&nbsp;forgive any loans or issue any loans to any current or former directors, officers, employees or consultants (who are natural persons) of the Company or any of its
Subsidiaries, or (J)&nbsp;terminate the employment of any employee other than for cause; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) become a party to, establish, adopt,
amend or commence participation in any collective bargaining agreement or other agreement with a labor union, works council or similar organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) take any action or omit to take any action that would reasonably be expected to result in any of the conditions to the Merger set
forth in <U>Article</U><U></U><U>&nbsp;VII</U> not being satisfied; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xviii) engage in (A)&nbsp;any trade loading practices or any other
promotional sales or discount activity or other practice with the effect of accelerating to <FONT STYLE="white-space:nowrap">pre-Closing</FONT> periods sales to the trade or otherwise that would otherwise be expected (in the ordinary course of
business) to occur in post-Closing periods, (B)&nbsp;any practice which would have the effect of accelerating collections to <FONT STYLE="white-space:nowrap">pre-Closing</FONT> periods of receivables that would otherwise be expected (in the ordinary
course of business) to occur in post-Closing periods, (C)&nbsp;any practice which would have the effect of postponing to post-Closing payments by the Company that would otherwise be expected (in the ordinary course of business) to be made in <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> periods, or (D)&nbsp;any promotional sales, discount activity, deferred revenue activity or inventory overstocking or understocking activity, in each case in this clause&nbsp;(D) in a manner outside the
ordinary course of business or contrary to generally accepted industry practices; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-52- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xix) sell, transfer or otherwise move any Inventory from the Company other than in the
ordinary course of business or hold; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xx) form one or more additional Subsidiaries; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxi) agree, authorize or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<I><U>Permitted Lien</U></I>&#148; means (i)&nbsp;Liens for Taxes not yet due and payable or that are
subject to a good faith contest if adequate reserves are maintained in accordance with GAAP, (ii)&nbsp;zoning, building, <FONT STYLE="white-space:nowrap">land-use</FONT> and similar restrictions imposed by Governmental Entities that do not impair in
any material respect to the continued conduct of the Company&#146;s business as currently conducted, (iii)&nbsp;Liens to secure landlords, lessors or renters under leases or rental agreements (to the extent the applicable Company is not in default
under such lease or rental agreement), (iv) pledges or deposits to secure obligations under workers&#146; compensation laws or similar legislation or to secure public or statutory obligations, (v)&nbsp;Liens incurred in the ordinary course of
business (A)&nbsp;in connection with workers&#146; compensation, unemployment insurance and other social security legislation, (B)&nbsp;in connection with mechanics, workmen, repairmen, warehousemen, or carriers, (C)&nbsp;securing the performance of
bids, trade contracts, leases or statutory obligations, or (D)&nbsp;securing liability for reimbursement or indemnification obligations of insurance carriers providing property, casualty, liability or other insurance to the Company and its
Subsidiaries or under self-insurance arrangements as well as Liens on insurance policies, (vi)&nbsp;Liens relating to the transferability of securities under applicable securities Laws, (viii)&nbsp;any condition that may be shown by a current and
accurate survey, or that would be apparent as part of a physical inspection, of the applicable parcel of real property, in each case, which does not materially adversely interfere with the present or intended use of the parcel of real property it
affects, and (ix)&nbsp;defects, exceptions, restrictions, easements, covenants, charges, rights of way and other <FONT STYLE="white-space:nowrap">non-monetary</FONT> Liens that do not materially detract from the current or intended use of the
applicable asset or real property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to making any written or oral communications to the directors, officers, employees or
consultants of the Company or any of its Subsidiaries pertaining to compensation or benefit matters that are affected by the Transactions, the Company shall provide Parent with a copy of the intended communication, Parent shall have a reasonable
period of time to review and comment on the communication, and Parent and the Company shall cooperate in providing any such mutually agreeable communication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) During the Interim Period, the Company shall (i)&nbsp;consult with Parent in connection with any proposed meeting with the FDA or any
other Governmental Entity relating to any Medical Device, (ii)&nbsp;promptly inform Parent of, and provide Parent with a reasonable opportunity to review, any material filing proposed to be made by or on behalf of the Company or any of its
Subsidiaries, and any material correspondence or other material communication proposed to be submitted or otherwise transmitted to the FDA or any other Governmental Entity by or on behalf of the Company or any of its Subsidiaries, (iii)&nbsp;keep
Parent promptly informed of (A)&nbsp;any communication (written or oral) with or from the FDA or any other Governmental Entity and (B)&nbsp;any material communications (written or oral) received from any Person relating to any material Company
Intellectual Property, (iv)&nbsp;promptly inform Parent and provide Parent or Merger Sub with a reasonable opportunity (but no more than three (3)&nbsp;business days) to comment, in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-53- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case, prior to making any material change to any study protocol, adding any new trial, making any material change to a manufacturing plan or process, making any material change to a development
timeline or initiating, or making any material change to, promotional or marketing materials or activities relating to any Medical Device, and (v)&nbsp;cooperate with, and provide reasonable access to, Parent&#146;s representative for purposes of
reviewing and assessing the Company&#146;s compliance with any and all relevant Laws, compliance programs, and procedures, and give due consideration to any resulting recommendations provided by Parent&#146;s representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall use reasonable best efforts through the Closing Date to take the actions described on Section&nbsp;6.1(d) of the Company
Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, nothing contained in this Agreement shall give Parent or Merger Sub, directly or
indirectly, the right to (i)&nbsp;control or direct the operations of the Company or its Subsidiaries prior to the Effective Time or (ii)&nbsp;operate to prevent or restrict any act or omission by the Company or its Subsidiaries that is required to
be taken (or omitted to be taken) prior to the Effective Time by applicable Law. Prior to the Effective Time, the Company and its Subsidiaries shall exercise, consistent with the terms and conditions of this Agreement, complete control and
supervision over their respective operations, finances and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2. <U>No Solicitation or Negotiation of Alternative
Proposals</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees that neither it nor any of its Subsidiaries shall, and that none of its or its Subsidiaries&#146;
directors, officers, Employees, investment bankers, attorneys, accountants and other advisors or representatives (solely to the extent such persons are acting on behalf or at the direction of the Company or its Subsidiaries) (such persons, other
than the Holder Representative, collectively, &#147;<I><U>Representatives</U></I>&#148;) shall, directly or indirectly: (i)&nbsp;initiate, solicit or knowingly encourage any inquiries or the making of any proposal or offer that constitutes, or could
reasonably be expected to lead to, any Acquisition Proposal; (ii)&nbsp;engage in, continue or otherwise participate in any discussions or negotiations regarding, or provide any <FONT STYLE="white-space:nowrap">non-public</FONT> information or data
to any Person relating to, any Acquisition Proposal; (iii)&nbsp;agree to, approve, endorse, recommend or consummate any Acquisition Proposal; (iv)&nbsp;enter into any letter of intent, memorandum of understanding, agreement in principle, merger
agreement, acquisition agreement or other agreement relating to an Acquisition Proposal; or (v)&nbsp;otherwise knowingly facilitate any effort or attempt to make an Acquisition Proposal. For purposes of this Agreement, &#147;<I><U>Acquisition
Proposal</U></I>&#148; means (i)&nbsp;any proposal or offer with respect to a merger, joint venture, partnership, consolidation, dissolution, liquidation, tender offer, recapitalization, reorganization, share exchange, business combination or
similar transaction involving the Company or any of its Subsidiaries pursuant to which the Holders immediately preceding such transaction would hold, directly or indirectly, less than eighty percent (80%) of the equity interests in the surviving or
resulting entity of such transaction and (ii)&nbsp;any acquisition by any Person resulting in, or proposal or offer, which if consummated would result in, any Person becoming the beneficial owner of, directly or indirectly, in one or a series of
related transactions, twenty-five percent (25%) or more of the total voting power or of any class of equity securities of the Company, or twenty-five percent (25%) or more of the consolidated total assets (including equity securities and assets of
its Subsidiaries) of the Company, in each case other than the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-54- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Change in Recommendation</U>. Except to the extent required by the directors&#146;
fiduciary duties prior to the time written consents constituting the Requisite Stockholder Approval have been delivered to Parent, the Company Board and each committee of the board shall not withhold, withdraw, qualify or modify (or propose or
resolve to withhold, withdraw, qualify or modify), in a manner adverse to Parent, the Company Recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Existing
Discussions</U>. The Company agrees that it will immediately cease and cause to be terminated any existing activities, discussions or negotiations with any parties conducted heretofore with respect to any Acquisition Proposal or any fundraising
effort, including exploration of or preparation for an initial public offering. The Company also agrees that it will promptly after announcement of this Agreement request each Person that has heretofore executed a confidentiality agreement in
connection with its consideration of an existing Acquisition Proposal or any fundraising effort to return or destroy all confidential information heretofore furnished to such Person by or on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Notice</U>. The Company agrees that it will promptly (and, in any event, within one (1)&nbsp;business day) notify Parent if any
inquiries, proposals or offers with respect to an Acquisition Proposal are received by, or any such information is requested from, or any such discussions or negotiation are sought to be initiated or continued with, it or any of its Representatives
indicating, in connection with such notice, the material financial terms and conditions of any proposals or offers (including, if applicable, copies of any written requests, proposals or offers, including proposed agreements) and thereafter shall
keep Parent informed, on a current basis, of the status and material financial terms of any such proposals or offers (including any amendments thereto) and the status of any such discussions or negotiations, including any change in the
Company&#146;s intentions as previously notified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3. <U>Requisite Stockholder Approval</U>. In accordance with applicable Laws,
including Section&nbsp;228, Section&nbsp;251(c) and Section&nbsp;262 of the DGCL, and the Company&#146;s Organizational Documents, immediately following the execution of this Agreement, the Company shall seek and shall use its reasonable best
efforts to obtain as promptly as practicable, and in any event, within forty-eight (48)&nbsp;hours following the execution and delivery of this Agreement by the parties hereto (the &#147;<I><U>Stockholder Consent Delivery Period</U></I>&#148;), a
written consent in the form attached to this Agreement as <U>Exhibit</U><U></U><U>&nbsp;3</U> from stockholders of the Company holding the number of Shares sufficient to satisfy the Requisite Stockholder Approval in lieu of a meeting pursuant to
Section&nbsp;228 of the DGCL (such written consent, as duly executed and delivered by such holders, the &#147;<I><U>Stockholder Written Consent</U></I>&#148;) for the purposes of adopting this Agreement and acknowledging that the adoption is
irrevocable and results in the waiver of any right of such stockholders to demand appraisal in connection with the Merger pursuant to Section&nbsp;262 of the DGCL. As promptly as practicable and, in any event, prior to the expiration of the
Stockholder Consent Delivery Period, if the Stockholder Written Consent is duly executed and delivered to the Company, the Company shall deliver to Parent a copy thereof (including by facsimile or other electronic image scan transmission), certified
as correct and complete by an executive officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4. <U>Additional Stockholder Consents</U>. After the date of this
Agreement and prior to the Effective Time, the Company shall use its reasonable best efforts to have written consents, to the extent not executed and delivered during the Stockholder Consent Delivery Period, executed and delivered by all remaining
Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-55- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5. <U>Information Statement; Stockholders Meeting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Information Statement</U>. As soon as reasonably practicable, and in any event no later than forty-eight (48)&nbsp;hours following the
date on which the Requisite Stockholder Approval is obtained by the due execution and delivery of the Stockholder Written Consent, the Company shall prepare, subject to the reasonable review, comment and approval of Parent, and deliver to its
stockholders an information statement related to the Stockholder Written Consent and the Merger consistent with the applicable provisions of the DGCL and its certificate of incorporation (including any amendments or supplements thereto, the
&#147;<I><U>Information Statement</U></I>&#148;). The Information Statement shall contain the notices of action by written consent required by Section&nbsp;228(e) of the DGCL and of availability of appraisal rights and related disclosure required by
Section&nbsp;262 of the DGCL. The Company agrees that none of the information it includes in the Information Statement will, at the date of delivery to stockholders of the Company or at the time of the Stockholders Meeting, knowingly contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholders Meeting</U>. In the event that the Stockholder Written Consent is not obtained and Parent has not terminated this
Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.4(a)</U>, then, as soon as reasonably practicable following the expiration of the Stockholder Consent Delivery Period, the Company shall take, in accordance with applicable Laws and its
certificate of incorporation and bylaws, all reasonable action necessary to duly call, give notice of, convene and hold a meeting of its stockholders for the purpose of adopting this Agreement (the &#147;<I><U>Stockholders Meeting</U></I>&#148;) and
shall use its reasonable best efforts to obtain the Requisite Stockholder Approval at the Stockholders Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6. <U>Cooperation</U>.
Subject to the terms and conditions set forth in this Agreement, the Company and Parent shall cooperate with each other and use (and shall cause their respective Subsidiaries to use) their respective commercially reasonable efforts to take or cause
to be taken all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on their respective parts under this Agreement and applicable Laws to consummate and make effective the Merger and the other Transactions as
soon as practicable; <U>provided</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;6.6</U> shall require, or be construed to require, Parent or its Subsidiaries to take (or fail to take) any action sought by any Governmental Entity in
connection with any antitrust Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7. <U>Access and Reports</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to applicable Law, during the Interim Period upon reasonable notice, the Company shall (and shall cause its Subsidiaries to)
afford Parent&#146;s officers and other authorized Representatives reasonable access, during normal business hours and in a manner that minimizes disruption to the business operations of the Company and its Subsidiaries, to its Employees,
properties, assets, books, Contracts, Tax Returns and records and, during such period, the Company shall (and shall cause its Subsidiaries to) furnish promptly to Parent all information concerning its business, properties, finances, operations,
assets, litigation matters, environmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-56- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compliance, cash-flow reports and personnel as may reasonably be requested; <U>provided</U>, that no investigation pursuant to this <U>Section</U><U></U><U>&nbsp;6.7</U> shall affect or be deemed
to modify any representation or warranty made by the Company herein or the conditions to the obligations of the parties hereto under this Agreement; and <U>provided</U>, <U>further</U>, that the foregoing shall not require the Company to
(i)&nbsp;permit any inspection, or to disclose any information, that in the reasonable judgment of the Company (after consultation with its outside legal counsel) would result in the disclosure of any trade secrets of third parties or violate any
contractual or legal obligations with respect to confidentiality if the Company shall have used reasonable best efforts to obtain the consent of such third party to such inspection or disclosure, or (ii)&nbsp;disclose any privileged information of
the Company or any of its Subsidiaries. All requests for information made pursuant to this <U>Section</U><U></U><U>&nbsp;6.7</U> shall be directed to the executive officer or other Person designated by the Company. All such information shall be
governed by the terms of the Confidentiality Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the Closing for a period of five (5)&nbsp;years, Parent shall
cause the Surviving Corporation and its Subsidiaries to, upon reasonable notice, afford the Holder Representative (but not, for the avoidance of doubt, any individual Holders) or its Representatives with reasonable access (for the purpose of
examining and copying), during normal business hours and in a manner that minimizes disruption to the business operations of Parent and its Subsidiaries (including the Surviving Corporation), to the books and records of the Company, its
Subsidiaries, and any successor entities, with respect to periods prior to the Closing Date, solely for purposes of (i)&nbsp;responding to the request or at the direction of a Governmental Entity or (ii)&nbsp;the preparation of Tax Returns or other
documents relating to Tax matters; <U>provided</U>, <U>however</U>, that the Holder Representative will agree in advance to a customary confidentiality agreement with respect to such information; <U>provided</U>, <U>further</U>, that the foregoing
shall not require the Surviving Corporation or any of its Subsidiaries to (i)&nbsp;permit any inspection, or to disclose any information, that in their reasonable judgment (after consultation with its outside legal counsel) would result in the
disclosure of any trade secrets of third parties or violate any contractual or legal obligations with respect to confidentiality if they shall have used reasonable best efforts to obtain the consent of such third party to such inspection or
disclosure, or (ii)&nbsp;disclose any privileged information of the Surviving Corporation or any of its Subsidiaries. Unless otherwise consented to in writing by the Holder Representative, Parent shall not permit the Surviving Corporation, any of
its Subsidiaries, or any successor entity thereof, for a period of seven (7)&nbsp;years following the Closing Date, to destroy or otherwise dispose of any books and records of such entities, or any portions thereof, relating to periods prior to the
Closing Date without first giving reasonable prior written notice to the Holder Representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8. <U>Publicity</U><U>; Employee
Communications</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Company and Parent shall consult with the other prior to issuing any press releases or otherwise
making public announcements with respect to the Merger and the other Transactions and prior to making any filings with any third party and/or any Governmental Entity (including any national securities exchange) with respect thereto, except
(a)&nbsp;in any case in which the management of any such party hereto shall have determined in good faith (after consultation with its outside legal counsel) that such disclosure is required by applicable Law or by obligations pursuant to any
listing agreement with or rules of any national securities exchange or by the request of any Governmental Entity, or (b)&nbsp;in any case in which such disclosure is made in connection with any dispute between the parties hereto regarding this
Agreement, the Merger or the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-57- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to the Closing Date, each of the Company and Parent shall consult with the other
in establishing a communication plan mutually acceptable to both parties prior to issuing any general communications to Company employees regarding the Merger or any of the other Transactions or actions to be taken by the Company or Holders in
connection with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.9. <U>Employee Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent agrees that, during the period commencing at the Effective Time and continuing through the first anniversary of the Effective Time,
the Employees of the Company and its Subsidiaries will be provided (i)&nbsp;a base salary or hourly wage and annual incentive compensation opportunities that are each no less favorable than, determined for the applicable Employee, the greater of
(A)&nbsp;the base salary or hourly wage and annual incentive compensation provided by the Company and its Subsidiaries to each such Employee of the Company and its Subsidiaries immediately prior to the Effective Time or (B)&nbsp;the base salary or
hourly wage and annual incentive compensation that are generally provided by Parent to similarly situated Employees of Parent, and (ii) &#147;employee welfare benefits&#148; (within the meaning of Section&nbsp;3(1) of ERISA) and &#147;employee
pension benefits&#148; (within the meaning of Section&nbsp;3(2) of ERISA) (excluding, in each case, equity awards and long-term incentive compensation) that are no less favorable in the aggregate, determined for the applicable Employee, than the
greater of (A)&nbsp;the employee welfare benefits and employee pension benefits that are generally provided by the Company and its Subsidiaries to similarly situated Employees of the Company and its Subsidiaries immediately prior to the Effective
Time, or (B)&nbsp;the employee welfare benefits and employee pension benefits that are generally provided by Parent to similarly situated Employees of Parent; <U>provided</U>, that Parent will be deemed to be in compliance with clause&nbsp;(ii)
during any period Parent allows Employees of the Company and its Subsidiaries to continue participating in the Company&#146;s welfare benefit plans and employee pension benefit plans in existence immediately prior to the Closing. Without limiting
the generality of the foregoing, Employees will be entitled to use any earned and unused vacation or accrued <FONT STYLE="white-space:nowrap">paid-time-off</FONT> entitlements accrued through the Closing Date (&#147;<I><U><FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Vacation Accruals</U></I>&#148;) to the extent such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Vacation Accruals are properly accrued on the Company&#146;s financial statements at Closing, in
accordance with the terms of the applicable plan or policy as in effect prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Immediately prior to the Effective
Time, if requested by Parent in writing no fewer than three (3)&nbsp;business days prior to the Closing Date, to the extent permitted by applicable Law and the terms of the applicable plan or arrangement, the Company shall cause the TriNet 401(k)
Plan For Employees of Biorez, Inc. (the &#147;<I><U>Company 401(k) Plan</U></I>&#148;) to be terminated. In the event that Parent requests that the Company 401(k) Plan be terminated, (y)&nbsp;the Company shall provide Parent with evidence that the
Company 401(k) Plan will be terminated pursuant to resolution of the Company Board (the form and substance of which shall be subject to review and approval by Parent at least two (2)&nbsp;business days prior to the date the Company 401(k) Plan is
terminated) not later than the day immediately preceding the date the Company 401(k) Plan is terminated, and (z)&nbsp;Parent shall permit the Employees of the Company to roll over their balances from the Company 401(k) Plan to Parent&#146;s 401(k)
plan, pursuant to the terms of Parent&#146;s 401(k) plan document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-58- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) (i) Prior to the Closing Date, the Company shall submit for approval by its
stockholders, in conformance with Section&nbsp;280G of the Code and the regulations thereunder (the &#147;<I><U>280G Stockholder Vote</U></I>&#148;), any payments that could constitute a &#147;parachute payment&#148; pursuant to Section&nbsp;280G of
the Code (each, a &#147;<I><U>Parachute Payment</U></I>&#148;), (ii) at least one (1)&nbsp;business day prior to the 280G Stockholder Vote, the right to any Parachute Payment submitted for approval shall have been irrevocably waived by each of the
applicable &#147;disqualified individuals&#148; (as defined under Section&nbsp;280G of the Code and the regulations promulgated thereunder) and (iii)&nbsp;the Company shall have delivered to Parent true and complete copies of all disclosures and
documents that comprise the stockholder approval of each Parachute Payment in sufficient time to allow Parent to comment thereon but no less than two (2)&nbsp;business days prior to the 280G Stockholder Vote, and shall reflect all reasonable
comments of Parent thereon. To the extent any disqualified individual fails to waive any Parachute Payments or the Company fails to perform a proper 280G Stockholder Vote with respect to any disqualified individual, despite the Company&#146;s
reasonable efforts to obtain such waiver or 280G Stockholder Vote, as applicable, then (i)&nbsp;such failure shall not, by itself, constitute a breach of this <U>Section</U><U></U><U>&nbsp;6.9(c)</U> and (ii)&nbsp;the value of any otherwise
available U.S. federal Tax deduction associated with Parachute Payments made by Parent, the Surviving Corporation or any of their affiliates on or following the Closing Date and lost pursuant to Section&nbsp;280G of the Code shall be treated as
Transaction Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Closing Date occurs prior to the Company&#146;s payment of 2022 annual incentive compensation, the
Surviving Corporation shall pay, on Parent&#146;s regularly scheduled annual bonus payment date in 2023 and no later than March&nbsp;15, 2023 (the &#147;<I><U>2022 Annual Bonus Payment Date</U></I>&#148;), to each Employee of the Company and its
Subsidiaries (subject to such Employee&#146;s continued employment through December&nbsp;31, 2022), 100% of such Employee&#146;s target annual bonus in respect of 2022 under the Company&#146;s 2022 annual incentive plan (or its successor) (the
&#147;<I><U>2022 Bonus Amount</U></I>&#148;), regardless of whether the target performance objectives under such Plan are achieved; <U>provided</U> that with respect to the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> portion, the 2022 Bonus
Amount is properly accrued on the Company&#146;s financial statements at Closing. The payment of the 2022 Bonus Amount pursuant to this <U>Section</U><U></U><U>&nbsp;6.9(d)</U> will apply towards satisfying Parent&#146;s obligations under
<U>Section</U><U></U><U>&nbsp;6.9(a)</U>; <U>provided</U>, <U>further</U>, that, notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;6.9(d)</U>, in the event that any Employees is involuntarily terminated (including, for
the avoidance of doubt, as a result of a constructive termination, which in no event shall arise from the occurrence of the transactions contemplated by this Agreement or any changes in position, reporting line, or employment terms or conditions as
a result of such transactions) on or prior to December&nbsp;31, 2022, such terminated Employee shall be entitled to receive the 2022 Bonus Amount that would have been payable to such Employee under this <U>Section</U><U></U><U>&nbsp;6.9(d)</U> if
such Employee were to have remained employed through December&nbsp;31, 2022 on the 2022 Annual Bonus Payment Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained
in this Agreement is intended to (i)&nbsp;be treated as an amendment of any particular Benefit Plan (other than <U>Section</U><U></U><U>&nbsp;6.9(b)</U>), (ii) create any third-party beneficiary rights in any employee of the Company or any of its
Subsidiaries, or any beneficiary or dependent thereof, with respect to the compensation, terms and conditions of employment and/or benefits that may be provided to any continuing employee by Parent, the Surviving Corporation or any of their
affiliates or under any benefit plan which Parent, the Surviving Corporation or any of their affiliates may maintain or (iii)&nbsp;prevent Parent, the Surviving Corporation or any of their affiliates from (A)&nbsp;amending or terminating any
particular benefit plan in accordance with its terms or (B)&nbsp;terminating the employment of any particular employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-59- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.10. <U>Insurance and Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>D&amp;O Insurance and Indemnification</U>. Prior to the Effective Time, the Company shall obtain and fully pay for &#147;tail&#148;
insurance policies (providing coverage for D&amp;O Indemnified Persons at least equal to coverage currently provided in the Company&#146;s policies) with a claims period of at least six (6)&nbsp;years from and after the Effective Time from an
insurance carrier with the same or better credit rating as the Company&#146;s current insurance carrier with respect to directors&#146; and officers&#146; liability insurance and fiduciary liability insurance (collectively, &#147;<I><U>D&amp;O
Insurance</U></I>&#148;) with benefits and levels of coverage at least as favorable as the Company&#146;s existing policies with respect to matters existing or occurring at or prior to the Effective Time (including in connection with this Agreement
or the Transactions); <U>provided</U>, <U>however</U>, that the premium under such D&amp;O Insurance shall not exceed three hundred percent (300%) of the amount per annum the Company paid in its last full fiscal year for D&amp;O Insurance, which
amount is set forth in Section&nbsp;6.10(a) of the Company Disclosure Letter. Parent agrees that all rights to indemnification or exculpation now existing in favor of the directors and officers of the Company (collectively, &#147;<I><U>D&amp;O
Indemnified Persons</U></I>&#148;), as provided in the Company&#146;s Organizational Documents in effect as of the date hereof, shall survive the Closing and shall continue in full force and effect until the date that is the sixth (6<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Closing Date, and that Parent shall, and shall cause the Surviving Corporation to, perform and discharge the Company&#146;s obligations to provide such indemnity and exculpation
after the Closing. To the maximum extent permitted by applicable Law, such indemnification shall be mandatory rather than permissive, and Parent and/or the Surviving Corporation shall advance expenses in connection with such indemnification as
provided in the Company&#146;s Organizational Documents, in each case, on the terms in such Organizational Documents as of the date hereof. The indemnification and liability limitation or exculpation provisions of the Company&#146;s Organizational
Documents, shall not be amended, repealed, or otherwise modified by the Surviving Corporation after the Effective Time in any manner that would adversely affect the rights thereunder of individuals who, as of the Closing Date or at any time prior to
the Closing Date, were D&amp;O Indemnified Persons, unless such modification is required under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent hereby
acknowledges that the D&amp;O Indemnified Persons may have certain rights to indemnification, advancement of expenses or insurance provided by other Persons. Parent hereby agrees that the Surviving Corporation will be the indemnitor of first resort
(i.e., its obligations to the D&amp;O Indemnified Persons are primary and any obligation of such other Persons to advance expenses or to provide indemnification for the same expenses or liabilities incurred by any such D&amp;O Indemnified Person are
secondary). Parent further agrees that no advancement or payment by any of such other Persons on behalf of any such D&amp;O Indemnified Person with respect to any claim for which such D&amp;O Indemnified Person has sought indemnification from the
Surviving Corporation or any of its Subsidiaries shall affect the foregoing and such other Persons shall have a right of contribution or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such D&amp;O
Indemnified Person against the Surviving Corporation or any of its Subsidiaries, as applicable. The covenants contained in this <U>Section</U><U></U><U>&nbsp;6.10</U> are intended to be for the benefit of, and shall be enforceable by, each of the
D&amp;O Indemnified Persons and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-60- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their respective heirs and legal representatives and shall not be deemed exclusive of any other rights to which a D&amp;O Indemnified Person is entitled, whether pursuant to Law, Contract or
otherwise. Notwithstanding anything contained in this Agreement to the contrary, this <U>Section</U><U></U><U>&nbsp;6.10</U> shall survive the consummation of the Merger until the date that is the sixth (6<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Closing Date and shall be binding on all successors and assigns of Parent and the Surviving Corporation. In the event that Parent or the Surviving Corporation or any of its
Subsidiaries or any of their respective successors or assigns consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or transfers or conveys all or
substantially all of its properties and assets to any other Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent, the Surviving Corporation or the applicable Subsidiary thereof, as the case
may be, shall assume and succeed to the obligations set forth in this <U>Section</U><U></U><U>&nbsp;6.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Product Liability
Insurance</U>. Prior to the Effective Time, the Company shall obtain and fully pay for a product liability &#147;tail&#148; insurance policy (the &#147;<I><U>Products Liability Insurance</U></I>&#148;) from an insurance carrier with the same or
better credit rating as the Company&#146;s current insurance, and with benefits and levels of coverage at least as favorable as the Company&#146;s policies, with respect to all products manufactured or distributed by the Company prior to the
Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.11. <U>Takeover Statutes</U>. If any Takeover Statute is or may become applicable to the Merger or the other Transactions, the
Company and the Company Board shall grant such approvals and take such actions as are necessary so that such Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or
minimize the effects of such statute or regulation on such Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.12. <U>Litigation</U>. Each party hereto shall promptly
provide the other parties hereto with prompt notice of, and copies of all pleadings and correspondence relating to, any civil, criminal or administrative actions, suits, claims, hearings, arbitrations, investigations or other proceedings against any
such party hereto or any of its directors or officers arising out of or relating to this Agreement or the Transactions (a &#147;<I><U>Transaction Proceeding</U></I>&#148;). Each of Parent, on the one hand, and the Company, on the other hand, shall
give the other party the opportunity to participate in the defense, settlement, or compromise of any such Transaction Proceeding against such party or any of its directors or officers, and no such settlement or compromise shall be agreed to without
the prior written consent of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.13. <U>Company Indebtedness</U>. At the Closing, Parent and the Company shall effect the
indefeasible payment in full in cash of all of the Funded Debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.14. <U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Post-Closing Actions</U>. Without the prior written consent of the Holder Representative (which consent shall not be unreasonably
withheld, conditioned or delayed), neither Parent, the Surviving Corporation, nor any Subsidiary thereof shall (a)&nbsp;file, amend or cause to be amended, any Tax Return for any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period for any
of the Surviving Corporation, the Company or its Subsidiaries, (b)&nbsp;make or change any election (including any election under Sections 336 or 338 of the Code) with respect to, or that has retroactive effect to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-61- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period for any of the Surviving Corporation, the Company or its Subsidiaries, with regard to any Tax or Tax Return of any of the
Surviving Corporation, the Company or its Subsidiaries for any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period, in each case, to the extent that such amendment or election would reasonably be expected to result in an indemnification
obligation of, or reduce amounts payable to, the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Tax Returns</U>. The Company shall prepare and timely file (including
extensions) all Tax Returns of the Company and its Subsidiaries that are required to be filed on or before the Closing Date, and such Tax Returns shall be prepared consistent with the past practice of the Company and its Subsidiaries unless
otherwise required by applicable Law. The Company shall timely pay or shall cause to be timely paid any and all Taxes due with respect to such Tax Returns. The Company shall provide the Parent a reasonable opportunity to review any Tax Returns which
the Company and its Subsidiaries file on or before the Closing Date and shall consider in good faith any reasonable written comments received from Parent with respect to such Tax Returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Transfer Taxes</U>. Notwithstanding anything herein to the contrary, all transfer, documentary, sales, use, stamp, registration and
other such Taxes and fees (including penalties and interest) incurred in connection with the Merger and the other Transactions (&#147;<I><U>Transfer Taxes</U></I>&#148;) shall be borne equally by Parent, on one hand, and the Holders, on the other
hand. Such Transfer Taxes shall be paid by the party legally responsible to pay such Taxes (with the other party paying the party that is legally responsible to pay the tax its share of such Tax at least five (5)&nbsp;business days before the Tax
payment due date). The Holder Representative shall arrange payment of all Transfer Taxes for which the Holders are liable pursuant to this <U>Section</U><U></U><U>&nbsp;6.14(c) </U>from the Holder Representative Expense Account to the extent funds
are available therein in the absence of which the Holders shall be responsible for paying such Transfer Taxes. The parties agree to cooperate in the filing of any returns with respect to Transfer Taxes, including by promptly supplying any
information in a party&#146;s possession that is reasonably necessary to complete such returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>FIRPTA Certificate</U>. On or
prior to the Closing Date, the Company shall have delivered to Parent a certificate pursuant to Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(c)(3),</FONT> duly executed and acknowledged, in form and substance
reasonably satisfactory to Parent, certifying that interests in the Company are not &#147;U.S. real property interests,&#148; together with the notice required to be mailed to the IRS under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Survival of Obligations</U>. Notwithstanding anything in this
Agreement to the contrary, the provisions of this <U>Section</U><U></U><U>&nbsp;6.14</U> shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) For purposes of this Agreement, (x)&nbsp;the term &#147;<I><U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period</U></I>&#148;
shall mean any taxable year or other taxable period (or portion thereof) ending on or before the Closing Date; and (y)&nbsp;the term &#147;<I><U>Straddle Period</U></I>&#148; shall mean any taxable period that begins on or before and ends after the
Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-62- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.15. <U>Third-Party Consents</U>. The Company shall use commercially reasonable efforts to
obtain prior to the Closing, and deliver to Parent at or prior to the Closing, all consents, waivers and approvals (i)&nbsp;under each Contract listed or described in Section&nbsp;6.15 of the Company Disclosure Letter hereto or (ii)&nbsp;requested
by Parent or identified by the Company prior to the Closing; <U>provided</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;6.15</U> shall obligate the Company to incur
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in order to obtain any such consent, waiver or approval that is not contingent upon the occurrence of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.16. <U>RWI Policy</U>. Parent has, or will have by the Closing Date, bound coverage under a representations and warranties insurance policy
(an &#147;<I><U>RWI Policy</U></I>&#148;). Parent shall deliver a copy of the RWI Policy to the Company and the Holder Representative. Subject to <U>Section</U><U></U><U>&nbsp;9.2</U>, the costs and expenses incurred in connection with obtaining the
RWI Policy, including all premiums, underwriting fees and similar costs, whether incurred prior to, at or after the Closing, shall be paid by Parent. The RWI Policy shall provide that the insurer has no right of subrogation with respect to the
Holders except in the case of Fraud, and Parent and its Affiliates shall not amend, waive or otherwise modify the subrogation provision under the RWI Policy in any manner inconsistent with the foregoing. There shall be no limitation set forth in
this Agreement or otherwise on survival claims for Fraud. For the avoidance of doubt and notwithstanding the foregoing, the limitations on survival set forth in this <U>Section</U><U></U><U>&nbsp;6.16</U> shall not control with respect to the RWI
Policy, which contains limitations on survival periods that shall control for purposes thereunder. For purposes of this Agreement, &#147;<I><U>Fraud</U></I>&#148; shall have the meaning under Delaware common law with respect to fraud in the making
of representations and warranties contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement; <U>provided</U>, that such Fraud specifically excludes any statement, representation or omission made negligently or
recklessly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.17. <U>Confidentiality</U>. The parties (other than the Holder Representative) acknowledge the Confidentiality Agreement,
which agreement shall be deemed incorporated herein as if it were set forth in its entirety, <I>mutatis mutandis</I>, and agree that the Confidentiality Agreement shall continue in full force and effect in accordance with its terms until the earlier
of (a)&nbsp;the Effective Time or (b)&nbsp;the expiration of the Confidentiality Agreement according to its terms; <U>provided</U>, <U>however</U>, that to the extent any provisions of the Confidentiality Agreement are inconsistent with any
provision of this Agreement, the provisions of this Agreement shall control. For the avoidance of doubt, the Holder Representative shall not be bound by the terms of the Confidentiality Agreement. The Holder Representative acknowledges that that
certain <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement, dated as of July&nbsp;14, 2022 by and between the Holder Representative and the Company, is intended to cover all information related to this Agreement and the Merger, will
survive the Closing, and will be enforceable by Parent and the Surviving Corporation. Notwithstanding anything herein to the contrary, following the Closing, the Holder Representative shall be permitted to: (i)&nbsp;after the public announcement of
the Merger by Parent, announce that it has been engaged to serve as the Holder Representative in connection herewith as long as such announcement does not disclose any of the terms of this Agreement; and (ii)&nbsp;disclose information as required by
Law or to Representatives of the Holder Representative and to the Holders, in each case who have a need to know such information, provided that each of such persons are subject to confidentiality obligations with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-63- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.18. <U>Notification</U>. During the Interim Period, the Company shall give prompt notice
to Parent, and Parent shall give prompt notice to the Company, of (a)&nbsp;any notice or other communication received by such party from any Governmental Entity in connection with the transactions contemplated by this Agreement or from any Person
alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement, (b)&nbsp;any material communications (written or oral) received from any Person relating to the Company Intellectual
Property and (c)&nbsp;any matter (including a breach of any representation, warranty, covenant or agreement contained in this Agreement) that would reasonably be expected to lead to the failure to satisfy any of the conditions to Closing in
<U>Article</U><U></U><U>&nbsp;VII</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;VII </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Conditions </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.
<U>Conditions to Each Party</U><U>&#146;</U><U>s Obligation to Effect the Merger</U>. The respective obligations of each party (other than the Holder Representative) to effect the Merger are subject to the satisfaction or waiver by such party at or
prior to the Effective Time of each of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stockholder Approval</U>. This Agreement shall have been duly
adopted by holders of Shares constituting the Requisite Stockholder Approval and shall have been duly adopted by Parent as the sole stockholder of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Order</U>. No court or other Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or
entered any Law (whether temporary, preliminary or permanent) that is in effect and restrains, enjoins or otherwise prohibits consummation of the Merger or the other Transactions (collectively, an &#147;<I><U>Order</U></I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governmental Consents</U>. Other than the filing pursuant to <U>Section</U><U></U><U>&nbsp;1.3</U>, all Company Approvals and all
Parent Approvals shall have been obtained or made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2. <U>Conditions to Obligations of Parent and Merger Sub</U>. The obligations of
Parent and Merger Sub to effect the Merger are also subject to the satisfaction or waiver by Parent at or prior to the Effective Time of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. (i)&nbsp;The representations and warranties of the Company set forth in
<U>Section</U><U></U><U>&nbsp;5.1(a)</U> (<I>Organization, Good Standing and Qualification</I>), <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U>, <U>(ii)</U> and <U>(iii)</U> (<I>Capital Structure</I>), <U>Section</U><U></U><U>&nbsp;5.1(c)</U>
(<I>Payment Schedule</I>), and <U>Section</U><U></U><U>&nbsp;5.1(e)(i)</U> (<I>Corporate Authority; Approval</I>) (collectively, together with the representations and warranties listed in clause (ii), the &#147;<I><U>Fundamental
Representations</U></I>&#148;) shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made on and as of such date and time (except to the extent that any such representation and warranty
expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date); (ii) the representations and warranties of the Company set forth in
<U>Section</U><U></U><U>&nbsp;5.1(e)(ii)</U> and <U>(iii)</U> (<I>Corporate Authority; Approval</I>) and <U>Section</U><U></U><U>&nbsp;5.1(u)</U> (<I>Brokers and Finders</I>) shall be true and correct in all material respects as of the date of this
Agreement and as of the Closing Date as though made on and as of such date and time (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true
and correct as of such earlier date); and (iii)&nbsp;the other representations and warranties of the Company set forth in <U>Section</U><U></U><U>&nbsp;5.1</U>, without giving effect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-64- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any &#147;materiality&#148; or &#147;Material Adverse Effect&#148; qualifier set forth therein, shall be true and correct as of the date of this Agreement and as of the Closing Date as though
made on and as of such date and time (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except,
in the case of this clause&nbsp;(iii) only, for any failure of any such representation and warranty to be so true and correct that has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
<U>provided</U>, <U>further</U>, that any failure to be so true and correct with respect to <U>Section</U><U></U><U>&nbsp;5.1(c)</U> (<I>Payment Schedule</I>) shall be cured to the extent that the Payment Schedule is amended to correct any such
failure prior to Closing. Parent shall have received at the Closing a certificate signed on behalf of the Company by the Chief Executive Officer of the Company to the effect that such Chief Executive Officer has read this
<U>Section</U><U></U><U>&nbsp;7.2(a)</U> and the conditions set forth in this <U>Section</U><U></U><U>&nbsp;7.2(a)</U> have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of the Company</U>. The Company shall have performed in all material respects all obligations required to be
performed by it under this Agreement at or prior to the Closing Date, and Parent shall have received a certificate signed on behalf of the Company by the Chief Executive Officer of the Company to the effect that the condition set forth in this
<U>Section</U><U></U><U>&nbsp;7.2(b)</U> has been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment of Transaction Expenses</U>. The Company shall have provided
copies of customary payoff letters in connection with the payment of Transaction Expenses from the Persons listed on <U>Schedule</U><U></U><U>&nbsp;7.2(c)</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect, and Parent
shall have received a certificate signed on behalf of the Company by the Chief Executive Officer of the Company to the effect that the condition set forth in this <U>Section</U><U></U><U>&nbsp;7.2(d)</U> has been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Written Consents; Appraisal Waivers</U>. Holders representing at least eighty-five percent (85%) of the Company&#146;s issued and
outstanding Shares shall have executed written consents, certified copies of which shall have been provided to Parent, and have validly waived all appraisal rights under DGCL and any other applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Convertible Promissory Note Election</U>. The Convertible Promissory Note Holder Election shall have been duly exercised and delivered
and remain in full force and effect, and the Company shall have provided to Parent a true and correct copy thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Certain
Employees</U>. Each Key Employee shall have remained actively employed by the Company through the Effective Time, other than for reasons of death or permanent and total disability, and, to the Company&#146;s knowledge, no Key Employee shall have any
intention not to honor such individual&#146;s New Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>280G Stockholder Vote</U>. The 280G Stockholder Vote shall
have occurred and any payments that could reasonably be expected to be <FONT STYLE="white-space:nowrap">non-deductible</FONT> under Section&nbsp;280G of the Code shall have been irrevocably waived by each of the applicable &#147;disqualified
individuals&#148; (as defined under Section&nbsp;280G of the Code and the regulations promulgated thereunder) and either approved or disapproved in the 280G Stockholder Vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-65- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3. <U>Conditions to Obligation of the Company</U>. The obligation of the Company to effect
the Merger is also subject to the satisfaction or waiver by the Company at or prior to the Effective Time of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. (i)&nbsp;The representations and warranties of Parent and Merger Sub set forth in
<U>Section</U><U></U><U>&nbsp;5.2(b)</U> (<I>Corporate Authority</I>), <U>Section</U><U></U><U>&nbsp;5.2(c)(i) and (ii)</U><I> (Governmental Filings; No Violations</I>) and <U>Section</U><U></U><U>&nbsp;5.2(d)</U> (<I>Available Funds</I>) shall be
true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made on and as of such date and time (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in
which case such representation and warranty shall be true and correct as of such earlier date); (ii) the other representations and warranties of Parent and Merger Sub set forth in <U>Section</U><U></U><U>&nbsp;5.2</U> shall be true and correct in
all material respects as of the date of this Agreement and as of the Closing Date as though made on and as of such date and time (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case
such representation and warranty shall be true and correct as of such earlier date), and (iii)&nbsp;the Company shall have received at the Closing a certificate signed on behalf of Parent and Merger Sub by any Vice President of Parent to the effect
that such Vice President has read this <U>Section</U><U></U><U>&nbsp;7.3(a)</U> and the conditions set forth in this <U>Section</U><U></U><U>&nbsp;7.3(a)</U> have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of Parent and Merger Sub</U>. Each of Parent and Merger Sub shall have performed in all material respects
all obligations required to be performed by it under this Agreement at or prior to the Closing Date, and the Company shall have received a certificate signed on behalf of Parent by any Vice President of Parent to the effect that the condition set
forth in this <U>Section</U><U></U><U>&nbsp;7.3(b)</U> has been satisfied. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;VIII </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Termination </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.
<U>Termination by Mutual Consent</U>. This Agreement may be terminated and the Merger and other Transactions may be abandoned at any time prior to the Effective Time by mutual written consent of the Company and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2. <U>Termination by Either Parent or the Company</U>. This Agreement may be terminated and the Merger and other Transactions may be
abandoned at any time prior to the Effective Time by either Parent or the Company if: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Merger shall not have been consummated by
5:00 p.m. (Eastern Time) on October&nbsp;30, 2022 (the &#147;<I><U>Termination Date</U></I>&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any Order permanently
restraining, enjoining or otherwise prohibiting consummation of the Merger shall become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> (whether before or after the adoption of this Agreement by the Requisite Stockholder Approval);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>provided</U>, that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;8.2</U> shall not be available
to any party that has breached in any material respect its obligations under this Agreement in any manner that shall have proximately caused the failure of a condition to the consummation of the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-66- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3. <U>Termination by the Company</U>. This Agreement may be terminated by the Company and
the Merger and other transactions contemplated by this Agreement may be abandoned at any time prior to the Effective Time by the Company if there has been a breach of any representation, warranty, covenant or agreement made by Parent or Merger Sub
in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that <U>Section</U><U></U><U>&nbsp;7.3(a)</U> or <U>Section</U><U></U><U>&nbsp;7.3(b)</U> would not be satisfied and such
breach or condition is not curable or, if curable, is not cured within the earlier of (x)&nbsp;thirty (30)&nbsp;days after written notice thereof is given by the Company to Parent and (y)&nbsp;the Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4. <U>Termination by Parent</U>. This Agreement may be terminated and the Merger and other transactions contemplated by this Agreement may
be abandoned at any time prior to the Effective Time by Parent if: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) a copy of the Stockholder Written Consent evidencing that the
Requisite Stockholder Approval has been obtained has not been delivered to Parent at or prior to the expiration of the Stockholder Consent Delivery Period; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) there has been a breach of any representation, warranty, covenant or agreement made by the Company in this Agreement, or any such
representation and warranty shall have become untrue after the date of this Agreement, such that <U>Section</U><U></U><U>&nbsp;7.2(a)</U> or <U>Section</U><U></U><U>&nbsp;7.2(b)</U> would not be satisfied and such breach or condition is not curable
or, if curable, is not cured within the earlier of (x) thirty (30)&nbsp;days after written notice thereof is given by Parent to the Company and (y)&nbsp;the Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5. <U>Effect of Termination</U>. If this Agreement is terminated pursuant to this <U>Article</U><U></U><U>&nbsp;VIII</U>, this Agreement
will forthwith become null and void, and there will be no liability to any Person on the part of any party hereto (or any of their respective Representatives or Affiliates) in respect of this Agreement, except as provided in this
<U>Section</U><U></U><U>&nbsp;8.5</U> and except that the provisions of <U>Article</U><U></U><U>&nbsp;X</U> will continue to apply following any termination; <U>provided</U>, <U>however</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;8.5</U>
shall release any party from liability for fraud or any willful and material breach of this Agreement by such party prior to the termination of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;IX </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Survival and Indemnification </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1. <U>Survival</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All
representations and warranties in this Agreement and the schedules and exhibits attached hereto (but excluding the exhibits attached hereto that will be governed by the terms set forth therein), and the right to commence any claim with respect
thereto, shall survive the Closing as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-67- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) all representations and warranties in this Agreement and the schedules attached hereto,
other than the Fundamental Representations and the representations set forth in <U>Section</U><U></U><U>&nbsp;5.1(p)</U>, and the right to commence any claim with respect thereto, shall survive the Closing and continue in effect until the second (2<SUP
STYLE="font-size:75%; vertical-align:top">nd</SUP>) anniversary of the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Fundamental Representations, and the right
to commence any claim with respect thereto, shall survive the Closing and continue in effect until the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Closing Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the representations set forth in <U>Section</U><U></U><U>&nbsp;5.1(p)</U>, and the right to commence any claim with respect thereto,
shall survive the Closing and continue in effect until the finalization of the Final Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement pursuant to the terms and conditions of <U>Section</U><U></U><U>&nbsp;4.2(c). </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The covenants and agreements of the parties contained in this Agreement and the schedules and exhibits attached hereto that are to be
performed by the parties following the Closing shall survive the Closing and continue in effect in accordance with the respective terms applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary herein, any representation or warranty or covenant or agreement in respect of which indemnity may
be sought under <U>Section</U><U></U><U>&nbsp;9.2</U> below, and the indemnity with respect thereto, shall survive the time at which it would otherwise terminate pursuant to this <U>Section</U><U></U><U>&nbsp;9.1</U> if notice of the claim,
inaccuracy or breach or potential inaccuracy or breach thereof giving rise to such right or potential right of indemnity shall have been given to the party against whom such indemnity may be sought prior to such time (regardless of when the Losses
in respect thereof may actually be incurred). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (x)&nbsp;the term &#147;<I><U>Losses</U></I>&#148; shall
mean any loss, Liabilities, cost, damage, royalty, deficiency, penalty, Tax, fine or expense, whether or not arising out of a Third Party Claim (including interest, penalties, reasonable attorneys&#146; fees and expenses and all reasonable amounts
paid in investigation or defense, and all amounts paid in settlement, of any of the foregoing) and (y)&nbsp;the term &#147;<I><U>Liabilities</U></I>&#148; shall mean any liabilities, obligations or commitments of any nature whatsoever, asserted or
unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2.
<U>Indemnification</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification by the Holders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Indemnification</U>. The Holders shall hold Parent, the Surviving Corporation and each of their respective officers, directors, and
employees (the &#147;<I><U>Parent Indemnified Parties</U></I>&#148;) harmless from and against any and all Losses when incurred as a result of, in connection with, relating to or arising out of: (A)&nbsp;any breach by the Company of any
representation or warranty made by the Company in this Agreement or any of the schedules and exhibits attached hereto (but excluding any agreements the forms of which are attached as exhibits hereto that will be governed by the terms set forth
therein), or in any of the certificates furnished by the Company pursuant to this Agreement determined without regard to any Material Adverse Effect or other materiality qualification contained in such representations and warranties; (B)&nbsp;any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-68- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach of any covenant or agreement that is required to be performed by the Holder Representative following the Closing under this Agreement or any of the schedules and exhibits attached hereto
(but excluding any agreements the forms of which are attached as exhibits hereto that will be governed by the terms set forth therein); (C) any claim asserted at any time by any actual or alleged holder of Company securities relating to the
allocation or entitlement to a portion of the Closing Consideration or <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration or other amount paid or to be paid in connection with the Transactions, including any assertion of contractual,
employment or other rights and any assertion of rights to own or acquire any security; or (D)&nbsp;the aggregate amount, if any, by which any payment provided to the Dissenting Stockholders pursuant to Section&nbsp;262 of the DGCL exceeds the
portion of the Closing Consideration to which such Dissenting Stockholders would otherwise be entitled pursuant to <U>Section</U><U></U><U>&nbsp;4.4(f)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Limitations on Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) The Holders shall not have any liability for any Loss with respect to any individual claim arising under clause&nbsp;(A)
of <U>Section</U><U></U><U>&nbsp;9.2(a)(i)</U> above (other than with respect to breaches of the Fundamental Representations), unless and until the aggregate amount of all Losses related thereto for which the Holders would, but for this
<U>Section</U><U></U><U>&nbsp;9.2(a)(ii)(A)</U>, be liable exceeds an amount equal to $100,000. Further to the foregoing, the Holders shall not have any liability for any Losses arising under clause&nbsp;(A) of
<U>Section</U><U></U><U>&nbsp;9.2(a)(i)</U> above (other than with respect to breaches of the Fundamental Representations), unless and until the aggregate amount of all Losses related thereto for which the Holders would, but for this
<U>Section</U><U></U><U>&nbsp;9.2(a)(ii)(A)</U>, be liable exceeds on a cumulative basis an amount equal to $1,125,000 (the &#147;<I><U>Deductible</U></I>&#148;), in which case the Holders shall be liable only for the amount of such Losses in excess
of the Deductible. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall limit or restrict any of Parent&#146;s right to maintain or recover any amounts in connection with any action or claim based upon Fraud.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) The Holders&#146; liability under clause&nbsp;(A) of <U>Section</U><U></U><U>&nbsp;9.2(a)(i)</U> above (including,
for the avoidance of doubt, with respect to breaches of the Fundamental Representations) shall not exceed $16,750,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)
<U>Payments; RWI Policy</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) All indemnification of the Parent Indemnified Parties by the Holders under this
<U>Section</U><U></U><U>&nbsp;9.2(a)</U> shall be satisfied as follows: (1)&nbsp;first, for any claims that are covered by the RWI Policy, by the assertion of claims by Parent Indemnified Parties thereunder until such time as the policy limit set
forth in the RWI Policy has been reached (<U>provided</U>, that the Holders shall be responsible for contributing to the retention amount under the RWI Policy in accordance with clause (2), subject to the limitations set forth in
<U>Section</U><U></U><U>&nbsp;9.2(a)(ii)</U>); and (2)&nbsp;with respect to any indemnification amounts not covered by the RWI Policy, by the Holders in accordance with <U>Section</U><U></U><U>&nbsp;9.2(a)(iii)(B)</U> below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-69- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) The sole and exclusive recourse for any and all amounts payable by the
Holders to any Parent Indemnified Party under this <U>Section</U><U></U><U>&nbsp;9.2(a)</U> will be Parent&#146;s right to setoff such amounts against the unpaid portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration (whether
or not accrued), if any, as of the date each Claim Notice asserting Losses is submitted by any Parent Indemnified Party to the Holder Representative. Any such setoff will be applied to the Holders in accordance with the Payment Schedule.
Notwithstanding the foregoing, neither the exercise of, nor the failure to exercise, such right of setoff will limit or affect (1)&nbsp;the rights of Parent under the RWI Policy, (2)&nbsp;the rights of the parties under
<U>Section</U><U></U><U>&nbsp;10.6(c)</U> with respect to any covenants to be performed by the parties, or (3)&nbsp;Parent&#146;s right to maintain or recover any amounts from any Holder in connection with any action or claim based upon Fraud. To
the extent that liability for or the amount of indemnifiable Losses in respect of a claim for indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;9.2(a)</U> has not yet been finally determined in accordance with this Agreement, Parent
will be entitled to withhold payment from the accrued and unpaid portion of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration otherwise due and payable to the Holders in an amount up to Parent&#146;s good faith estimate of such
Losses set forth in the Claim Notice until the amount of such indemnifiable Losses has been finally determined (any such claim, an &#147;<I><U>Unpaid Indemnification Claim</U></I>&#148;). The exercise of such right of setoff by Parent in accordance
with the terms of this <U>Section</U><U></U><U>&nbsp;9.2(a)(iii)(B)</U> will not constitute a breach of Parent&#146;s obligation to pay the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration or any other amounts due under this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification by Parent and Surviving Corporation</U>. Parent and, after the Closing, Parent and the Surviving Corporation each
agree to and shall indemnify the Holders and hold them harmless against any Losses which any such Holder may suffer, sustain or become subject to, as the result of, in connection with, relating or incidental to or by virtue of the breach by Parent
of (i)&nbsp;any representation or warranty made by Parent or Merger Sub under this Agreement or (ii)&nbsp;any covenant or agreement that is required to be performed by Parent following the Closing under this Agreement or any of the schedules or
exhibits attached hereto or any of the certificates furnished by Parent pursuant to this Agreement (but excluding any agreements the forms of which are attached as exhibits hereto that will be governed by the terms set forth therein). The amount of
Parent&#146;s and, after the Closing, Parent&#146;s and the Surviving Corporation&#146;s aggregate liability (x)&nbsp;under <U>Section</U><U></U><U>&nbsp;9.2(b)(i)</U> above shall not exceed $16,750,000 and (y)&nbsp;under
<U>Section</U><U></U><U>&nbsp;9.2(b)(ii)</U> above shall not exceed the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap (provided, that such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap shall be adjusted downward pursuant to
<U>Section</U><U></U><U>&nbsp;9.2(a)(iii)(B)</U> to the extent that Parent exercises its right of setoff against the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration). All indemnification of the Holders by Parent under this
<U>Section</U><U></U><U>&nbsp;9.2(b)</U> shall be effected by payment by Parent to the Paying Agent in immediately available funds by wire transfer to be distributed to the Holders in proportion to their respective portion of the Closing
Consideration and <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration in accordance with the Payment Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For
purposes of this <U>Article</U><U></U><U>&nbsp;IX</U>, the amount of any Indemnified Party&#146;s Losses will be reduced by (i)&nbsp;any amounts actually recovered by such Indemnified Party under any insurance policies, (ii)&nbsp;any amounts
actually recovered by such Indemnified Party pursuant to any indemnification right, claim, recovery, settlement, reimbursement arrangement, contract or payment by or against a third-party following its commercially reasonable efforts with respect to
the settlement or resolution of any claim for which any Indemnified Party is entitled to indemnification hereunder, and any such amounts actually received by the Indemnified Party following the payment of an indemnification claim under this
<U>Article</U><U></U><U>&nbsp;IX</U> shall be remitted to the applicable Indemnifying Party promptly following receipt thereof and (iii)&nbsp;any Tax benefit realized by the Indemnified Party or its respective Affiliates in the year in which the
Loss was incurred or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-70- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the immediately following year (calculated on a with versus without basis) arising from the incurrence or payment of any such indemnifiable claims. Parent will not permit the RWI Policy to be
terminated prior to the expiration of all of the Holders&#146; indemnification obligations under <U>Section</U><U></U><U>&nbsp;9.2(a)</U>, nor will Parent waive or permit to be waived any right under the RWI Policy in a manner adverse to the Holders
in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Indemnification Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Definitions</U>. For purposes of this Agreement, a party entitled to indemnification under this Agreement shall be referred to as an
&#147;<I><U>Indemnified Party</U></I>,&#148; and a party obligated to indemnify an Indemnified Party under this Agreement shall be referred to as an &#147;<I><U>Indemnifying Party</U></I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Claim Notices</U>. Each Indemnified Party shall provide written notice to the Indemnifying Party of any claim or demand that it may
have under this <U>Section</U><U></U><U>&nbsp;9.2</U> (a &#147;<I><U>Claim Notice</U></I>&#148;), and, in the event that there is asserted against an Indemnified Party any claim, demand, action, proceeding or investigation instituted by a Person
other than Parent or the Holder Representative on behalf of the Holders for which the Indemnifying Party may be obligated to indemnify hereunder (such claim, a &#147;<I><U>Third Party Claim</U></I>&#148;), such Indemnified Party shall provide a
Claim Notice with respect thereto within thirty (30)&nbsp;days following such Indemnified Party&#146;s receipt of such Third Party Claim; <U>provided</U>, <U>however</U>, that failure to give such notification shall not affect the indemnification
provided hereunder except to the extent the Indemnifying Party shall have been actually prejudiced as a result of such failure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) A Claim Notice with respect to a claim other than a Third Party Claim shall contain a reasonably detailed summary of the
facts underlying or related to such claim to the extent then known by the Indemnified Party, the subsection(s) of this <U>Section</U><U></U><U>&nbsp;9.2</U> pursuant to which the Indemnified Party is seeking indemnification, a list of those
representations, warranties and covenants that the Indemnified Party believes may have been breached in relation to such claim (if any), the Indemnified Party&#146;s good faith estimate of the Losses incurred as a result of, in connection with,
relating to or arising out of such claim, and a statement that the Indemnified Party seeks indemnification for Losses relating to such claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) A Claim Notice with respect to a Third Party Claim shall contain a reasonably detailed summary of the facts underlying or
relating to such claim to the extent then known by the Indemnified Party and any correspondence or notices (including court papers) received from the relevant third party (to the extent not prohibited by contract or applicable Law from furnishing),
the subsection(s) of this <U>Section</U><U></U><U>&nbsp;9.2</U> pursuant to which the Indemnified Party is seeking indemnification, a list of those representations, warranties and covenants that the Indemnified Party believes may have been breached
in relation to such claim (if any), the amount of damages alleged to have been suffered by the relevant third party or the Indemnified Party&#146;s good faith estimate of the Losses incurred as a result of, in connection with, relating to or arising
out of such claim, and a statement that the Indemnified Party seeks indemnification for Losses relating to such claim. From and after the delivery of a Claim Notice with respect to a Third Party Claim, the Indemnified Party shall deliver to the
Indemnifying Party, within ten (10) business days after the Indemnified Party&#146;s receipt thereof, copies of all notices and documents (including court papers) received by the Indemnified Party relating to the Third Party Claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-71- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Control of Contests by Indemnifying Party</U>. The Indemnifying Party shall be
entitled to assume, conduct and control, through counsel of its own choosing (reasonably acceptable to the Indemnified Party) and at its own expense, the defense of any Third Party Claim (unless (A)&nbsp;the claim for indemnification relates to or
arises in connection with any criminal or <FONT STYLE="white-space:nowrap">quasi-criminal</FONT> proceeding, action, indictment, allegation or investigation; (B)&nbsp;the Indemnified Party reasonably believes an adverse determination with respect to
the action, lawsuit, investigation, proceeding or other claim giving rise to such claim for indemnification would be detrimental to or injure the Indemnified Party&#146;s reputation or future business prospects; (C)&nbsp;the claim seeks an
injunction or equitable relief against the Indemnified Party; (D)&nbsp;the Indemnified Party has been advised by counsel that a reasonable likelihood exists of a conflict of interest between the Indemnifying Party and the Indemnified Party;
(E)&nbsp;upon petition by the Indemnified Party, the appropriate court rules that the Indemnifying Party failed or is failing to vigorously prosecute or defend such claim; or (F)&nbsp;the Indemnified Party reasonably believes that the Loss relating
to the claim would materially exceed the maximum amount that such Indemnified Party could then be entitled to recover under the applicable provisions of this <U>Section</U><U></U><U>&nbsp;9.2</U>; in which case the Indemnified Party could elect in
its sole discretion to assume, conduct and control such defense and the Indemnifying Party, if it had previously assumed such defense but no longer meets all of the conditions set forth in clauses&nbsp;(A) through (F)&nbsp;above, will cooperate with
the Indemnified Party with respect to the prompt transfer of such defense from the Indemnifying Party to the Indemnified Party if so elected by the indemnified party). The Holder Representative shall act on behalf of the Holders where they are
Indemnifying Parties hereunder in assuming, conducting and controlling the defense of Third Party Claims. Unless the Indemnified Party shall have notified the Indemnifying Party of the existence of one or more of the conditions set forth in
clauses&nbsp;(A) through (F)&nbsp;of the first sentence of this <U>Section</U><U></U><U>&nbsp;9.2(d)(iii)</U>, the Indemnifying Party shall have thirty (30)&nbsp;days (or such lesser number of days set forth in the Claim Notice as may be required by
any Governmental Entity, any court proceedings or regulatory inquiry or investigation) from receipt of the Claim Notice with respect to a Third Party Claim (the &#147;<I><U>Notice Period</U></I>&#148;) to notify the Indemnified Party of its election
to assume the defense of such Third Party Claim. If the Indemnifying Party notifies the Indemnified Party within the Notice Period that it elects to assume the defense of such Third Party Claim, it shall be conclusively established for purposes of
this Agreement that the Indemnifying Party is obligated to and shall indemnify and hold harmless the Indemnified Party from, against and in respect of all Losses incurred or suffered by the Indemnified Party to the extent arising from such Third
Party Claim, without any reservation of rights, subject only to the limitations contained in this <U>Section</U><U></U><U>&nbsp;9.2</U>. If the Indemnifying Party notifies the Indemnified Party within the Notice Period that it elects to defend such
Third Party Claim, it shall have the right to so defend, with counsel selected by the Indemnifying Party that is reasonably acceptable to the Indemnified Party, at the Indemnifying Party&#146;s expense. Once the Indemnifying Party has duly assumed
the defense of a Third Party Claim, the Indemnified Party shall have the right, but not the obligation, to participate in the defense thereof, including the opportunity to participate in any discussions or correspondence with any Governmental Entity
and to employ counsel separate from the counsel employed by the Indemnifying Party. The Indemnified Party shall participate in any such defense at its own expense unless (x)&nbsp;the Indemnifying Party and the Indemnified Party are both named
parties to the proceedings and the Indemnified Party shall have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-72- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concluded in good faith that representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or the availability to the
Indemnified Party of one or more defenses or counterclaims that are inconsistent with one or more of those that may be available to the Indemnifying Party in respect thereof or (y)&nbsp;the Indemnified Party assumes the defense of a Third Party
Claim after the Indemnifying Party has failed to diligently pursue a Third Party Claim it has assumed, as provided hereunder, and in the case of both (x)&nbsp;or (y), all such expenses incurred by the Indemnified Party in connection with such
participation shall be borne by the Indemnifying Party.<U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Control of Contests by Indemnified Party</U>. In the event the
Indemnifying Party (A)&nbsp;elects not to defend the Indemnified Party against a Third Party Claim, whether by not giving the Indemnified Party timely notice of its desire to so defend or otherwise, (B)&nbsp;is not entitled to defend the Third Party
Claim as a result of the Indemnified Party&#146;s election to defend the Third Party Claim as provided hereunder, or (C)&nbsp;after assuming the defense of a Third Party Claim, fails to conduct the defense of such Third Party Claim in a reasonably
diligent manner within ten (10)&nbsp;days after receiving written notice from the Indemnified Party to the effect that the Indemnifying Party has so failed, the Indemnified Party shall have the right but not the obligation to assume its own defense;
it being understood that the Indemnified Party&#146;s right to indemnification for such Third Party Claim shall not be adversely affected by assuming the defense of such Third Party Claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) <U>Settlement of Claims</U>. Whether or not the Indemnifying Party shall have assumed the defense of a Third Party Claim, the
Indemnifying Party shall have no Liability with respect to any compromise or settlement of such claims effected without its written consent (such consent not to be unreasonably withheld, delayed or conditioned) unless (A)&nbsp;there is no finding or
admission of any violation of Law or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnifying Party or any of its Affiliates, (B)&nbsp;there is no imposition of a consent order, decree,
injunction or other equitable relief that would restrict the future activity of the Indemnifying Party or its Affiliates, (C)&nbsp;the sole relief provided is monetary damages and a full, complete and unconditional release from all Liabilities with
respect to such claim is provided to the Indemnifying Party and its Affiliates, and (D)&nbsp;the monetary damages payable in connection with such compromise or settlement does not exceed $100,000. The Indemnifying Party shall not consent to the
entry of judgment, admit any liability with respect to, or settle, compromise or discharge, such Third Party Claim without the Indemnified Party&#146;s prior written consent (which consent shall not be unreasonably withheld, delayed or conditioned)
unless (x)&nbsp;there is no finding or admission of any violation of Law or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnified Party or any of its Affiliates, (y)&nbsp;there is no
imposition of a consent order, decree, injunction or other equitable relief that would restrict the future activity of the Indemnified Party or its Affiliates, and (z)&nbsp;the sole relief provided is monetary damages that are concurrently paid in
full by the Indemnifying Party and a full, complete and unconditional release from all Liabilities with respect to such claim is provided to the Indemnified Party and its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) <U>Cooperation</U>. Each party shall cooperate, and cause their respective Affiliates to cooperate, in the defense or prosecution of any
Third Party Claim and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-73- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therewith. Such cooperation also shall include the retention and, upon the Indemnifying Party&#146;s request, the provision to the Indemnifying Party of records and information which are
reasonably relevant to such Third Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder; <U>provided</U>, that such cooperation shall not
unreasonably interfere with the business or operations of such party. All Losses incurred or suffered by the Indemnified Party in connection with responding to, complying with or satisfying the Indemnifying Party&#146;s requests for cooperation
shall be promptly reimbursed by the Indemnifying Party. If the Indemnifying Party disputes the amount of, or otherwise refuses or fails to reimburse, any such Losses which the Indemnified Party has incurred and for which the Indemnified Party has
sought reimbursement from the Indemnifying Party, the Indemnified Party shall not be obligated to continue providing cooperation with respect to the defense of the relevant Third Party Claim until such dispute has been resolved or all such Losses
have been reimbursed in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Type of Damages</U>. Notwithstanding anything to the contrary in this Agreement, no Person shall be
liable under this <U>Article</U><U></U><U>&nbsp;IX</U> for any consequential, special, exemplary or punitive damages, except to the extent awarded in a final determination in connection with a Third Party Claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Mitigation</U>. Each Indemnified Party shall use commercially reasonable efforts to mitigate any indemnifiable Loss, and if the
Indemnified Party fails to use such efforts, the Indemnified Party shall not be entitled to be indemnified for any portion of such Loss that reasonably could have been avoided had the Indemnified Party so complied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Characterization of Indemnification Payments</U>. The parties agree to treat all payments made pursuant to this
<U>Article</U><U></U><U>&nbsp;IX</U> as adjustments to the Closing Consideration for Tax purposes, unless otherwise required by applicable Law.<U> </U> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE&nbsp;X </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous and General </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1. <U>Holder Representative</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Appointment of Holder Representative</U>. By the adoption of the Merger, and by receiving the benefits thereof, including any
consideration payable hereunder, each Holder shall be deemed to have approved Shareholder Representative Services LLC as the Holder Representative as of the Closing and is hereby designated to, and shall act as, the representative of the Holders,
and is hereby authorized to act on behalf of the Holders for all purposes in connection with this Agreement and any related agreement. The Holder Representative shall have the sole and exclusive right to seek to enforce any and all rights of the
Holders under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Scope of Authority of Holder Representative</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Without limiting <U>Section</U><U></U><U>&nbsp;10.1(a)</U>, effective as of the Closing, the Holder Representative shall have the power
and authority to take all such actions on behalf of each Holder as the Holder Representative, in its sole reasonable discretion, may deem to be appropriate on all matters related to or arising in connection with this Agreement. Such powers shall
include: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-74- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) executing and delivering this Agreement and any and all supplements,
amendments, waivers or modifications thereto in accordance with the terms thereof and all certificates, consents and other documents contemplated by this Agreement or as may be necessary or appropriate to effect the transactions contemplated by this
Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) giving and receiving notices and other communications relating to this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) taking or refraining from taking any actions (whether by negotiation, settlement, litigation or otherwise) to resolve or
settle all matters and disputes arising out of or related to this Agreement and the performance or enforcement of the obligations, duties and rights pursuant to this Agreement, including in connection with any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) reviewing and disputing the Final Closing Statement and the related working papers in accordance with
<U>Sections</U><U></U><U>&nbsp;4.1(b)</U> and <U>(c)</U>&nbsp;of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) paying the reasonable fees of any
Accounting Firm in accordance with <U>Sections</U><U></U><U>&nbsp;4.1(c)</U> and <U>4.2(c)</U> of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3)
authorizing or disputing any adjustment to the Closing Consideration and delivering instructions to the Paying Agent in connection therewith, including the release of any amounts funded in respect of the Purchase Price Adjustment Holdback (if any),
in each case in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) authorizing and/or disputing tax payment
obligations, and retaining books and records in accordance with <U>Sections</U><U></U><U>&nbsp;4.2</U>, <U>6.7</U> and <U>6.14</U> of this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(5) conducting and controlling the defense of, and negotiating, agreeing to, settling, paying or contesting, Third Party
Claims in accordance with <U>Section</U><U></U><U>&nbsp;9.2(d)</U> of this Agreement and paying reasonable expenses in connection therewith; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) directing the deposit into escrow for purposes of indemnification any amounts otherwise payable to the Holders hereunder
and directing the actions of any escrow agent with respect thereto (including with respect to the investment and disposal of amounts in escrow); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(E) delivering any funds held in the Holder Representative Expense Account to the Paying Agent for further distribution to
each Holder in accordance herewith; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-75- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(F) taking all actions necessary or appropriate in the judgment of the
Holder Representative for the accomplishment of the foregoing, and taking all other actions to be taken by or on behalf of the Holders following the Closing Date in connection with this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company (prior to the Closing) and the Holders (after the Closing) shall reimburse the Holder Representative for its reasonable costs
and expenses (including attorneys&#146; fees) incurred in connection with its duties as the Holder Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The Holder
Representative may perform any and all of its duties through its agents, representatives, attorneys, custodians, and/or nominees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Indemnification</U>. The Holders shall indemnify the Holder Representative against any reasonable, documented, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> Losses, Liabilities and expenses
(&#147;<I><U>Representative Losses</U></I>&#148;) arising out of or in connection with this Agreement and any related agreements, in each case as such Representative Loss is suffered or incurred; <U>provided</U>, that in the event that any such
Representative Loss is finally adjudicated to have been caused by the fraud, bad faith, gross negligence or willful misconduct of the Holder Representative, Holder Representative will reimburse the Holders the amount of such indemnified
Representative Loss to the extent attributable to such gross negligence or willful misconduct. If not paid directly to the Holder Representative, Representative Losses will be recovered by the Holder Representative (i)&nbsp;first, from the funds in
the Holder Representative Expense Account, (ii)&nbsp;second, once the Holder Representative Expense Account has been exhausted, from any other readily available funds that become payable to the Holders under this Agreement at such time as such
amounts would otherwise be distributable to the Holders, and (iii)&nbsp;third, from the Holders directly. Notwithstanding the foregoing to the contrary, nothing in this <U>Section</U><U></U><U>&nbsp;10.1</U> shall relieve the Holders from their
obligation to promptly pay such Representative Losses as they are suffered or incurred. In no event will the Holder Representative be required to advance its own funds on behalf of the Holders or otherwise. Notwithstanding anything in this Agreement
to the contrary, any restrictions or limitations on liability or indemnification obligations of, or provisions limiting the recourse against <FONT STYLE="white-space:nowrap">non-parties</FONT> otherwise applicable to, the Holders set forth elsewhere
in this Agreement are not intended to be applicable to the indemnities provided to the Holder Representative hereunder. This <U>Section</U><U></U><U>&nbsp;10.1(c)</U> shall survive the Closing, the resignation or removal of the Holder Representative
or the termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Limitation of Liability</U>. THE HOLDER REPRESENTATIVE WILL INCUR NO LIABILITY IN CONNECTION
WITH ITS SERVICES PURSUANT TO THIS AGREEMENT AND ANY RELATED AGREEMENTS EXCEPT TO THE EXTENT RESULTING FROM ITS FRAUD, BAD FAITH, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. THE HOLDER REPRESENTATIVE SHALL NOT BE LIABLE FOR ANY ACTION OR OMISSION
PURSUANT TO THE ADVICE OF COUNSEL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-76- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Resignation; Successor Holder Representative</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Holder Representative may resign at any time by providing notice of its resignation (A)&nbsp;pursuant to that certain engagement
letter, dated August&nbsp;1, 2022, entered into by and among Shareholder Representative Services LLC and certain of the Holders and (B)&nbsp;to Parent and the Surviving Corporation. In addition, the Holder Representative may be removed in its
capacity as such upon the affirmative vote of the Holders of a majority of the Shares, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, as determined in accordance with the Payment Schedule. Such
resignation or removal shall be effective twenty (20)&nbsp;days after the delivery of such notice or upon the earlier appointment by the Holders of a successor, and the Holder Representative&#146;s sole responsibility thereafter shall be to safely
keep any assets then held by it on behalf of the Holders and to deliver the same to a successor Holder Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Any
corporation or association into which the Holder Representative may be converted or merged, or with which it may be consolidated, or to which it may sell or transfer all or substantially all of its corporate trust business and assets as a whole or
substantially as a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the Holder Representative is a party, shall be and become the successor Holder Representative under this
Agreement and shall have and succeed to the rights, powers, duties, immunities, privileges, liabilities and obligations of its predecessor, without the execution or filing of any instrument or paper or the performance of any further act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Termination of Holder Representative Role</U>. Subject to <U>Section</U><U></U><U>&nbsp;8.5</U>, upon the termination of this Agreement
in accordance with its terms or the resignation or removal of the Holder Representative in accordance with this <U>Section</U><U></U><U>&nbsp;10.1</U>, the Holder Representative shall have no further responsibilities hereunder or authority to act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Effect on Rights of Parent and Merger Sub</U>. Anything set forth in this <U>Section</U><U></U><U>&nbsp;10.1</U> to the contrary
notwithstanding, in no event shall anything contained in this <U>Section</U><U></U><U>&nbsp;10.1</U> amend, alter, waive, terminate (or otherwise limit) or be deemed to amend, alter, waive, terminate (or otherwise limit) any of the rights and
remedies of Parent or Merger Sub set forth in any other provision of this Agreement (including the schedules and exhibits hereto), including <U>Section</U><U></U><U>&nbsp;4.1</U>, <U>Section</U><U></U><U>&nbsp;4.2</U> and
<U>Section</U><U></U><U>&nbsp;9.2</U> of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2. <U>Actions of the Holder Representative</U>. Following the Closing, a
decision, act, consent or instruction of the Holder Representative shall constitute a decision of all Holders and shall be final, binding and conclusive upon each such Holder, and Parent, Merger Sub and, following the Closing, the Surviving
Corporation, shall be entitled to rely conclusively on the decisions, actions, consents or instructions of the Holder Representative as being the decision, action, consent or instruction of each and all such Holders. Parent is hereby relieved from
any liability to any Person for any acts done by them in accordance with such decision, act, consent or instruction of the Holder Representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.3. <U>Modification or Amendment</U>. Any provision of this Agreement may be amended, modified, supplemented or waived only by an instrument
in writing duly executed by, if executed prior to the Effective Time, Parent, the Company, and solely to the extent any such amendment, modification, supplement or waiver affects any rights or obligations of the Holder Representative under this
Agreement, the Holder Representative, and if executed after the Effective Time, Parent and the Holder Representative. Any such amendment, modification, supplement or waiver shall be for such period and subject to such conditions as shall be
specified in the instrument effecting the same and shall be binding upon the parties thereto, and any such waiver shall be effective only in the specific instance and for the purposes for which given. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-77- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.4. <U>Waiver of Conditions</U>. The conditions to each of the parties&#146; obligations
to consummate the Merger are for the sole benefit of such party and may be waived by such party in whole or in part to the extent permitted by applicable Laws; <U>provided</U>, that no failure on the part of any party to exercise and no delay in
exercising, and no course of dealing with respect to, any right, remedy, power or privilege under this Agreement shall operate as a waiver of such right, remedy, power or privilege, nor shall any single or partial exercise of any right, remedy,
power or privilege under this Agreement preclude any other or further exercise of any such right, remedy, power or privilege or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges provided in this
Agreement are cumulative and not exclusive of any rights, remedies, powers and privileges provided by applicable Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.5.
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. Execution or delivery of an
executed counterpart of a signature page to this Agreement may be made by electronic or digital delivery such as in Adobe Portable Document Format or using generally recognized <FONT STYLE="white-space:nowrap">e-signature</FONT> technology (e.g.,
DocuSign or Adobe Sign). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.6. <U>GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL; SPECIFIC PERFORMANCE</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE
LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION. The parties hereby irrevocably submit to the personal jurisdiction of the courts
of the State of Delaware and the Federal courts of the United States of America located in the State of Delaware solely in respect of the interpretation and enforcement of the provisions of this Agreement and of the documents referred to in this
Agreement, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to the negotiation, execution or performance of this Agreement, the Merger and the Transactions, and hereby waive the right to
assert, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not
maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims relating to such action,
proceeding, or transactions shall be heard and determined in such a Delaware State or Federal court. The parties hereby consent to and grant any such court jurisdiction over the person of such parties and, to the extent permitted by applicable Law,
over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in <U>Section</U><U></U><U>&nbsp;10.7</U> or in such other manner as may be permitted
by Law shall be valid and sufficient service thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-78- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING
OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER OR THE TRANSACTIONS. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii)&nbsp;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv)&nbsp;EACH PARTY HAS BEEN
INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;10.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached, and monetary damages, even if available, would not be an adequate remedy for any such failure to perform or any breach of this Agreement. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the Court of Chancery of the State of Delaware without proof of actual damages, this
being in addition to any other remedy to which such party is entitled at Law or in equity. Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief as provided herein on the
basis that the other party has an adequate remedy at Law. Any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement shall not be required to provide
any bond or other security in connection with any such order or injunction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the extent the Company brings any action to enforce
specifically the performance of the terms and provisions of this Agreement when expressly available to the Company pursuant to the terms of this Agreement, the Termination Date shall automatically be extended by (i)&nbsp;the amount of time during
which such action is pending, plus ten (10)&nbsp;business days or (ii)&nbsp;such other time period established by the court presiding over such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No action shall be brought or maintained by any party hereto or any of their respective Affiliates or their respective successors or
permitted assigns against any current or former direct or indirect equity holder, officer, director, employee or Affiliate of any Holder (who shall be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;10.6(e)</U>), who is not otherwise
expressly identified as a party hereto, and no recourse shall be brought or granted against any of them, by virtue of or based upon any alleged misrepresentation or inaccuracy in or breach of any of the representations, warranties or covenants of
any party hereto set forth or contained in this Agreement or any exhibit or schedule hereto or any certificate delivered hereunder; provided, that this <U>Section</U><U></U><U>&nbsp;10.6(e)</U> shall not apply to the terms and conditions of
<U>Section</U><U></U><U>&nbsp;10.1</U>, which shall be enforceable by the Holder Representative in its entirety against the Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-79- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.7. <U>Notices</U>. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted hereunder shall be in writing and shall be deemed given: (a)&nbsp;on the date delivered if delivered personally, (b)&nbsp;on the date delivered by a private courier, (c)&nbsp;on the date sent by
electronic mail, with confirmation of receipt, if sent prior to 5:00 p.m. New York time or, if sent later, then on the next business day, (d)&nbsp;on the next business day after the date mailed, by nationally recognized overnight courier specifying
next day delivery or (e)&nbsp;on the fifth (5th) business day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications, to be valid, must be addressed as follows (or to such other persons
or addresses as may be designated in writing by the party to receive such notice as provided below): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>If to Parent or Merger Sub</U>:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">CONMED Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11311
Concept Boulevard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Largo, FL 33773 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peter Shagory, EVP, Strategy and Corporate Development
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Dan Jonas, EVP, Legal Affairs, General Counsel&nbsp;&amp; Secretary </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;petershagory@conmed.com
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">danieljonas@conmed.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">CONMED Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11311 Concept
Boulevard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Largo, FL 33773 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patrick Beyer, President International and Global Orthopedics
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Sarah Oliker, Assistant General Counsel, Assistant Secretary </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;patrickbeyer@conmed.com
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">saraholiker@conmed.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Sullivan&nbsp;&amp; Cromwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">125 Broad Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New York, NY
10004 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bob Downes </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Melissa Sawyer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Lauren Boehmke
</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;downesr@sullcrom.com
</P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">sawyerm@sullcrom.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">boehmkel@sullcrom.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>If to
the Company</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Biorez, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">470 James Street, Suite #14 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New
Haven, CT 06513 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kevin A. Rocco, President and Chief Executive Officer
</P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;krocco@biorez.com
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-80- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Shipman&nbsp;&amp; Goodwin LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">One Constitution Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Hartford,
CT 06103-1919 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Matthew J. Monteith </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MMonteith@goodwin.com </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins
LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">200 Clarendon Street, 27th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Boston, MA 02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attention: Ian
N. Bushner; Navneeta Rekhi Email: Ian.Bushner@lw.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Navneeta.Rekhi@lw.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>If to the Holder Representative</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Shareholder Representative Services LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">950 17<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street, Suite 1400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Denver, CO 80202 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Managing</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Director </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deals@srsacquiom.com</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.8. <U>Entire Agreement</U>. This Agreement (including any schedules, annexes and exhibits hereto), the Company Disclosure Letter and that
certain Confidential Disclosure Agreement, dated May&nbsp;16, 2022, between Parent and the Company (the &#147;<I><U>Confidentiality Agreement</U></I>&#148;) constitute the entire agreement, and supersede all other prior agreements, understandings,
representations and warranties both written and oral, among the parties, with respect to the subject matter hereof. Any matter, information or item disclosed in any section of the Company Disclosure Letter (whether or not an explicit cross reference
appears) shall be deemed to have been disclosed for purposes of any other section of the Company Disclosure Letter in respect of which the relevance of such disclosure is reasonably apparent on its face. Except for information required by a
provision of this Agreement to be listed in the Company Disclosure Letter, the inclusion of any matter, information or item in any exhibit or schedule to this Agreement shall not be deemed to constitute an admission of any liability by the Company
to any third party, broaden the scope of any representation, warranty or covenant of the Company herein or otherwise imply that any such matter, information or item is material or creates a measure for materiality for the purposes of this Agreement,
or that the disclosure of such matter, information or item means that such matter, information or item is required to be disclosed by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No party shall be bound by, or be liable for, any alleged representation, promise, inducement or statement of intention not contained herein.
The Confidentiality Agreement shall survive any termination of this Agreement, <I>mutatis mutandis</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-81- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.9. <U>No Other Representations or Warranties</U>. EACH PARTY HERETO AGREES THAT, EXCEPT
FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT, (A)&nbsp;NONE OF PARENT, MERGER SUB, THE COMPANY OR ANY OTHER PERSON MAKES ANY OTHER REPRESENTATIONS OR WARRANTIES, AND EACH HEREBY DISCLAIMS ANY OTHER REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, OR AS TO THE ACCURACY OR COMPLETENESS OF ANY OTHER INFORMATION, MADE BY, OR MADE AVAILABLE BY, ITSELF, ANY OF ITS REPRESENTATIVES OR THE OTHER PARTY OR ANY OF THE OTHER PARTY&#146;S REPRESENTATIVES OR AFFILIATES, WITH
RESPECT TO, OR IN CONNECTION WITH, THE NEGOTIATION, EXECUTION OR DELIVERY OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE OTHER OR THE OTHER&#146;S REPRESENTATIVES OF ANY DOCUMENTATION OR
OTHER INFORMATION WITH RESPECT TO ANY ONE OR MORE OF THE FOREGOING, INCLUDING, WITHOUT LIMITATION, ANY OTHER REPRESENTATION OR WARRANTY OF MERCHANTABILITY OR THE <FONT STYLE="white-space:nowrap">PRO-FORMA</FONT> FINANCIAL INFORMATION, FINANCIAL
PROJECTIONS OR OTHER <FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES, AS APPLICABLE, AND (B)&nbsp;NONE OF PARENT, MERGER SUB OR THE COMPANY OR ANY OF THEIR RESPECTIVE AFFILIATES OR
REPRESENTATIVES IS RELYING, AND EACH OF PARENT, MERGER SUB AND THE COMPANY AND EACH OF THEIR RESPECTIVE AFFILIATES AND REPRESENTATIVES HAS NOT RELIED UPON ANY OTHER EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE OTHER PARTY,
THIS AGREEMENT OR THE TRANSACTIONS. EACH OF PARENT AND MERGER SUB ACKNOWLEDGES THAT IT AND ITS REPRESENTATIVES HAVE BEEN PERMITTED ACCESS TO THE BOOKS AND RECORDS, FACILITIES, EQUIPMENT, TAX RETURNS, CONTRACTS, INSURANCE POLICIES (OR SUMMARIES
THEREOF) AND OTHER PROPERTIES AND ASSETS OF THE COMPANY AND ITS SUBSIDIARIES AND THAT IT AND ITS REPRESENTATIVES HAVE HAD THE OPPORTUNITY TO MEET WITH THE OFFICERS OF THE COMPANY TO DISCUSS THE BUSINESS OF THE COMPANY AND ITS SUBSIDIARIES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.10. <U>Expenses</U>. Except as otherwise provided in this Agreement, whether or not the Transactions are consummated, each party hereto will
pay its own costs and expenses incurred in connection with the negotiation, execution and consummation of the Transactions, including the Merger. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.11. <U>Assignment</U>. This Agreement shall not be assignable by operation of Law or otherwise; <U>provided</U>, <U>however</U>, that prior
to the Effective Time, Parent may designate, by written notice to the Company, another wholly-owned direct or indirect Subsidiary in lieu of Merger Sub, in which event all references herein to Merger Sub shall be deemed references to such other
Subsidiary, except that all representations and warranties made herein with respect to Merger Sub as of the date hereof shall be deemed representations and warranties made with respect to such other Subsidiary as of the date of such designation. Any
purported assignment in violation of this Agreement is void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.12. <U>No Third Party Beneficiaries</U>. Except as provided in
<U>Section</U><U></U><U>&nbsp;6.10(a)</U> (<I>D&amp;O Insurance and Indemnification</I>), <U>Section</U><U></U><U>&nbsp;9.2</U> (<I>Indemnification</I>), Section<U></U><U>&nbsp;10.9</U> (<I>No Other Representations or Warranties</I>) and
<U>Section</U><U></U><U>&nbsp;10.17</U> (<I>Waiver of Conflicts; Privilege</I>), Parent and the Company hereby agree that their respective representations, warranties and covenants set forth herein are solely for the benefit of the other party
hereto, in accordance with and subject to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-82- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of this Agreement, and this Agreement is not intended to, and does not, confer upon any Person other than the parties hereto any rights or remedies hereunder, including the right to rely
upon the representations and warranties set forth herein. The representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such
representations and warranties are subject to waiver by the parties hereto in accordance with <U>Section</U><U></U><U>&nbsp;10.4</U> without notice or liability to any other Person. Persons other than the parties hereto may not rely upon the
representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date hereof or as of any other date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.13. <U>Obligations of Parent and of the Company</U>. Whenever this Agreement requires a Subsidiary of Parent to take any action, such
requirement shall be deemed to include an undertaking on the part of Parent to cause such Subsidiary to take such action. Whenever this Agreement requires a Subsidiary of the Company to take any action, such requirement shall be deemed to include an
undertaking on the part of the Company to cause such Subsidiary to take such action and, after the Effective Time, on the part of the Surviving Corporation to cause such Subsidiary to take such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.14. <U>Definitions</U>. For the convenience of the parties hereto, each of the terms set forth in <U>Annex</U><U></U><U>&nbsp;A</U> is
defined in the Section of this Agreement set forth opposite such term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.15. <U>Severability</U>. The provisions of this Agreement shall
be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application of such provision to any Person or any
circumstance, is invalid or unenforceable, (a)&nbsp;a suitable and equitable provision agreed by all parties shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or
unenforceable provision and (b)&nbsp;the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.16.
<U>Interpretation; Construction</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The table of contents, captions and headings appearing in this Agreement are for convenience of
reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof. Where a reference in this Agreement is made to an Article, Section, Annex, Exhibit or Schedule, such
reference shall be to an Article, Section, Annex, Exhibit or Schedule to this Agreement unless otherwise indicated. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be
deemed to be followed by the words &#147;without limitation&#148; or words of like import. The use of the masculine, feminine or neuter gender, or the singular or plural form of words used herein (including defined terms) shall not limit any
provision of this Agreement. Reference herein to a particular Person includes such Person&#146;s successors and assigns to the extent such successors and assigns are permitted by the terms of any applicable Contract. Reference to a particular
Contract (including this Agreement), document or instrument means such Contract, document or instrument as amended or modified and in effect from time to time in accordance with the terms thereof. Any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-83- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reference to a particular Law means such Law as amended, modified or supplemented (including all rules and regulations promulgated thereunder) and, unless otherwise provided, as in effect from
time to time. The terms &#147;cash&#148; and &#147;$&#148; mean United States Dollars. The use of the terms &#147;hereunder,&#148; &#147;hereof,&#148; &#147;hereto&#148; and words of similar import shall refer to this Agreement as a whole and not to
any particular Article, Section, paragraph or clause of, or Annex to, this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties have participated jointly in
negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.17. <U></U><U>Waiver of Conflicts;
Privilege</U>. Recognizing that each of Shipman&nbsp;&amp; Goodwin LLP (&#147;<I><U>Shipman</U></I>&#148;) and Latham&nbsp;&amp; Watkins LLP (&#147;<I><U>Latham</U></I>&#148; and together with Shipman, &#147;<I><U>Company Counsel</U></I>&#148;) has
acted as legal counsel to the Company and its Subsidiaries and that Company Counsel may act as legal counsel to the Holder Representative or certain of the Holders and their respective Affiliates (which will no longer include the Company and its
Subsidiaries after the Closing), Parent hereby waives, on behalf of itself and its Affiliates (which will include the Surviving Corporation and the Subsidiaries of the Surviving Corporation after the Closing), any conflicts that may arise in
connection with Company Counsel representing the Holder Representative, any Holder or their Affiliates after the Closing as such representation may relate to Parent, the Surviving Corporation, the Subsidiaries of the Surviving Corporation and their
respective Affiliates or the transactions contemplated by this Agreement. In addition, all communications involving attorney-client confidences between any of the Holders (including, for the avoidance of doubt, Holders of Convertible Promissory
Notes), the Company and its Subsidiaries or their respective Affiliates, on the one hand, and Company Counsel, on the other hand, relating to the transactions contemplated by this Agreement or the subject matter thereof shall be deemed to be
attorney-client confidences that belong to the Holders and their respective Affiliates (and not the Surviving Corporation or any of its Subsidiaries or Affiliates) from and after the Closing in connection with any dispute between the parties
relating to the transactions contemplated by this Agreement. Accordingly, none of Parent, the Surviving Corporation, or any Subsidiaries of the Company or the Surviving Corporation shall knowingly and intentionally access any such communications or
any of the files of Company Counsel relating to such engagement from and after the Closing. Without limiting the generality of the foregoing, from and after the Closing, (a)&nbsp;the Holders and their respective Affiliates (and not the Parent, the
Surviving Corporation, or any of their respective Affiliates or Subsidiaries) shall be the holders of the attorney-client privilege with respect to such engagement, and the attorney-client privilege and the expectation of client confidence shall not
pass to or be claimed by any of Parent, the Surviving Corporation, or any of their respective Affiliates or Subsidiaries, (b)&nbsp;to the extent that files of Company Counsel in respect of such engagement constitute property of the client, only the
Holders and their respective Affiliates (and not the Parent, the Surviving Corporation, or any of their respective Affiliates or Subsidiaries) shall hold such property rights and (c)&nbsp;Company Counsel shall have no duty whatsoever to reveal or
disclose any such attorney-client communications or files to Parent, the Surviving Corporation, or any of their respective Affiliates or Subsidiaries by reason of any attorney-client relationship between the Company, the Surviving Corporation, or
any of their respective Affiliates or Subsidiaries or otherwise, in each case in connection with any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-84- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dispute between the parties relating to the transactions contemplated by the Agreement. Parent, the Company, the Surviving Corporation and their respective Subsidiaries are not waiving any
attorney-client privilege in connection with any third party claim. If any such attorney-client privileged information is accessed by or provided to Parent or its Affiliates, inadvertently or otherwise, such access or production shall in no way
prejudice or otherwise constitute a waiver of any claim of privilege as against any third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-85- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized officers of the parties hereto as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BIOREZ, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Rocco</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Kevin Rocco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CONMED CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Curt R. Hartman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Curt R. Hartman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chair, President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PROMETHEUS MERGER SUB, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel S. Jonas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Daniel S. Jonas, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President, Legal Affairs, General Counsel and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHAREHOLDER REPRESENTATIVE SERVICES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sam Riffe</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sam Riffe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Defined Terms </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; ">Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; ">Section</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2022 Annual Bonus Payment Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2022 Bonus Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">280G Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accounting Firm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accrued Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acquisition Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Affiliate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreed Accounting Principles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Applicable L4Q Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Applicable Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bankruptcy and Equity Exception</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(e)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Book-Entry Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">business day</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Canaccord</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Carve-Out</FONT> Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change of Control Transaction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Charter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claim Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(d)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Net Working Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(iii)(A)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commencement Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company 401(k) Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(f)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Cash</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Disclosure Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company&#146;s Knowledge</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(h)(vi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Privacy Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(e)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Registered IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Warrants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confidentiality Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contract</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(f)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Controlled Group Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible Promissory Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible Promissory Note Holder Election</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D&amp;O Indemnified Persons</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D&amp;O Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Debt Repayment Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(A)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Deductible</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(a)(ii)(A)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Delaware Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DGCL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disputed Calculations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissenting Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DOJ</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(xix)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Downward Adjustment Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Notice of Disagreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Payout Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Environmental Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(o)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ERISA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ERISA Affiliate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ERISA Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Estimated Closing Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Estimated Closing Net Working Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(iii)(A)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Estimated Closing Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(viii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDCA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDCA Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Final Closing Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Final Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(g)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fraud</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fundamental Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Funded Debt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GAAP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Governmental Entity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(f)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hazardous Substance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(o)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Health Care Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(xix)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">HHS-OIG</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(xx)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Highwater Mark</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder Entitlement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Percentage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder Representative Expense Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder Representative Expense Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indebtedness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnified Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(d)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnifying Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(d)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Information Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Insurance Policies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(t)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intellectual Property Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interim Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Inventory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(s)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IRS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(j)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Key Employee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Knowledge of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(h)(vi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Latham</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leased Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(m)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Letter of Transmittal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lien</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Losses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(l)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Medical Device</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Most Recent Company Balance Sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(g)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Most Recent Subsidiary Balance Sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(g)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Working Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Working Capital Upper Boundary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(iii)(C)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Working Capital Lower Boundary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(iii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Employment Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of Disagreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(d)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Cancellation Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Cashout Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(ii)</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Order</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parachute Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Participating Employee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Participating Employees&#146; Percentage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paying Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Payment Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Percentage Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permitted Lien</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Per Share Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Personal Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.14(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Vacation Accruals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.9(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Privacy Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Products Liability Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.10(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Purchase Price Adjustment Holdback</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Quarter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Regulatory Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(k)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Representatives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Requisite Stockholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(e)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Residual <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RWI Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SEC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shipman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Software</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stockholder Consent Delivery Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stockholder Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stockholders Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Straddle Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.14(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subsidiary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Takeover Statute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(n)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(p)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Return</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(p)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(d)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trade Secrets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(r)(xi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transaction Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(b)(ii)(B)</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transaction Proceeding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(e)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transfer Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.14(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unpaid Indemnification Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.2(a)(iii)(B)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Upward Adjustment Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1(c)(ii)(A)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Cancellation Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)(v)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d220699dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECOND AMENDMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND
AMENDMENT, dated as of August&nbsp;1, 2022 (this &#147;<U>Amendment</U>&#148;), to the Seventh Amended and Restated Credit Agreement, dated as of July&nbsp;16, 2021 (as amended, supplemented or otherwise modified from time to time, the
&#147;<U>Credit Agreement</U>&#148;), among CONMED Corporation, a Delaware corporation (the &#147;<U>Parent Borrower</U>&#148;), the Foreign Subsidiary Borrowers (as defined therein) from time to time parties thereto, the several banks and other
financial institutions or entities from time to time parties thereto (the &#147;<U>Lenders</U>&#148;) and JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the &#147;<U>Administrative Agent</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Credit Agreement, the Lenders have agreed to make, and have made, certain loans and other extensions of credit to the
Borrowers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parent Borrower has further requested that the Credit Agreement be amended as set forth herein; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Lenders constituting the Required Lenders are willing to agree to this Amendment on the terms set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Capitalized Terms</U>. Capitalized terms used herein and not otherwise defined herein shall have the meanings given to them in
the Credit Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Amendments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Section 1.1 (<I>Defined Terms</I>) of the Credit Agreement is hereby amended as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The definition of &#147;<U>Consolidated Senior Secured Leverage Ratio</U>&#148; is hereby amended by deleting the
reference therein to &#147;$75,000,000&#148; and substituting in lieu thereof the dollar amount &#147;$100,000,000&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The definition of &#147;<U>Consolidated Total Leverage Ratio</U>&#148; is hereby amended by deleting the
reference therein to &#147;$75,000,000&#148; and substituting in lieu thereof the dollar amount &#147;$100,000,000&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The definition of &#147;<U>Indebtedness</U>&#148; is hereby amended by inserting the following proviso at the
end thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;; <U>provided,</U> <U>further,</U> that no <FONT STYLE="white-space:nowrap">earn-out</FONT> obligation arising in
connection with any other acquisition by the Parent Borrower or any of its Subsidiaries shall constitute Indebtedness unless and until such obligation is finally determined to be due and payable under the relevant acquisition agreement and solely if
not paid within five days after the date it is finally determined to be due and payable.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Section 7.1(b) (<I>Consolidated Total Leverage Ratio</I>) of the
Credit Agreement is hereby amended and restated as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Permit the Consolidated Total Leverage Ratio as at the last day of any period of four
consecutive fiscal quarters of the Parent Borrower and its Subsidiaries to exceed (i)&nbsp;with respect to the period of four consecutive fiscal quarters ending June&nbsp;30, 2021 and September&nbsp;30, 2021, 5.25 to 1.00, (ii) with respect to the
period of four consecutive fiscal quarters ending December&nbsp;31, 2021 and March&nbsp;31, 2022, 5.00 to 1.00, (iii) with respect to the period of four consecutive fiscal quarters ending June&nbsp;30, 2022, September&nbsp;30, 2022 and
December&nbsp;31, 2022, 6.25 to 1.00, (iv) with respect to the four consecutive fiscal quarters ending March&nbsp;31, 2023 and June&nbsp;30, 2023, 6.00 to 1.00, (v) with respect to the four consecutive fiscal quarters ending September&nbsp;30, 2023
and December&nbsp;31, 2023, 5.75 to 1.00 and (vi)&nbsp;otherwise, 5.50 to 1.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Parent Borrower or any of its
Subsidiaries consummates a Material Acquisition, at the election of the Parent Borrower (the notice of which election shall be given prior to the earlier of (i)&nbsp;the date that is thirty (30)&nbsp;days after consummating the relevant Material
Acquisition and (ii)&nbsp;the date by which the Parent Borrower has to deliver financial statements in accordance with Section&nbsp;6.1(a) or (b)&nbsp;in respect of the fiscal quarter in which such Material Acquisition was consummated), the
Consolidated Total Leverage Ratio may be 0.50 to 1.00 (or such lesser amount as is required to comply with clause (x)&nbsp;of the proviso below) greater than the ratio set forth above for four consecutive fiscal quarters starting with the fiscal
quarter in which such Material Acquisition is consummated; provided that (x)&nbsp;the required Consolidated Total Leverage Ratio that would apply as a result of any such <FONT STYLE="white-space:nowrap">step-up</FONT> shall be no more than 6.00 to
1.00, (y) such <FONT STYLE="white-space:nowrap">step-up</FONT> shall be permitted only twice during this Agreement and (z)&nbsp;there shall be at least two fiscal quarters in between any such <FONT STYLE="white-space:nowrap">step-ups.&#148;</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Conditions to Effectiveness of Amendment</U>. The amendments set forth in this Amendment shall become effective on the date
(the &#147;<U>Second Amendment Effective Date</U>&#148;) on which the following conditions precedent have been satisfied: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall have received this Amendment executed and delivered by the Administrative Agent,
the Parent Borrower, each Foreign Subsidiary Borrower party to the Credit Agreement on the Second Amendment Effective Date and Lenders constituting the Required Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Lenders and the Administrative Agent shall have received (to the extent invoiced at least two Business Days
prior to the Second Amendment Effective Date) all fees and reasonable and documented expenses required to be paid on or before the Second Amendment Effective Date pursuant to the Credit Agreement and this Amendment (including the reasonable and
documented fees and expenses of one legal counsel pursuant to Section&nbsp;6 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Representations and Warranties</U>.
Each Borrower hereby represents and warrants that (a)&nbsp;each of the representations and warranties made by any Loan Party in or pursuant to the Loan Documents is, after giving effect to this Amendment, true and correct in all material respects
(or in all respects if qualified by materiality) on and as of the Second Amendment Effective Date as if made on and as of the Second Amendment Effective Date, except for representations and warranties expressly stated to relate to a specific earlier
date, in which case such representations and warranties were true and correct in all material respects (or in all respects if qualified by materiality) as of such earlier date and (b)&nbsp;after giving effect to this Amendment, no Default or Event
of Default has occurred and is continuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Effects on Credit Documents</U>. (a)&nbsp;Except as expressly set forth herein,
this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the rights and remedies of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms,
conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of the Credit Agreement or of any other Loan Document, all of which are ratified and affirmed in all respects and shall continue in full force
and effect. Nothing herein shall be deemed to entitle the Parent Borrower or any Foreign Subsidiary Borrower to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements
contained in the Credit Agreement or any other Loan Document in similar or different circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;On and
after the Second Amendment Effective Date, each reference in the Credit Agreement to &#147;this Agreement,&#148; &#147;hereunder,&#148; &#147;hereof,&#148; &#147;herein,&#148; or words of like import, and each reference to the Credit Agreement in
any other Loan Document shall be deemed a reference to the Credit Agreement as amended hereby. This Amendment shall constitute a &#147;Loan Document&#148; for all purposes of the Credit Agreement and the other Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Expenses</U>. The Parent Borrower agrees to reimburse the Administrative Agent for its reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with this Amendment, including the reasonable and documented fees, charges and disbursements of one counsel for the
Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 7.<B>&nbsp;<U>GOVERNING LAW</U></B>. <B>THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER
THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 8.
<U>Counterparts</U>. This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument.
Delivery of an executed signature page of this Amendment by facsimile or other electronic transmission shall be as effective as delivery of a manually executed counterpart hereof. A set of the copies of this Amendment signed by all the parties shall
be lodged with the Parent Borrower and the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;<U>Headings</U>. The Section headings used in this
Amendment are for convenience of reference only and are not to affect the construction hereof or be taken into consideration in the interpretation hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and
delivered by their respective proper and duly authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CONMED CORPORATION,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as the Parent Borrower</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel S. Jonas, Esq.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Daniel S. Jonas, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Vice President, Legal Affairs, General</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Counsel&nbsp;&amp; Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Johonna Pelletier</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Johonna Pelletier</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treasurer and Vice President, Tax</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LINVATEC NEDERLAND B.V.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Foreign Subsidiary Borrower</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel S. Jonas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Daniel S. Jonas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JPMORGAN CHASE BANK, N.A.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as Administrative Agent and a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Judy Marsh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Judy Marsh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorized Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BANK OF AMERICA, N.A.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael W. Brunner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael W. Brunner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WELLS FARGO BANK, NATIONAL ASSOCIATION,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yinghua Zhang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Yinghua Zhang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BARCLAYS BANK PLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ronnie Glenn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ronnie Glenn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DNB CAPITAL LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dania Hinedi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dania Hinedi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Devon Patel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Devon Patel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MUFG BANK, LTD.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Spencer Hughes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Spencer Hughes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CAPITAL ONE, N.A.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen M. Dahlquist</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Karen M. Dahlquist</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HSBC BANK USA, N.A.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kyle Patterson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kyle Patterson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD BANK N.A.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steve Levi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steve Levi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TRUIST BANK,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jared Cohen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jared Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second
Amendment to Seventh Amended and Restated Credit Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d220699dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<TD VALIGN="top">


<IMG SRC="g220699g0802002644007.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:24pt; font-family:Times New Roman"><B>NEWS RELEASE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman"><B><I>CONMED Corporation</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman"><B>Todd Garner</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman"><B>Chief Financial Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">727-214-2975</FONT></FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman"><B>ToddGarner@conmed.com</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONMED Announces Definitive Agreement to Acquire Biorez, Inc. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B><I>&#149;</I></B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Through this acquisition, CONMED acquires next generation bioinductive collagen scaffold technology for
application in sports medicine soft tissue healing </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B><I>&#149;</I></B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>CONMED to host conference call today at 4:30 p.m. ET </I></B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Largo, Florida, August</B><B></B><B>&nbsp;1, 2022 &#150; CONMED Corporation (NYSE: CNMD)</B> today announced a definitive agreement to acquire privately
held Biorez, Inc. (Biorez), on a cash-free, debt-free basis, for cash consideration of $85&nbsp;million at closing, subject to adjustment, and up to an additional $165&nbsp;million in growth-based earnout payments over a four-year period. The
transaction is expected to be financed through the company&#146;s existing credit facility. The transaction is expected to close in early August 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biorez is a medical device <FONT STYLE="white-space:nowrap">start-up</FONT> based in New Haven, CT and is focused on advancing the healing of soft tissue
using its proprietary BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Implant technology. The BioBrace implant is an innovative bioinductive scaffold that is intended to reinforce soft tissue where weakness exists and facilitate
healing. BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is cleared for use by the FDA in multiple product sizes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The addition
of Biorez and its BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> platform represents an important step forward for our sports medicine portfolio,&#148; commented Curt R. Hartman, CONMED&#146;s Chair of the Board, President, and
Chief Executive Officer. &#147;BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> fits seamlessly into our existing suite of products, and we are excited to advance the next generation of healing in sports medicine. BioBrace<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> represents the type of high-growth, high-margin platform that drives our long-term vision for CONMED.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin Rocco, Chief Executive Officer of Biorez added, &#147;I am proud of the Biorez team for developing an innovative healing solution that provides a new
treatment option for surgeons and patients. We are thrilled to join CONMED to accelerate the growth of our technology on a global scale.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Kevin and his team have created an extraordinary biomedical device that can improve the standard of care in sports medicine procedures,&#148; commented
Pat Beyer, CONMED&#146;s President of International and Global Orthopedics. &#147;I look forward to working closely with the Biorez team and leveraging their technical experience as we work to generate clinical data and bring this product to a
broader group of customers and patients.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Highlights and Update to 2022 Outlook </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED expects this acquisition to add approximately $1&nbsp;million in revenue to its recently provided full-year 2022 revenue guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED expects the acquisition to be approximately $0.10 to $0.15 dilutive to adjusted cash earnings per share in 2022 and 2023, and accretive thereafter.
Therefore, CONMED now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.25 to $3.45. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management will host a conference call today at&nbsp;4:30 p.m. ET&nbsp;to discuss its definitive agreement to acquire Biorez, Inc.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To participate in the conference call via telephone, please&nbsp;<U>click here</U>&nbsp;to <FONT STYLE="white-space:nowrap">pre-register</FONT> and obtain the
<FONT STYLE="white-space:nowrap">dial-in</FONT> number and passcode. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This conference call will also be webcast and can be accessed from the
&#147;Investors&#148; section of CONMED&#146;s website at&nbsp;<U>www.conmed.com</U>. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sullivan&nbsp;&amp; Cromwell LLP and DLA Piper
LLP are acting as legal counsel for CONMED. Canaccord Genuity LLC is acting as financial advisor and Shipman&nbsp;&amp; Goodwin LLP, Burns&nbsp;&amp; Levinson LLP, and Latham&nbsp;&amp; Watkins LLP are acting as legal counsel for Biorez, Inc. in
connection with the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CONMED Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company&#146;s products are used by
surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit <U>www.conmed.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biorez, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biorez is a New Haven, CT based
medical device <FONT STYLE="white-space:nowrap">start-up</FONT> focused on advancing the healing of soft tissues using its proprietary BioBrace<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Implant technology. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-Looking Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could
cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could
cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company&#146;s business, financial condition, and results of operations by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply
chain reliability; the ability of CONMED to advance Biorez&#146;s product lines following the Merger, including challenges and uncertainties inherent in product research and development, and the uncertain impact, outcome and cost of ongoing and
future clinical trials and market studies; uncertainties as to the timing for completion of the Merger; the possibility that various conditions to complete the Merger may not be satisfied or waived; transaction costs in connection with the Merger;
the potential effects of the Merger on relationships with employees, customers, other business partners or governmental entities; any assumptions underlying any of the foregoing; as well as risk factors discussed in the Company&#146;s Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the full year ended December&nbsp;31, 2021 and other risks and uncertainties which may be detailed from time to time in reports filed by CONMED with the SEC. CONMED&#146;s shareholders and
other investors are cautioned that any such forward-looking statements are not guarantees of future performance and to not place undue reliance on these forward-looking statements, as actual results may differ materially from those currently
anticipated. All forward-looking statements are based on information currently available to CONMED, and CONMED undertakes no obligation to update any such forward-looking statements as a result of new information, future developments or otherwise,
except as expressly required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no
assurance that management&#146;s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cnmd-20220801.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/2/2022 5:06:55 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:cnmd="http://www.conmed.com/20220801"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.conmed.com/20220801"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cnmd-20220801_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cnmd-20220801_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cnmd-20220801_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/2/2022 5:06:55 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cnmd-20220801_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/2/2022 5:06:55 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cnmd-20220801.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g220699g0802002644007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g220699g0802002644007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q 04# 2(  A$! Q$!_\0
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MDL3DD]Z2@#['^$.I7VK_  STN]U&[FN[J0S;YIG+,V)6 R3[ "NXKSWX(?\
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MABMX5AAC2.)!A410 H] !0!@>!O#!\'>#[#0VNOM+6X8M*%V@EF+' ] 3BO
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M%[93I/:SH)(I4.0RGH:\:^/'@_Q!XHO]$?1-+FO5@BE$IC(^4DKCJ1Z&N/\
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140042651627232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CONMED Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000816956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  01,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-0977505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11311 Concept Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Largo<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-6464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d220699d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnmd-20220801.xsd" xlink:type="simple"/>
    <context id="duration_2022-08-01_to_2022-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000816956</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-08-01_to_2022-08-01"
      id="Hidden_dei_EntityRegistrantName">CONMED Corp</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-08-01_to_2022-08-01">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-08-01_to_2022-08-01"
      id="Hidden_dei_EntityCentralIndexKey">0000816956</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-08-01_to_2022-08-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-08-01_to_2022-08-01">2022-08-01</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-08-01_to_2022-08-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-08-01_to_2022-08-01">001-39218</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-08-01_to_2022-08-01">16-0977505</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-08-01_to_2022-08-01">11311 Concept Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-08-01_to_2022-08-01">Largo</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-08-01_to_2022-08-01">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-08-01_to_2022-08-01">33773</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-08-01_to_2022-08-01">(727)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-08-01_to_2022-08-01">392-6464</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-08-01_to_2022-08-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-08-01_to_2022-08-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-08-01_to_2022-08-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-08-01_to_2022-08-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-08-01_to_2022-08-01">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-08-01_to_2022-08-01">CNMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-08-01_to_2022-08-01">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-08-01_to_2022-08-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !!J@%5EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " !!J@%5!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $&J 57#'K0Q[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( $&J 5697)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 0:H!5:_I=9,_!   >Q   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( $&J 56?H!OPL0(  .(,   -              "  8(,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ 0:H!59>*NQS     $P(   L
M     ( !7@\  %]R96QS+RYR96QS4$L! A0#%     @ 0:H!51PX9>H_ 0
M/ (   \              ( !1Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( $&J 54D'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $&J 55ED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d220699d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d220699d8k.htm">d220699d8k.htm</File>
    <File>cnmd-20220801.xsd</File>
    <File>cnmd-20220801_lab.xml</File>
    <File>cnmd-20220801_pre.xml</File>
    <File>d220699dex101.htm</File>
    <File>d220699dex102.htm</File>
    <File>d220699dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d220699d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d220699d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cnmd-20220801_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnmd-20220801_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cnmd-20220801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cnmd",
   "nsuri": "http://www.conmed.com/20220801",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d220699d8k.htm",
      "contextRef": "duration_2022-08-01_to_2022-08-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d220699d8k.htm",
      "contextRef": "duration_2022-08-01_to_2022-08-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.conmed.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-209154-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-209154-xbrl.zip
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M^$$<AQNA8I_]19?-;_38%5[#*-A-V09A*Q)M#"RJ+0U!6@ET*<R;-^W9J!J
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MHSB@_,09Z(PKID;"P]C&9S)D,E$,5 &(4SRIJ-Y9M9Q5GX$73!_Q7B"8)X(
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MCW4$)8=ID/!01*D*QDP!NZO^F&8P+T0]0)?V#TQJW\GPI3!.S'@XMO?Z40!
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MZ@A>I=RE(/.IS"$15I/;9(+.G,9NA B1,@0VE.7A.F)'"8D7\WF-G8?."S/
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MTT?6"LE#;?S[X[/>T<7)V3GI!"<?0&/HP1_SQ/0S.INUA+X?/WZQ2@G]/JO
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M(<53D=-E60[IH^LDG^+-=Z>D=*!!FDT:T1I&F/>>%@,2L2QK8%]Q>#0^!E]
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M"W;0>.[5)GT&NO KMM&83(<<? M]_^MD E?X78D.WVI&4Z"YHMI__-/62N8
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MA%4!=QNIC'O<9 ,@,"]G(/FB(-WT)OB3)V/<P.S17<8-Q>GARN$63Y%<R:8
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MDYF4BG= CDRGXMWB_BU:J;J)W??/1<TI;PKO#H!IO>P-U-E$K'K=1F.+HQ8
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M>'BU""LW&%$Z#:/OY\LW>-8,3GW'(9/)8^1-]+=5T6]-PDBA0WS7@0Y!4LN
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M&;3$[$ \VNK"6-U6V8M%ZGUC'/RI L]">Z.B\C I&4]CE;6>LH,2--\!=7S
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M(26%*BBA-%>XZ#%E+4H'(7+O+G)$%66Q@Z%/T+WZN6ZD0*L@@^=62^YDX+'
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MU=JQME)$*TNI.!Q8%OQI]^T)"04NH,T5!!'U3]']6YW2X)3#D3B$5>F&K%6
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M>/U93IR_XJ0K]DA<DA6">V+2D?'@>9%AY:6E4=E2%W;JO1K)#^PNM4.:[HD
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MW?A(^#N3B[%T&<X>A])0QU<)1TRX%]T<:1);2;I, RP-%"2KE+[+5%'35GB
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M)M5@J@.W1&3R4*+*.[TH^K5D+[(&TLZB?,[NI)=K=]+7PU<C%P-=;NU1FA9
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M;@I?3P8I><QZ+2 >?]LVRQ(EU-!Y(A_"!6;D/,2^VGXLN)D/_B]RIBW?Q]F
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M?_ 6_6P-DB9SA^'V5(S4%3JNM2_+'B]= @@A7\1"\)&,\<@Z=Q-^?.3W.R8
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M/5RPF65*\%*$(^G<'<WU9!,43_W_@VSNX^_9W"]ZO.[3X!. F)8$@[74,2(
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MI7.6$L1:/B5)2Y:_ QT1;M]".4]WEV#H'SY&98+PLR>GP[GXVEKD=XZ;]G5
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MK<F\&Q^J"<C,/=+DEO6%0Z4JA[N4*7OVW)[S\E;[<DSH 3K>X_VVCSR-%=?
MJC@N.PP7@W6'GR16GDSQ#G<$*:[NTJIE: 7-*@%?!/^" GVDN[(4_4/:.&PE
M@G<@8^#K-C8O:P=B?&,>BF8JX3*D%)1 1ZSVBPVYC3J15I9(D.-#XBJDO%T<
M-X>LPWO,+5#\4U?:\.KN"%]2+V>^$M9H:BZ(;_0!DY+OP8GL#6DS:O=EY*B
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M Y9XRTPLW^=@SO.^,6IBB16FE:YYO!B74>E9@OH/Z0-B!=-_& $T@$$4US;
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M"4-)57C.[CP40#/)3?^70/@.3/%?O[X;G./9^%L@AO43M%^\]Q*2Q>3_.I]
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MH$J:<VL#9,P"5O;6T,R_.$@W-\P*"Z9I 6[OYE06!1M.B8^W#4MOB+WQ!3O
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M'%4S@:*5"YG'K:<(!-]_XRMR>Y(*>0JU-F+C<3]HO<SCKV0>C,WFW\/CT#C
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MHN(T+( [(7FY+D]RM[C(S3H]VL$$3S=UYN,R(5B2MIGYS1AV-Q5>#<?L8&2
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M.N@K-5F_I<HL9T7LUW8TX%)EJAP  ,A<5YDN183@9[%LPXT52WS8+>"V<C#
M<2UVT##%^$,)=XBK%7R?P1LB2:FVS?6[[E L^5JI;%%V63JJ1#\QZ[JY(?)M
M4]%P O+:(0G_'Z5;;$<JO,(C6YW9-K:=I9:[UBZXII7F*VHZ&+;P;9" ',0C
M(,X@:\*,U/Q4FNP0'BJ23!1SF%=>H@L7U9P+@),*,5 +V"R;4VS.AB1*,3-%
MD%Y]4>-UABL1P!SP!2.,+( .0A5SXX#)P@JV]Q1[3(7Q>A)?FLN;8!0@P)+%
M_2^0[1C=-%+>\89+73R:4F<H2L1-8P_57@S;.L+"]TD-*W:XN<']"W87':<W
M-4" 0J&\IOF!HXO !0 E2=0XZ1U)4'OP(F/(F1-D!'@\AU'E0,T%IST'(69N
M8PH?.E#XFD&NW.6]$ C']2D8CW240*P<F%PBY4)6D/]<:,J3;]/$\1@O'C*-
M@\O?["!6!DDHP<96]??6OAM[K(K7 $$(V:ND0N?4!&.J]L'HMD5*/JP73K^B
MAPRR6Q*YU\?UJ_I<H]GFAC2Q+C6XC]/),^>6B*FMUF@@Q;=FF/^:CVXX5/>2
MT=(NR&;3%(LU(RW6)19PRM!&1;-*Q[NQIE+BC:4Z7I>9"M$0AEK.$FR"E)U7
MM=:MV!=SZUQ>)5#M<AFYB!74P"S]65&C6=.P@G35XHYSEDXETN1C[/M0,1)B
M\,63R^B25C:/LVM;75\]/M],AFG3$<N1I0K^EZHN]*@&:4R^EL?X+#B)3O3]
MR] '*+9?U4(1>=2FFQM,:&IFTBWTN"TLO,--UXS#!9 #Z+67EM<)5Y#":2L1
MH8<*]0V66=HUJ:Q5=5<KB-DB/W<]ES>%"!YSF.W%4YAMC883D5(;E50 ^#IP
M#) =&'XRMB53Y809EGY[U?Q&@Z1*;10X2LN?+WCN8:!M"WB1- E()-PG+[45
M'A<>4S+W(E43.M?4)MP2<M6^@AKO-C?,_"#N?>D,LR+=O>MJM8TU3@/=?U2J
M/I7\6MB],C7KEI3)P))FT6B[4";CYE1H17";#X*! $AS0$0YE6P@ZMR^/P2X
M;W1%K$*<IPRW]C9"\9AN0MLSC]Z17?@%;A3S&"ZKS8.V$IF/ .7#Y46(R/IN
M4<"=Y@,2$ /_WAR<%O0RC.(JS_E3I[.LRW#OY7?0D#"J[EEG_ZAMQQ&0]WO[
MH.,]Q['OEDY&\)!^X9N=W1W<I7UO"]O,ET$.(NP7%C_P#[E*T>*G':X%&43.
MJU3MQ_K"%4H.TD$KNIS0-E9\4_&6Q\"6)//9*^? M*_WHEFYZ*'HG T].FEG
M8CIQ__GA\^74'*')+EH<;I=5KW"H'!(TU$H8#3Q(IZP9F30(9MF#.JG<T5[(
M[=8%S9L#44?5:U7QH?^:0+U%S'[NVD]'/E>+>3GO9V]^T42FF\IWC]/@!/(<
M4G8 =$69BTI6WI'813N>QN@&_VE,@GR0]!5V&*Z)T<]])#0#0G#X7\6C$XJ+
M-$")1-404[4JV-E;E@/ W&<I>3OF7%#_),$N@PL339QB3SS0NPGH>*A<3*!9
M+Y[\F2:J2P\CK68T5\E%0J@K=2@,M;VK19"_0N;"KJB7M&BJ<M3;0C]=>N)K
M(2XPTW'$Q7'@W9T7%&"!;1<#H.6UZ&(7()\%]Y?BX:%\".4[(9+X\.'"-SM[
M$BU4M\*)K\&5*^\.KU/]OKZWT_8_7J_4S<*DJVOV^B1T6:DO5N9-M+IU*R+B
MGVU$G);41B;H6ET80B]DP?V4RV(A?K6SRRP5P98YOQK3+S3Z+QU U[L$90;!
M_Q"OD[A%'8"A7_Z"BVTS&QN<A."#I4JBGQ,W@OUHFL!9[2%O!(;,5GP+$3!M
M;L!3A$J@Q^0Y_!!^XY('Q3)<&I#$JH/6?':5&A?AYA=U!YOG%A5BN=1OR?YQ
MN0,X.L@:C?$9\BJ]K,U\,HA(E6UN%&2HM@1<\:UEF82TD6\,+;42=&0Y1DL@
M)]58.7"_(]<#9D 8+"9RS?P#Z59 P,0MSG96]!39^H)"ED6MU TTRL ?<ZC@
MG,;1%QE\-)$(/+X0HTR<:8,PT[+G+E@L-17]ANU?B'QAA;V]Y]D$65QX7)9+
MYVI"/W?/?)>E7Z1@YQ!479;3DY8*E?6LETB7KN#\8<0K> CI@M[$5<0K*A,L
M,DS8G<5MN1"0BN8F_J!4OOIX Z0OGP*D]VNFI6M(CG="W1$__1)8OH*/<O);
MA+K+=AA_3.@@,R60,\KMA$NU[SVO)D#0^HLHCY6NII!KBD+F+G)51;AX9&'0
M,40%8U9FA!DUJK60R)]&%UDT0.I: *"AX@!M;SZDJ*XBZM2@("3\ICX0"9Y1
MJ$"91]3OS/U'EY?03HV=JT&-U/V"-^MRQC5OPO43*1:ZK&J*!K66J-O6_CPK
M(;G:,'GQN^#I,R $I;A8$GB?-C=D+M8CLO657K*!>;LXMBW%$@*"[Y7; +8=
M]1 [;%Y]P4A1Y%42#X,V]N2 [W5"4#+%3\L\Q0.4*IRZKQ.R X2ET6A8O/#&
MB1571M+-*E!]VRHO]33GJ9-#FL2#YF)6IYH/<ECTT=5BU]6$XVP8^9^<CAK+
MS94CX]/]/J7-#?<(I-#5U')*0==6B:ON\T6R^;#"Z,E,6616D< +D9F\4F2:
MP%9TS:A5Y+N+Y81U*'!2"P99?YZ;\4$L<AK=I,-A,(J)*J8F43==_'Y']B@@
MRU+]3Q:KU9O5Z\VJ5B?Q'_98#B247',9T?KV$BH2J3-E0K*'5"T3KC]7S%-X
MN.8%^A!)T]2/?(I64+R#Q8?H83>8.A8_<VY88LCD94=);O;C,W6XT$Y+9;<U
MFI@OB;FWH$+\YAGVH5O"H9]>_;W([R/=QY1 8 ""^<Q62''N1N<<I"&V (Z5
M2UMK$FLD08;'+X2B-;NBKE7 3UP;(WXPXA;&@;1!\AHP?#67"[_?/PHLQ0'Z
MK3ZV1R-8$L-MCG$C0#2,Y!2A['+H CX&-OOVR,FEZ,3Z3W/>4KY4G10SVY+U
MDYP;E6V],L4!B#NUMORT!#98I9J]9NR2[8I=(3/A@WGP&^B2EIR*)3<W+-^P
M0LW\/;XI$N#ZO+(1!U8=P6RA.TOX9LOA_S!0J>8AX@E%.9M*@S@B\&N;3N."
M-8@^#XQ,$ZPO[H&%02J<3EL;"FAOM3-AD &P[1.DV4(OXBJ=I)FE$6)71QX,
M:]AV7)JJ5/7!M_ *MW#OI^?OO73PIU3P!."85/Y98#"+-QFI!38+N*JVOZ0X
MY6(%KO)).GDV , H/*Y2:NNAR]$5@Z-5V'*EDYN8D5ZG?1P(:SLC<[HZ0*DS
M"H 8B9$H![(&6T8A#H%LF;ML$ ]1HE<9DIS\3*$GJ"PRG6E\$$5X&9>0>O$L
M K/]D;WGRGUZS*6/KYXB>^M+ K]8F 2N]2_3NH^X;*]7/@U1C%ME>_4CGU*^
M$N>O3K#?+L%D_=6:7-**R5=$:$FV;6TY_KECGNJ57QQBA86QG(VS]"E)1Y*Y
M7#5)9?T"&&S+ A1!6K20H#+B]M=)>]XBM"R]5P^0]EPU&[5<2I?ON^JVK$X^
M8HWQRMG'1[[)*G_ V.KK3B!4)!\K')"[!Y"K98+)X3Y!4?NIF0]V;ZB/>Y$&
MN% D>ESXAA<T7AIL>+'6F/&+1Q@S7E#7Y8/AEP[Q;>+)=$3K \K!^N+)2^5U
M50&]E436Q+XV-VXK07>*(#]4W7QCA?-GT+<W(0771.7\3U(YKP=B!.3C''H]
M)"Q869/-#2TS_B+[P+K^<3*HJK/E[T47YN^(1%]%/EME 9MAC6E8-4#Y&@U$
MLS$\J'+ZB8M."PO:U@#[4H5<\#G6N+Q&+]UE?>,%HPR283.- FK.A3P"*A)-
M]@-MG:]^?OX\F.Z,C>?1CG*S?A.<'E0$!"?]67H19W3N7SSG9N02#9;>NP-&
MF%1EB%@@T@0V-^P"%J*[Z![T04AA/#8+4VD\,]B5B^/9<ZPKCQ>["@F@ADBM
M@S[,*D&J: I$V)$*4MFJ?P:%\\!JL*^BLL->G./%'1O;OS 1P@-N0C7D!@:T
M$",'#I8<V.*D;@E_^Y/G( CIN+B'V'9)\48+)8Q7*W;;L<&BFP*ET*-(\%QI
MCU20C_LA^F\)/-A8]8A23FI)E]@H8\$UN=?(W&..T[U^BM.M[]Y\475OWOZ:
M+$;6(,=8>6W>I@'X/D:+?X=R1MS:P??MD$4WW@/\<[X,U\KY&7FNB%O1Q>9[
M%N^#^82\;:O"ZY+^^&Q4&RM[EG"CKNI#N&J[B]CY$=3!AP5CLJ*9TD,"X#<G
M4L@T"V$S^,=0_3DFLDE.+4@, =K4'4AL@@V?+YX+W 0 K=.RB&DJW>Y,C60>
M#[WP19'66<XB3FO1"&G$EGU9=29IQ/>U6F]Y_(!$]&[GCQ>X*?/5QS#4EDRA
M^"*(P;"8]#6F '3$+&Q;M7K$MMM);2HEZZO S<O1AC)BDWZ9C.^ 'G;# !'6
M#'[PX,]W4J&>HEZH.,'F;EAS[MU"<^ZMJ#F#Y8IS<^-NFC.XI]+T8U/:T__Q
ME"8A&C.> -0'ND&1TNR4/)XDUSJSRE58#$#1$7=$/Q6H_ZC^9G;%_,DHC1.H
MRH&E SPR&US,8HMVA5B70@#-C@9#A##F+;@=<MP\#M0MCV#,IVXOP2QE"O@3
MR&2LEU)Q,C@1072^5"*T8OVJV1 ;"I=TAKAM/HS;XF7^-QVA1$/LP>( ZX;*
MR^*UY'9\52B[VP$L\YRD,#*+H0XO5MN!Y:=N$X>(8 .@D+P_,(WAG,3 .HE.
MC98=<H4ZX5T=:JKE+RX\?@\2W.W\NZG0KB6#@"7N^*1P=Q[3O333VQTB!I>1
MD3)JPB9J00'54C3IJK0FEE1P\;2 ,S/J0S2;4>Q#5-'%?,:PIX(!4OM9@A)B
M]7>)Z?VX@+=8ZO':=GD9&_TA*K(^G42$^_7Z;- 3A1=*?U@%\""2UZ,V$6"6
M1QD:>?,4&JDY,;LO;GUDDFTN\[C_B?$%/Q0". L8HMKQ@ZKRGEE%%<_M^G&W
MIHR:<-O3$ZQR>+ 4P '@<A;3@=KF,9BVP=;>K[WS4[/SO(=N/]Z\,MN#U=']
M:/0,=_UGL[5_^VUBKF_S'2SKF6!I/"+7E(LL?KFO3KV+A' !RX+M*RPXAI ?
M8L6' #]T%6R]Q!5??;UG5RNO-^8H[GF=WFG1:] 2'OI B!UXM_V!- ^CH\CR
M'F+JAYVNI=F?=I1-GIW,A7D#P%5F54D/N4IY2%*00I;W@C5ZB:5X.V@U-1-Q
M.,,4!@4/& 1)E*RMLQ+L\470[[<T82P%;E5WHGYG)7+P[0]M!3 XB;?UX7@#
M79WXK+D>M?YV/<1R 5LYD+;\<GR(BG(Y=(.1CZH8D>^<4JT:,SW/;FQ\,H?*
M.BGR62S33#5BMM5LG#OZ[IFKZF$,@8+U2F,21$R7^G49R5NF(-\2=@9$>P25
ME9$R01-A)WX$_0]1'Q?.!8^F*7:%1 #*7?$)B>\P%$>6$-$Q922(:T0_P]*/
MN+4I=C90F(CWG*$1+P$J#I;%.,+2C^*V*W"[9=U9"KYAV2-QFP// 6TW8Y0?
M(6LFIE6\G3&?@6=&B)!*;1Y"U[+]\![6_=CN:(Y^R8/TO%@:.*-&C#UQQ/$%
MY(0'NAK ?1]'T#B4I3?1"$*NT!W23\PE!HA_2"-L_G$6?0OAWHF))1!;9AW3
MC?D=\K\8P< ZACF%F@+D" N8(PPO0X4T*]24H2,K#C4QF%&M0!M\DU,SDJ/;
ML>0^$4';>5\BAG9@S4U0G2>3:_,.17%HID>#EV\[4G?ZAC$%9B.)( ]5;"RP
M1"[;Y3AF>5?<4E=MC2/H&^D]\=#K"$LYF=E+"^&6(T C,TL?S?(T1@['R.Q_
M-F,@Q_E$?@RQ+PPG/9_@/T.@S4U'<^(O<=18(5PBV9S:=>83_B&$.!,&B?&W
MZ@>KJA[^J!@M3/5OA0!-<Z&1\ECDKN<67#>TA[9VJP;G^F5\MF1('=E>6TPH
M57$DT %T#6A^O#BEWFPCQX,$:KO3C'R8S8U8.B[+M5MLL]IAQJ0Q2N=FVUP?
MV1@U/,-@#^R=(:D%F BI0[H"+ 57E",;6CX?@6H**S "0@],&TP)3YO]'&RU
M%' V7XR%'!0=T5*N2=LK*Z6N B\F?\?P&:Z)LWE9@8U5US7B7<I#HMP]^0XQ
M-@Z489"-4'(T4+>K<S:;-\\F27Y5P6Y82YUDE#;91)RP@BVA"U^2'368! Y#
M5V%&"0P4'U;/^J\HLBA&;7X)MMXY2>"2MD<9\?OI*>)W=S@R/X-=[8,XHO;Z
M%@-W411Y2ZI=Q,KZO[OHB\V-1A6&#<J;\[2_K>(EUIK1%2/< D'V.DX7R!Q@
M+A;)VV$-&IV/YE21'@%[/]*^8[L&*.V1)?".+&-S(60%Y12)>8O]XJWC*Z4G
M,!@%FIYD>9)'(PR0-1@VNG#<8ZF$M<%UX^&3&XVK%<KMZU$="E"&M,%[W^:_
MP3U(]F/41P$.U/K>8#7)UH&R@2TF&D\,RPZ0,\1L'TN0Z[CWD"/@ZP=)+C@E
MJI@E]^X%OUG]]9YL%2)]0*XX1KI"B+RLLI?FB0Q  GJ_;@!%_QSII5!T!K?
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M),E\@X0>F5BA(IFU/'K2(A96E]$T,1A'>M!B2%O;IM:>J0@=TCWN=*PKU+@
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M;2I ^7,^N.1,ZP :-GSHT,+Q#MV PL(PP;N_,KI08'+*VEE.^4*U3_TL)27
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M%:\PO6;[1]B/]K96[K &Q (!16Y22%,=;&AS7QK?K95WP1#10HA@W!)(4)'
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M^O53/&/-Q>==IU%^@2(6"%X8A7&W8J;OY7=N+Z@[ Z>3U&+ ECL:.1<WJO/
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MJE #"&PW[7M+(A8%1.S5 S^%N,;FQL0/BF#LV 9GN/E"WGI;7&#[5BR[!<A
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MZ" XZ'3-G(*6F?"9F0Q\L75\ H^!'>ST#CI8L> #*+$_G&19?)WV$4C*F.X
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MLX Y0ZP3RNU;^ XIQUPP&-@&1F>[R BM,<WXH9L;XRC!H+6@K.=04BN"S6^
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M RQI. DZ1IED%I>V8X8_GEAJ2?#KMY=1$0N_,#RU^OORY3*LWEO[S57=1?/
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MH_@FFD[YD!6CN42,"93$"KW>5Q"AQ[-,-YC3[L2@U8+JBRKEU4+-!>P0 QB
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M4E.4YMW8/ _JU7\ 2,U&.':[GSO4>G#_K&E#^ Z]]OZCUGE_ ;NG=Y5,QVL
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M) 0:Y,AXW+C_BPY8+&3WB2#9@#"I(1)I6!-N3^\?*3^5ZQ;5KKM09JX!&=%
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MT)U)G1*XR>BG!H?4Q24$T6&1X:H5UWSW;U60,[1\\]T4SDK/8(4)6=,J.8\
M/&098-6PHJNT97-$.,GI@6!=]EW 0<"LN@VTSU<N>A7KLTT1\?4BG.]2OBU
M5RM_3)62'TF$;)FPV#,]G35<":B[-PZB:P!PG(:H<T BJ1Z9>-I XS47-^#
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M4$L! A0#%     @ 0:H!5313YI)@'P  <JD   X              ( !Z X
M &0R,C V.3ED.&LN:'1M4$L! A0#%     @ 0:H!5<N&Z:N*9 $ W?,' !$
M             ( !="X  &0R,C V.3ED97@Q,#$N:'1M4$L! A0#%     @
M0:H!5>N]#Y@L$P  NI0  !$              ( !+9,! &0R,C V.3ED97@Q
M,#(N:'1M4$L! A0#%     @ 0:H!54A5XK&>#P  93<  !$
M ( !B*8! &0R,C V.3ED97@Y.3$N:'1M4$L%!@     '  < O@$  %6V 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
